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CHAPTER I 
 
INTRODUCTION 
 
 
   “It is not the answers you give, but the questions you ask.” 
 
Voltaire  
(°1694 - †1778, French Enlightenment writer, historian and philosopher) 
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CHAPTER I 
INTRODUCTION 
1. CELL-PENETRATING PEPTIDES 
The ability of peptides to traverse the phospholipid bilayer of cell membranes was discovered more 
than 20 years ago, when it was demonstrated that the Trans-activator of transcription (Tat) protein 
of the Human Immunodeficiency Virus (HIV) and, a few years later, the third helix of the 
Antennapedia transcription factor protein of Drosophila Melanogaster were able to enter cells [1-5]. 
Since then, hundreds of studies have described peptides crossing cellular membranes, which are 
most commonly called cell-penetrating peptides (CPPs). These CPPs are extensively investigated to 
act as intracellular delivery tools for (non-) covalently attached bioactive cargoes like siRNA, double 
stranded DNA, antisense oligonucleotides, peptides, proteins, nanoparticles, liposomes and small 
molecules [4-7]. Successful developmental applications have already been reported for CPPs coupled 
to therapeutic cargoes for treatment of cancer, muscular dystrophy, cardiology, antiprion diseases, 
as well as bacterial and viral infections [4].  Beside their use as carrier for intracellular delivery, CPPs 
can also exert a biological activity themselves [6,8-10]. Studies on the biological effect of CPPs, which 
can be toxic or of therapeutic interest, are limited. Generally, CPPs are considered to have a low 
toxicity profile as demonstrated both in vivo and in vitro, making them such interesting vectors for 
hydrophilic macromolecules [4,11-13]. 
Cell-penetrating peptides constitute a structural diverse group of peptides, characterized by a 
relatively short sequence of less than 40 amino acids. They can be classified based on their origin 
resulting in the protein-derived, chimeric or synthetic CPP subgroups, with chimeric implying a fusion 
peptide being an unnatural, multifunctional construct of at least two different peptides [14,15]. Cell-
penetrating peptides derived from heparin-binding proteins, DNA and/or RNA-binding proteins, 
homeoproteins (a family of transcription factors containing a conserved DNA-binding motif), signal 
peptides, antimicrobial peptides and viral proteins have already been identified. In some cases, the 
cell-penetrating property of the CPPs is linked to the function of the native protein or peptide, like 
for viral proteins to gain cell entry, but sometimes the role of the CPP sequence in the parent protein 
or peptide is unknown [6]. Cell-penetrating peptides are mostly described as short, cationic peptide 
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sequences, but actually they show a great sequence variety. When classified based on their 
physicochemical properties, traditionally three major classes can be distinguished: the cationic, 
amphipathic and hydrophobic CPPs [6]. The cationic CPPs are characterized by a stretch of positive 
charges derived from arginine and lysine residues in their sequence. The second group comprises the 
amphipathic CPPs. Primary amphipathic peptides are featured by a hydrophilic and hydrophobic part 
in their sequence, while for the secondary amphipathic peptides the hydrophobic and hydrophilic 
amino acids become separated through formation of a helix structure. The hydrophobic CPPs are rich 
in apolar amino acids and have a low net charge. However, a clear overlap exists between these 
chemical groups, emphasizing that CPPs represent a chemically diverse group of peptides [6]. In 
Table 1, some examples of CPPs from the different classes and origin can be found. 
Table 1: Examples of CPPs. 
Name Sequence Chemical class Origin Reference 
Tat 47-57 YGRKKRRQRRR Cationic Protein (viral) [16] 
SynB3 RRLSYSRRRF Cationic Protein (antimicrobial) [17] 
Oligo-arginine Rn (n = 6-12) Cationic Synthetic [18] 
Penetratin RQIKIWFQNRRMKWKK Cationic Protein (DNA-binding) [3] 
pVEC LLIILRRRIRKQAHAHSK Amphipathic (secondary) Protein  [19] 
TP10 AGYLLGKINLKALAALAKKIL Amphipathic (primary) Chimeric [20] 
K-FGF AAVLLPVLLAAP Hydrophobic Peptide (signal) [21] 
Bip VPTLK Hydrophobic Protein (DNA-binding) [22] 
 
Although CPPs are intensively investigated, the exact cellular uptake mechanism of these peptides 
remains elusive. A variety of methods is used to determine the cellular uptake mechanism and 
subcellular localization of CPPs. Both biological methods, using cell cultures, and biophysical 
methods, using model membranes and molecular modeling, are applied. In biological methods, CPPs 
are mainly fluorescently labeled and their uptake is indirectly quantified using fluorimetry or 
fluorescence-assisted cell sorting (FACS), and the cellular localization is studied using confocal 
microscopy [23]. Beside these fluorescence-based methods, functional assays in which the biological 
activity of the conjugated cargo is detected and matrix-assisted laser desorption/ionization-time-of-
flight mass spectrometry (MALDI-TOF MS), allowing to directly quantify the internalized CPPs, are 
also widely applied [5,23]. Chromatographic separation techniques are no standard method to study 
the cellular uptake of peptides, and if used, the peptides are chemically modified [24,25]. The 
mechanism of uptake is evaluated using an inhibitor of one or more of the possible influx pathways 
[23]. Moreover, available studies differ in the applied experimental conditions like the cell line used, 
the extracellular peptide concentration, coupled cargo and label, temperature and incubation time 
[5]. These different parameters are known to influence the uptake of CPPs, complicating to draw 
general conclusions on the influx efficacy, used influx mechanism and the structural features 
determining cellular influx [5,23]. Currently, a consensus exists that both endocytosis, which is 
energy-dependent, and a direct penetration mechanism, which is energy-independent, are involved, 
   CHAPTER I – INTRODUCTION 
  
 
21 
whether or not simultaneously occurring, depending on the applied conditions [4,5,23]. In addition, 
the involvement of receptors in the uptake of CPPs was recently demonstrated [26]. From the limited 
available structure-activity relationship (SAR) studies, it can be concluded that the number and 
density of positive charges, hydrogen bonding, presence of hydrophobic α-helical structures, thus the 
secondary structure, as well as the peptide length determine the cellular uptake of peptides [23,27-
29].   
In Figure 1, an overview of the different endocytosis-dependent and direct penetration mechanisms 
is shown [30]. Endocytosis, which is a natural process that occurs in all cells, is subdivided in 
macropinocytosis, endocytosis dependent on the coat proteins clathrin or caveolin and endocytosis 
independent of these coat proteins [23].  Endocytosis is triggered by an electrostatic interaction 
between the cationic CPPs and the negatively charged proteoglycans of the cell surface or through 
direct interaction with the plasma membrane [5]. Direct translocation involves the destabilization of 
the plasma membrane following an interaction of the CPP and the cell membrane either by an 
hydrophobic or electrostatic interaction [5,23]. Subsequently, the peptide folds on the lipid bilayer 
and internalizes using different mechanisms, i.e. inverted micelle model, through pore formation, 
including the barrel stave or toroidal pore model, or carpet-like model,  depending on the peptide 
concentration, peptide sequence and composition of the cell membrane [23]. Endocytosis is assumed 
to be the main mechanism at lower peptide concentrations. When a certain concentration threshold 
is reached, which depends again on the cell type, the CPP sequence and the attached cargo, the CPPs 
enters the cell through direct penetration [23]. 
 
Figure 1: Overview of the proposed mechanisms for cellular influx of CPPs (adopted from Trabulo et al. [30]). 
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2. BLOOD-BRAIN BARRIER 
In the central nervous system (CNS), neurons communicate through a combination of chemical 
signals, i.e. neurotransmitters, and electrical signals like synaptic and action potentials within 
complex networks [31,32]. Therefore, a strict regulation of the local microenvironment around 
synapses, glial cells and neurons is required for reliable neural signaling. This need for homeostasis is 
argued to be the strongest evolutionary pressure driving the development of CNS barriers [31-33]. 
The existence of these barriers was already demonstrated in 1885 by Paul Ehrlich, who described 
how dye injection resulted in staining of peripheral organs, but not of the brain and spinal cord 
[34,35]. Later, Ehrlich’s student Edwin Goldmann confirmed these findings by showing that injection 
of trypan blue in the cerebrospinal fluid stained the cells of the CNS but not in the periphery [34,36]. 
In the CNS, three brain barriers can be distinguished: (1) the blood-brain barrier (BBB) constituted by 
the endothelial cells lining the brain capillaries, (2) the blood-cerebrospinal fluid barrier formed by 
the epithelial cells of the choroid plexus facing the cerebrospinal fluid and (3) the arachnoid barrier 
provided by the avascular arachnoid epithelium underlying the dura [31]. These three interfaces form 
a physical barrier, with tight junctions sealing the endothelial cells that also lack fenestrations and 
show limited transcellular transport of ions, water, solutes, macromolecules and blood cells, as well 
as a transport barrier, fulfilled by the specific transporters which strictly regulate the transport of 
solutes, ions, and macromolecules [31-33]. Intra- and extracellular enzymes are capable of 
metabolizing (toxic) molecules during transit, forming an enzymatic barrier. Finally, specialization of 
the endothelial cells and other residing cells helps to regulate the transport of leucocytes, 
contributing to the immunological barrier [31,32,37]. 
The tight junctions between the cerebral endothelial cells are the key feature of the BBB, restricting 
the paracellular diffusion of ions, polar solutes and water between endothelial cells and blocking the 
transport of macromolecules. The restriction of paracellular transport is accomplished by the high 
trans-endothelial electrical resistance (TEER) of the BBB [31,33,37].  The junctional complexes 
between the endothelial cells comprise both the tight junctions (TJs) and adherens junctions (AJs), as 
well as the gap junctions (GJs) (Figure 2). In the adherens junctions, cadherin proteins span the cleft 
between endothelial cells and are intracellularly linked with the scaffold proteins α-, β- and γ-
catenin. Adherens junctions give structural support by holding endothelial cells together and are 
essential for the formation of tight junctions. Occludin and claudin proteins span the intercellular 
cleft and form the tight junctions together with the junctional adhesion molecules (JAMs), which are 
assumed to act as cell-adhesion molecules for leukocytes. These proteins are intracellularly anchored 
with scaffolding and regulatory proteins like ZO-1, ZO-2, ZO-3, cingulin, afadin (AF-6) and 7H6 
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antigen. The association with these adaptor proteins ensures the stabilization of the tight junctions 
as well as the dynamic regulation of the junction opening or closure, either directly, through linking 
claudin and occludin with the actin filaments of the cytoskeleton, and indirectly, via binding to 
second-order adaptor proteins [31,33]. Connexin (Cx) proteins also constitute an important part of 
the junctional complex. These proteins form gap junction channels, directly connecting the 
cytoplasm of adjacent endothelial cells, and are assembled by head-to-head docking of two half gap 
junction channels or hemi-channels (CxHC, see Figure 2). The connexin hemi-channels allow contact 
between the cytosol and the extracellular space. Although connexins are rather unexplored, studies 
indicate their involvement in the junction complex having important regulatory functions, allowing 
autocrine and paracrine signaling and direct transfer of nutrients, metabolites, ions and signaling 
molecules [33]. 
 
Figure 2: Junctional complexes between the endothelial cells of the BBB with TJ are the tight juctions, AJ the 
adherens junctions and GJ the gap junctions (adapted from De Bock et al. [33]). 
 
Several cellular and non-cellular components interact with the cerebral endothelial cells and are 
involved in the development and maintenance of the BBB. This interplay is called the neurovascular 
unit (Figure 3) and comprises the cerebral endothelial cells, as well as pericytes, astrocytes, neurons, 
microglial cells and leucocytes. The structural and functional support of the BBB is further 
accomplished by the extracellular matrix and basement membrane ensheating the brain capillaries 
[31,32,37,38]. Pericytes contribute to the vessel stability and regulate the capillary diameter and 
hence blood flow. These cells also control the integrity and function of the BBB by enhancing the 
formation of tight junctions between endothelial cells [31,32,37,38]. Astrocytes also modulate the 
BBB tight junctions: in vitro co-culture experiments indicated an improved barrier function if brain 
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endothelial cells were co-cultured with astrocytes, probably by secretion of soluble factors like 
interleukin-6, glial cell line-derived neurotrophic factor and fibroblast growth factor 2 [37]. Beside, 
astrocytes also provide nutrition for neurons, regulate brain and electrolyte metabolism, control 
immune reactions and carry out the clearance and recycling of neurotransmitters [37,38]. Microglia 
are the CNS-resident immune cells and play a critical role in the immune responses of the CNS, while 
circulating leukocytes are involved in the surveillance and immune protection of the CNS [32,38]. The 
extracellular matrix consists of the interstitial matrix and basement membrane, which is formed by 
extracellular matrix molecules secreted by the endothelial cells, pericytes and astrocytes [37]. The 
basement membrane holds the cells of the neurovascular unit in their place and regulates the 
intercellular communication [37]. 
 
Figure 3: Cellular interplay at the neurovascular unit of the central nervous system  
(adopted from Obermeier et al. [37]). 
 
At the BBB, several routes of transport exist for different types of molecules. Lipophilic compounds, 
like the blood gases oxygen and carbon dioxide, can cross the BBB by passive diffusion, with the rate 
of brain entry is correlated with their lipid solubility [31,32]. Solute carriers in the luminal and 
abluminal membranes regulate the transport of ions, nutrients and molecules essential for normal 
brain function like amino acids, glucose (GLUT-1), nucleosides, monocarboxylic acids, as well as clear 
waste products from the brain [32]. The ATP-binding cassette (ABC) transporters, like Multidrug 
Resistance-associated Proteins (MRPs), e.g. P-glycoprotein (Pgp), and Breast Cancer Resistance 
Proteins (BRCPs), are active efflux pumps mainly present in the luminal membrane that transport a 
diversity of lipophilic compounds out of the brain. They fulfill an important neuroprotective role as 
they remove potential neurotoxic compounds, as demonstrated for several drugs [31,32]. The 
transcytosis mechanism of macromolecules like proteins and peptides via endocytosis is less clear. 
Both adsorptive-mediated and receptor-mediated transcytosis are identified and are further 
described in the next section [31,32]. 
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3. BLOOD-BRAIN BARRIER TRANSPORT OF PEPTIDES 
Historically, peptides were believed not to cross the BBB. Despite this general skepticism, Kastin and 
Banks initiated their research on the BBB transport of peptides in the mid-1970s following the 
observation that pituitary peptide hormones outside the brain had effects on behavior [39,40]. At 
that time, the brain uptake index (BUI) was traditionally used to study the in vivo BBB transport, 
although this method was lacking sensitivity, illustrated by the example of morphine which could not 
be reliably detected by BUI although it has a pronounced CNS effect [39,41]. During BUI experiments, 
a single pass uptake from blood over a few seconds is measured rendering this method suitable for 
compounds showing a rapid uptake in the brain like glucose [42,43]. Only very small fractions of 
peripherally delivered peptides reach the brain parenchyma, which could not be detected using the 
BUI method [38]. The introduction of the multiple time regression (MTR) analysis method, combined 
with a graphical evaluation of the brain uptake data [44,45] and perfusion methods [46-48], both 
using radioactively labeled peptides, allowed sensitive and accurate determination of the BBB influx 
kinetics of (slowly penetrating) peptides [39,41,42]. Since then, numerous studies have described the 
ability of peptides to cross the BBB. Quantitative data on the BBB transport of peptides are compiled 
in the Brainpeps database, managed by our research group in collaboration with the database 
research group (TELIN) of our university, and the resulting data of this Ph.D. project were used to 
update the database [49]. It was in fact noted that BBB transport data of peptides are scattered in 
literature and suffer from, as observed for the studies on CPPs, a wide variety of used methods and 
experimental set-ups. However, overall, the available data persuasively prove that peptides do cross 
the BBB, demonstrating that its barrier function is not fixed but can be modulated and regulated and 
is affected by developmental, physiological and pathological events [31,50]. For example, the BBB is 
involved in the regulation of feeding as ingestive peptides interact with the BBB [51]. Although 
peptides cross the BBB in small amounts, their high specificity and potency renders them to be 
functionally active leading to possible therapeutic applications [52].  
Both saturable and non-saturable transport systems are identified for peptides when crossing the 
BBB from blood-to-brain. Saturable transport systems, showing inhibition at higher doses, are 
endocytosis-driven and thus energy-requiring, which can be receptor-, adsorptive- or carrier-
mediated [53,54]. The intracellular trafficking of the peptides in the endothelial cells, as well the 
exocytosis mechanism are still elusive [53,54]. Receptor-mediated transcytosis is triggered by a 
specific interaction between the peptide and a receptor at the luminal face of the brain endothelial 
cells, followed by an endocytotic uptake, movement across the cytoplasm of the endothelial cell and 
exocytosis at the abluminal side [53]. At the BBB, a receptor has already been demonstrated for 
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insulin, transferrin and low density lipoproteins (LDL) [42,54]. Adsorptive-mediated transcytosis of 
peptides at the BBB follows an electrostatic interaction between positive charges of the peptide and 
negative charges present on the plasma membrane [42,55]. The BBB is well “equipped” for this 
transport mechanism: both the luminal and abluminal membranes as well as the basal membrane 
are negatively charged, facilitating both the endocytosis and exocytosis of (cationic) peptides. The 
brain capillary endothelium is enriched in clathrin-coated pits, which are involved in the endocytosis 
process. The density of mitochondria in cerebral endothelial cells is about five times higher than in 
other endothelial cells, which increases the energy potential of the BBB, enabling the energy-
requiring adsorptive-mediated transcytosis process [55]. Both receptor- and adsorptive-mediated 
transcytosis are time- and concentration-dependent, with the receptor-mediated transport 
mechanism being characterized by a higher specificity, higher affinity and lower capacity compared 
to adsorptive-mediated transcytosis [53,55].  Carrier-mediated transcytosis involves an interaction of 
the peptide with a transporter on the endothelial cell surface [56,57]. Carrier-mediated transcytosis 
can be both energy-dependent and -independent [56]. For some peptides, the used transporter has 
been identified such as for the enkephalin analogs, biphalin and DPDPE, all opioid peptides, which 
are assumed to cross the BBB by the large neutral amino acid carrier (system L), as well as by an 
unknown transporter other than system L [57]. For other peptides, the exact identification of the 
involved transporter is lacking and a generic name is attributed (Peptide Transport System (PTS)) 
[58]. Another possible mechanism for BBB transport of peptides is fluid-phase endocytosis, involving 
no specific interaction but the peptide is simply present in the extracellular fluid at the site where the 
plasma membrane invaginates to form an endocytotic vesicle. The peptide bathing in the 
extracellular fluid is captured within the lumen of the budding caveolar vesicle and enters the brain 
capillary endothelial cell [55,59]. However, caveolae rarely occur at the BBB, thus the use of this 
transport system is presumed to be limited at the BBB [55]. Beside the saturable transport systems, 
peptides also can cross the BBB by passive diffusion, which is non-saturable and currently assumed to 
be used by the majority of the peptides [42]. The rate of diffusion depends on the physicochemical 
properties like lipophilicity and is inversely related with the size, number of hydrogen bonds and the 
square root of the molecular weight [42]. Peptide transport from brain-to-blood involves both 
specific, saturable carrier-mediated transport systems, as well as non-saturable, non-specific 
transport of peptides out of the brain by reabsorption of the peptide in the circulation of the 
cerebrospinal fluid [60]. As for the brain influx transporters, efflux transport systems are poorly 
characterized, but use of Pgp, PTS-transporters and proton-coupled oligopeptide transport (POT) 
family has already been reported [58].  
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4. BLOOD-BRAIN BARRIER AND AGING 
The aging process is associated with a gradual change of multiple physiological, biological, physical 
and social functions [61]. At the BBB, several important structural and functional changes occur, 
ultimately resulting in an increased BBB permeability. With age, the BBB also becomes more 
susceptible for external factors like disease, e.g. hypertension, and drugs [62-66]. In Table 2, an 
overview is provided of the molecular mechanisms contributing to the age-related BBB dysfunction 
[66].  
Table 2: Molecular mechanisms of BBB disruption, caused by aging and age-associated diseases  
(adopted from Popescu et al. [66]). 
Mechanism Cause 
Increased oxidative stress Aging 
Microglia activation Aging 
Increased transport of TNF-α through BBB Aging 
Decreased expression of GLUT-1 Aging, diabetes 
Iron accumulation Aging, high cholesterol, Parkinson’s disease 
Decreased activity of Pgp Aging, Alzheimer’s, Parkinson’s disease 
Decreased estrogen level Aging 
Reduced sensitivity to insulin Aging 
Decreased occludin expression Diabetes 
Decreased ZO-1 expression Diabetes 
Decreased ZO-2 expression Hypertension 
Increased endothelia-monocytes interaction Diabetes 
Activation of δPKC Hypertension 
Alteration of adherens and tight junctions function Stroke 
RAGE up-regulation Aging, Alzheimer’s disease 
LRP down-regulation Aging, Alzheimer’s disease 
 δPKC = δ protein kinase C; RAGE = receptor for advanced glycation end products; LRP = low-density lipoprotein receptor-related protein; 
RAGE and LRP = involved in the transport of amyloid β in and out of the brain.  
 
Aging is associated with a heightened peripheral inflammation leading to increased TNF-α levels at 
the BBB, resulting in vascular inflammation [62]. Increased levels of TNF-α suppress the expression of 
junctional protein complexes like occludin and ZO-1, causing loosening of the tight junctions [66,67]. 
Disruption of the BBB is also associated with microglial activation, which together with the 
accumulated iron in both glial cells and astrocytes, form a source of oxidative stress to the cells of the 
neurovascular unit [66,68,69]. Moreover, aging is associated with decreased estrogen levels, which is 
known to have protective function on the BBB endothelial cells [66]. Alterations in transporter 
functions, like of the glucose transporter GLUT-1 and of Pgp, cause an imbalanced uptake or efflux of 
compounds as demonstrated for glucose and amyloid β (Aβ), that shows accumulation in the aged 
brain [62,66]. The resulting increased permeability of the BBB in turn enables passage of pro-
inflammatory compounds and cells, as well of toxic compounds, which further enhances the BBB 
dysfunction. 
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Alterations in BBB permeability can also be attributed to several diseases with high incidence rates in 
the elderly population like Alzheimer’s and Parkinson’s disease as shown in Table 2 [66]. Moreover, 
for these disorders, a pathogenic link between the BBB dysfunction and the onset or the progression 
of the disease has been demonstrated [62,66,70]. Changes of the BBB permeability, either due to 
aging or disease, also impact the brain pharmacokinetics of (peptide) drugs, which can complicate 
the treatment of CNS disorders and can cause CNS adverse drug reactions if not appropriately dosed 
[70]. This stresses the importance of including the elderly patient in clinical trials, especially those 
with (neurodegenerative) comorbidities. 
 
5. STUDY OBJECTIVES 
Cell-penetrating peptides are a class of peptides that traverse cellular bilayers. It is also generally 
accepted that peptides are able to cross the BBB. As CPPs are mainly investigated for their carrier 
functionality, studies evaluating, mostly qualitatively, the BBB transport of CPPs in vivo and in vitro, 
focus on CPPs coupled to cargoes of different chemical nature. This BBB transport is indirectly 
estimated by measuring the pharmacological effect of the attached cargo or by in vivo imaging and 
fluorescence microscopy techniques using (fluorescently) labeled peptides. Beside their application 
as carriers, CPPs can also be formed endogenously through metabolization of proteins and also can 
possess biological activity. It is of general importance to know whether this group of peptides is able 
to enter the brain and hence might exert CNS effects on their own.  Therefore, the main goal of this 
research project was to quantitatively investigate whether uncoupled CPPs selectively cross the 
BBB in vivo and whether this is related to their cell-penetrating properties. 
In order to answer the central question of this research project, following objectives were set: 
(1) Select model peptides representative for the chemically and functionally diverse group of 
CPPs. 
Cell-penetrating peptides are a chemically diverse group of peptides, showing a varying extent of 
cellular uptake which is influenced by multiple factors like the cell line used, extracellular 
concentration, attached label and incubation temperature. The exploration of the chemical space 
is performed to classify CPPs according to their structural characteristics. Selection of model 
peptides is also based on their cellular influx properties. As a plethora of experimental set-ups 
and methods is used to investigate these peptides, an approach to globally estimate the extent 
of cellular uptake is investigated. By combining the knowledge on the chemical and functional 
properties of these peptides, the structural features that determine the cellular uptake of 
peptides can be identified.   
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(2) Define a method that allows the overall and objective comparison of peptides regarding their 
BBB transport, based on the exploration of already available quantitative BBB transport data 
of peptides. 
Numerous studies have already described the ability of peptides to cross the BBB. Quantitative 
BBB transport data of peptides scattered in literature, are compiled in the Brainpeps database. 
From the exploration of this database, it became clear that the BBB influx is evaluated using a 
diversity of techniques and inherently is expressed using different BBB influx response types. 
Available quantitative data are used to propose a method that enables the comparison of 
peptides regarding their BBB transport despite differences in used response types, aiming at an 
objective and overall evaluation of the obtained BBB transport results of CPPs during this 
research.  
(3) Evaluate the quality of the peptides investigated for their BBB transport characteristics, using a 
chromatographic system optimized for analysis of cationic peptides. 
In order to obtain reliable research outcomes, it is imperative that the quality of the externally 
purchased peptides is verified. Currently, analysis of the cationic CPPs is hardly described and an 
initial analysis of the cationic CPPs using our traditional liquid chromatography (LC) systems 
indicated analytical difficulties. Moreover, the evaluation of the impurity profile of the CPPs used 
during cellular uptake studies is often ignored throughout biomedical literature, which might 
explain the discrepancy in study results. Therefore, we want to comparatively investigate 
selected chromatographic and detection systems to solve the analytical quality control (QC) 
challenges for this group of peptides. 
(4) Characterize the BBB transport of a chemically and functionally diverse set of CPPs. 
Several studies have demonstrated the ability of CPPs, mostly coupled to cargoes, to reach the 
brain parenchyma. The question is whether this is a general characteristic of CPPs. Therefore, the 
BBB transport of uncoupled CPPs is quantitatively evaluated in order to verify whether cell-
penetrating properties of peptides inherently imply the ability to cross the BBB. For investigation 
of the BBB transport studies, CPPs will be selected, as well as “new” CPPs like the short, proline-
rich antimicrobial peptides (PrAMPs) and disulfide-rich (cyclic) peptides, which are biofunctional 
peptides that also possess cell-penetrating properties. 
(5) Explore the regulatory status of the development of geriatric medicines. 
The aging process is associated with gradual changes of several physiological, biological, physical 
and social functions. Changes of organ functions, like the increase in BBB permeability, affect the 
pharmacokinetics of drugs and should be taken into account when developing geriatric 
medicines. As with the current demographic trend of an aging population, the geriatric patients 
will soon outweigh the other population subgroups, and therefore, it was evaluated what 
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regulatory framework is currently provided for the development of geriatric medicines. This 
study fits into the DruQuaR tradition to include a regulatory-oriented aspect of the Ph.D. 
research.   
 
6. THESIS OUTLINE 
The coherence of the different aspects covered in this research are outlined in Figure 4. Chapters of 
this thesis are logically ordered, but to ensure a fluent reading, each chapter is presented as a stand-
alone text, with the introduction delineating the specific context of that section. 
 
Figure 4: Thesis outline. 
In Chapter II, a database is built consisting of peptides, quantitatively investigated for their cellular 
uptake. Using chemo-molecular descriptors, numerically expressing the peptide structure, the 
chemical space of the CPPs is explored applying multivariate data analysis techniques. The cell-
penetrating (CP) response is introduced, which is a unified response expressing the extent of cellular 
uptake of peptides independent of the experimental set-up and method used to investigate the 
peptide. A quantitative structure-property relationship (QSPR) study is performed, using the new CP-
response, to identify the structural features determining cell-penetrating properties of peptides.  
Chapter III describes the method for an objective and overall comparison of peptides regarding their 
BBB influx. Therefore, four different BBB influx response types were selected for which quantitative 
data are available in the Brainpeps database. Based on the distribution of the available data, a 
classification system and derived unified BBB influx reponse (BBBin) is proposed and its use and 
possible applications are demonstrated.  
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Prior to performing the BBB transport studies, the quality of the used peptides is verified, which is 
described in Chapter IV. Five chromatographic systems are used to perform the quality control of five 
cationic CPPs and to identify the most suitable C18-chromatographic method for the quality control 
(QC) of these cationic peptides. The use of single quad MS detectors during QC of these peptides is 
indicated. 
Chapter V comprises the in vivo BBB transport study of five CPPs, selected based on the different 
identified CPP-subgroups and CP-response described in Chapter II, as well as of four PrAMPs and 
three disulfide-rich (cyclic) peptides, which are “new” CPPs that are demonstrated to fit in the 
chemical space of the “traditional” CPPs. The brain influx and efflux characteristics, as well as the 
parenchymal/capillary distribution and tissue distribution are investigated. The in vitro metabolic 
stability in serum and several tissue homogenates is also verified. For the CPPs, the regional brain 
distribution and possible brain influx mechanism is evaluated. Finally, the obtained BBB transport 
characteristics are linked with the cell-penetrating properties of the selected peptides. 
At last, in Chapter VI, the current regulatory status for the development of geriatric medicines is 
provided. The views of the different involved stakeholders are explained and the current challenges 
encountered in this field are identified. While this study is not immediately related to the laboratory-
based experimental research of the previous chapters, it is a pertinent regulatory issue which is to 
some extent linked to the BBB functionality. 
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“The voyage of discovery lies not in seeking new horizons,  
but in seeing with new eyes” 
 
Marcel Proust  
(°1871 - †1922, French novelist) 
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ABSTRACT 
Cell-penetrating peptides (CPPs) are a promising tool to overcome cell membrane barriers. They 
have already been successfully applied as carriers for several problematic cargoes, like e.g. plasmid 
DNA and (si)RNA, opening doors for new therapeutics. Cellular uptake studies of these peptides 
suffer from inconsistencies in used techniques and other experimental conditions, leading to 
uncertainties about their uptake mechanisms and structural properties. To clarify the structural 
characteristics influencing the cell-penetrating properties of peptides, the chemical-functional 
space of peptides, already investigated for cellular uptake, was explored. For 186 peptides, a new 
cell-penetrating (CP) response was proposed, based upon the scattered quantitative results for 
cellular influx available in the literature. Principal component analysis (PCA) and a quantitative 
structure-property relationship study (QSPR), using chemo-molecular descriptors and our newly 
defined CP-response, learned that besides typical well-known properties of CPPs, i.e. positive 
charge and amphipathicity, the shape, structure complexity and the 3D-pattern of constituting 
atoms influence the cellular uptake capacity of peptides. 
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CHAPTER II 
CHEMICAL-FUNCTIONAL DIVERSITY IN  
CELL-PENETRATING PEPTIDES 
Main focus in this chapter: 
 To explore the chemical-functional space of cell-penetrating peptides. 
 To present a unified response for cell-penetrating properties of peptides allowing their direct 
comparison.  
 To identify structural properties that determine cellular uptake of peptides. 
 
1. DIVERSITY ASPECTS OF CELL-PENETRATING PEPTIDES 
Since the discovery about 20 years ago by Frankel and Pabo that the Tat protein of the human 
immunodeficiency virus (HIV-1) can enter cells [1], cell-penetrating peptides (CPPs) are an 
increasingly growing part of fundamental and applied biomedical research. Throughout the 
literature, cell-penetrating peptides are traditionally defined as containing less than 40 amino acids, 
characterized by a net positive charge, which are able to cross cell barriers without causing 
significant membrane damage [2]. This property makes CPPs suitable to deliver hydrophilic 
macromolecules into the cell interior and to the different cellular compartments in vitro and in vivo 
[3]. They have already been successfully applied as carriers for cell membrane-impermeable cargoes 
like plasmid DNA, oligonucleotides, short interfering RNA ((si)RNA), peptide-nucleic acids (PNA), 
proteins and other peptides, small molecules and liposome nanoparticles [4]. This implies that doors 
have been opened to new efficient (peptide) drugs [5]. 
During the last decade, several hundreds of CPPs have already been reported in the literature. In 
contrast to the traditional definition, CPPs actually present a chemically diverse group of peptides, 
showing a variety in constituent amino acids and 3D-structure. Three major classes can be 
distinguished: cationic, amphipathic and hydrophobic CPPs. This structural diversity accounts for the 
difference in uptake mechanism and level under different conditions between the groups of CPPs. 
Moreover, coupling the CPP to a cargo can also influence the level and mode of uptake into the cell 
[6]. Only a few structure-activity relationship (SAR) studies have tried to reveal which structural 
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features are crucial for cellular uptake [7-16]. Hydrophobic α-helical structures seem to be important, 
as well as the positive charges from basic amino acids, with arginine favored over lysine. Although 
equally contributing to the overall charge, the guanidinum group of arginine can donate two 
hydrogen bonds compared to one by lysine. Other factors apparently influencing cellular uptake are 
the peptide length and the conformation of the structure, which was demonstrated by the difference 
in cellular influx for pVEC and its scrambled analogue [2,17]. The latter showed a reduced uptake into 
the cell, probably due to the loss of the N-terminal hydrophobic domain [7]. The influence of the 
peptide length was demonstrated for the SV40 T antigen, which showed an increase in cellular influx 
by adding a N-terminal sequence [17].  
The available SAR studies only cover a limited set out of the diverse group of CPPs. Moreover, some 
publications show contradictory results [8,9], possibly due to different experimental set-ups. This 
impedes drawing general conclusions about the structural features important for cellular uptake. 
Furthermore, the uptake mechanism of the different CPP groups is still under debate. Today, 
endocytosis (energy-dependent) and direct penetration (energy-independent) are suggested to be 
the two major cellular uptake mechanisms. Depending on the experimental conditions, CPPs use two 
or more different mechanisms [2].  
One approach for predicting CPPs is trial and error, which implies identifying sequences of a suitable 
length and rich in positive charges in a protein structure [18]. Another approach are the Sandberg 
expanded z-descriptors, used by Hällbrink et al. [19]. They calculated the bulk property values for a 
training set of known CPPs and known non-penetrating peptides and averaged over the total number 
of amino acids. The most relevant descriptors were Z1, Z2 and Z3, describing respectively 
lipophilicity, steric bulk properties and polarity, the latter having the highest predictive power. Cell-
penetrating properties of new sequences were predicted based on whether their bulk property 
values fall within preset intervals, derived from the values of the training set. Z-descriptors make it 
possible to predict cell-penetrating properties in silico, but a major disadvantage is that the sum of 
descriptors is calculated, hereby neglecting the order of the amino acids. Moreover, the Tat peptide 
was not considered a CPP by their search criteria [19]. Another way to predict CPPs is data mining, 
which is based on finding similarity patterns in a large set of (experimental) data [18]. Artificial neural 
networks have already been used by Karelson and Dobchev to predict CPPs, based on quantitative 
structure-activity relationship (QSAR) derived features of a training set of about 100 known (non-) 
penetrating peptides [20]. Sanders et al. used support vector machine (SVM) classifiers, based on 
primary features derived from the biochemical properties of 111 known CPPs and 34 non-CPPs, to 
predict cell-penetrating properties [21]. The authors could experimentally confirm the cell-
penetrating ability of the SVM-classified CPPs. As primary biochemical properties of peptides were 
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used, their classifiers provided insight in the structural requirements for cellular penetration, e.g. 
positional preference for certain amino acids, like positively charged and aromatic residues. 
One can conclude that, although CPPs have been studied for over 20 years, a lot of structural and 
mechanistic properties still need to be unraveled. Furthermore, it is obvious that the variety of 
techniques and experimental conditions used to quantify the cellular uptake of CPPs, impedes to 
directly compare their extent of uptake. Together with the fact that the CPPs differ structurally and 
mechanistically, controversies about the uptake mechanisms and artifactual results in the past [22], 
make it difficult to predict whether a peptide is cell-penetrating or not.  
In this article, we explored the chemical space of a set of 186 peptides, for which quantitative data 
for cellular uptake are available, by use of chemo-molecular descriptors, which numerically express 
the peptide structure. In addition, we defined a new cell-penetrating (CP)-response, in order to 
compare the cell-penetrating properties of these peptides in a one-merit figure. This CP-response 
allows the use and comparison of experimental data obtained with a different experimental set-up. 
By combining the chemical descriptors and the CP-responses, biomolecular modeling and clustering 
of peptides was performed. Our results confirm already described determining features for cellular 
uptake, but also provide new insights in structural requirements for cellular uptake of peptides. 
 
2. MULTIVARIATE DATA ANALYSIS METHODS 
Data 
Articles describing the uptake of CPPs covering the period 2007 – March 2012, were gathered using 
the search engines Web of Knowledge, Google and PubMed. The terms “cell penetrating peptides”, 
“uptake cell penetrating peptides”, “protein transduction domain” each separately, as well as 
“cellular uptake”, “characterization”, “kinetics”, “quantification cellular uptake” and “studying 
uptake”, using the Boolean operator “AND” were used. Specific names of known CPPs (e.g. 
penetratin) were also included as search terms. More publications were obtained by searching in the 
reference list of suitable articles and reviews. This resulted in publications dating before 2007 (1998-
2006). Only those were withheld, where the experimental set-up was correct, i.e. use of non-fixed 
cells and removing or quenching of extracellular bound peptide [22]. Moreover, the publications 
should contain quantitative data or graphs expressing the cellular uptake of CPPs. When no 
quantitative data were explicitly mentioned in the text, these data were deduced from the available 
graphs. 
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Calculating chemo-molecular descriptors 
Before the chemo-molecular descriptors of the 186 selected peptides could be calculated, the MM+ 
in vacuo optimized structure of the peptides (not amidated), representing the most fundamental 
peptide structure, was drawn and optimized using HyperChem 8.0 (Hypercube, Gainesville, FL, USA). 
The geometry optimization was obtained by the molecular mechanics force field method using the 
Polak–Ribière conjugate gradient algorithm with a root mean square gradient of 0.1 kcal/(Å × mol) as 
stop criterion. Afterwards, these Cartesian coordinate matrices were used to calculate more than 
3000 descriptors, using Dragon 5.5 (Talete, Milan, Italy), HyperChem 8.0 and MarvinSketch 5.10.3 
(ChemAxon, Budapest, Hungary) software programs. The specific peptide descriptor LogSumAA, 
introduced by our research group, was also included in the descriptor set [23]. The non-
discriminative descriptors, i.e. constant for all peptides, and one of two highly correlated descriptors, 
calculated using the Pearson correlation coefficient (absolute correlation > 0.95), were eliminated, 
resulting in a final 186 × 454 data matrix for the original descriptors. When all descriptors were 
divided by the molecular weight, a data matrix of 186 × 416 was obtained. Next, the data were 
transformed by z-scaling, ensuring equal contribution of each descriptor to the resulting model [24]. 
 
Multivariate data analysis 
Multivariate data analyses of the data matrix of descriptors were performed using Principal 
Component Analysis (PCA) and Hierarchical Cluster Analysis (HCA) with SIMCA-P+ 12.0.0.0 (Umetrics 
AB, Umeå, Sweden) and SPSS Statistics 20.0.0 (IBM Corp., Armonk, NY, USA) software programs, 
respectively. Average-linkage HCA clustering was performed using the Euclidean distance as the 
dissimilarity criterion. After a first PCA analysis of the data set, feature selection was performed by 
selecting the descriptors having a predicted variation value of more than 0.30, resulting in a 186 × 
248 data matrix. For the descriptor set divided by the molecular weight, a 186 × 210 matrix was 
obtained. 
Multiple Linear Regression (MLR) analysis of the chemo-molecular descriptors, using SPSS Statistics 
20.0.0, was performed to build a predictive model for cellular uptake of CPPs. The stepwise method 
was performed during the MLR process to identify the most significant descriptors using the 
following criteria: probability of F to enter ≤ 0.05 and probability of F to remove ≥ 0.10. After 
eliminating 12 outliers identified by the Grubbs outlier test (α = 0.05), the CP-responses of 174 
peptides were used to build the model (information about the outliers see Table S2 of the 
Supplementary Information). In order to identify the descriptors robustly influencing the CP-
response, a noise factor of 0.90, 0.95, 1.00, 1.05 or 1.10 was randomly introduced into the CP-
responses. The in silico noised responses cover a variability with a range of 20%, an arbitrarily 
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assigned value lower than the experimental variability of the CP-responses, but this introduced 
variability allowed the identification of robust descriptors, which was the purpose of this robustness 
test. 
 
Statistics 
All statistical analyses of the data were performed using SPSS Statistics 20.0.0 software. Throughout 
this article, the median of data sets was used as the best measure for central tendency for not 
normally distributed data. 
 
3. EXPLORATION OF THE CHEMICAL-FUNCTIONAL SPACE OF CELL-
PENETRATING PEPTIDES 
Data 
Studies were selected if protocols were used in which the cellular uptake was determined in non-
fixed cells and after removing or quenching of extracellular bound peptide according to Richard et al. 
[22]. Only pure peptides, not coupled to cargoes or to fatty acid chains, were withheld for this study. 
At last, we selected only those peptides for which standardizing to the cellular influx of penetratin 
was possible, allowing to calculate the CP-response for cellular uptake. Finally, a data set of 186 
peptides was obtained, showing high to no or (very) low cellular uptake [7,9,11-13,16,17,25-69] (see 
Table S1 of the Supplementary Information). The different studies showed a remarkable variety in 
used techniques and operational parameters to test cellular uptake (Table 1).  
Inherent to the different techniques used, the protocols of the experiments varied between research 
groups. This may explain the inconsistent cellular uptake results for some CPPs in the literature, like 
Tat 48-60, which normally demonstrates a cellular uptake within the same range as penetratin and 
R9, but was not in reference [17]. The model amphipathic peptide (MAP) showed an unusual low 
uptake in the study of Wada et al., which is explained by the cell-specific uptake of this CPP [52].  
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Table 1. Experimental differences between studies for cellular uptake of peptides. 
Operational parameter Examples 
Technique 
Spectrofluorometry MALDI-TOF MS Confocal laser scanning microscopy (CLSM) 
RP-HPLC Flow cytometry (FACS) Atomic Absorption Spectrometry 
Scintillometry Splice correction assay Quantitative analysis of CLSM images 
Fluorescence microscopy   
Positive control 
No Tat 48-60 TP10 
Penetratin Tat 47-57 Transportan 
MAP R9 YGR6 
pVEC D-R9 R8 
Negative control 
No Dextran Perforin 
No peptide used YDEGE STRRSAMAPR 
Green fluorescent peptide YDEEGGG APRTPGGRR 
Units of quantitative data 
µM or nM pmol or nmol/mg cell protein SI/mg cell protein 
ng/mg cell protein a.u. Fold change in GeoMean fluorescence 
Mean fluorescence intensity RLU/mg Mean fluorescence intensity/mg cell protein 
Fold/basal fluorescence Relative fluorescence intensity Relative cellular uptake (to control) 
% of total peptide % of added peptide % cellular uptake 
Cellular fluorescence Fold change in FITC medium  
Label 
FITC 5,6-carboxyfluorescein 2-aminobenzoic acid 
Biotin Deuterium Rhodamine 
NBD TAMRA Alexa 488 
GaDOTA Texas Red 125I 
Cell line 
AEC BMC HaCaT HEK293 MC57 S. cerevisiae 
HBCEC CHO (-K1) Caco-2 HL60 A549 C. albicans 
bEnd U2OS Cos-7 MDCK A431 E. coli 
MCF-7 Jurkat MOLT-4 HeLa Hela pLuc705 B. megaterium 
NIH-3T3 RAW264.7 BA/F3 K562 BT-20 N2a 
KB RAW U373 MG Daudi Sf9 MDA-MB-231 
HT-29 SKMel37 DAMI A549 U251 KG1a 
TF-1 ESC NC Sca-1+Lin- HEK293 L929 
Calu-3 MDA HER TM12 CCRF-CEM  
Incubation concentration 
10 nM 200 nM 0.1 µM 0.33 µM 0.4 µM 0.8 µM 
1 µM 1.8 µM 2 µM 2.5 µM 3 µM 3.1 µM 
3.5 µM 4 µM 4.5 µM 5 µM 6 µM 6.3 µM 
7.5 µM 10 µM 12.5 µM 15 µM 20 µM 25 µM 
30 µM 40 µM 50 µM 100 µM 110 µM 200 µM 
400 µM 800 µM 1.6 mM    
 
Defining a CP-response 
Because of the variety in experimental settings throughout the literature, the cellular uptake results 
of the available CPPs are difficult to be directly compared and are expressed using different units, as 
listed in Table 1. Therefore, a CP-response, a unified response expressing the cellular uptake 
efficiency of CPPs, would be of great help to obtain a clear overview of the cellular influx capacities of 
the available CPPs. 
Penetratin, one of the first discovered CPPs and often described in the literature, is the most used 
positive control in uptake studies of other peptides. Therefore, penetratin was considered as a 
general positive control and used to normalize the responses for cellular uptake. Before a CP-
response could be defined, several assumptions were made: (1) cell and label differences were 
neglected. As shown in Table 1, about 50 different cell lines and 12 different labels were used. The 
different nature of the labels was not considered when chemically defining the peptide structure. (2) 
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The uptake of the negative control was considered to be negligible. (3) The maximal values of cellular 
uptake during an experiment were used to cope with a possible time effect. (4) If a positive control 
was used in a study, it was considered as an internal standard and could be used to average 
variations in operational parameters. Finally, (5) a linear correlation between the extracellular and 
intracellular peptide concentration was assumed, although it cannot be excluded that there is a 
specific concentration effect [37,39,41,42,60]. This last assumption was necessary, because to 
calculate the CP-response, the quantitative value for cellular uptake was first corrected for the 
incubation (extracellular) concentration resulting in a concentration normalized response. Then, the 
latter response was normalized to the positive control penetratin, according to the following 
equation:  
 
penpen
CPPCPP
CP
CP         (1) 
where PCPP/CCPP and Ppen/Cpen are the concentration-normalized influx responses for a CPP and 
penetratin respectively in the same study.  
As already mentioned before, not all studies included penetratin as a positive control. When another 
positive control than penetratin was used, the median of all available ratios of that alternative 
positive control over penetratin was used to normalize the response to penetratin:  
 factor response
CP
CP
PCPC
CPPCPP
         (2) 
where PCPP/CCPP is the concentration normalized influx response for a CPP, PPC/CPC for a positive 
control in the same study different from penetratin and the response factor is the median of all 
ratios of the concentration normalized responses of the positive control over the concentration 
normalized responses of penetratin, i.e. the median CP-response of the positive control, as expressed 
in formula (1) (Table 2).  
Table 2. Overview of the used positive controls in studies for cellular uptake of peptides and their median CP-
response (response factor). 
Positive control CP-response 
MAP 2.05 
Penetratin 1.00 
pVEC 1.31 
R9 1.00 
Tat 47-57 0.31 
Tat 48-60 0.22 
TP10 1.64 
 
A third possibility was that no positive control was used in the cellular uptake study. Then, the CP- 
response was calculated using the following equation: 
penpen
CPPCPP
CP
CP        (3) 
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with PCPP/CCPP being the concentration normalized influx response for a CPP and penpen CP  the median 
of all concentration normalized influx responses of penetratin, obtained using the same technique as 
the considered influx response (i.e. having the same unit).  
If more than one CP-response was available for a peptide, the median CP-response was calculated. 
Over all peptides, the CP-response ranged from 0.001378 to 2.744. The ranking of the peptides based 
on their CP-response, roughly corresponded with those found in the literature, e.g. the CP-response 
increased as follows: Tat 48-60 < R9 ≈ penetratin < pVEC < TP10 < MAP < transportan. This was in 
agreement with the overall study conclusions: Tat 48-60 mostly showed the lowest cellular influx 
[17,26,30,31,33,34,38], followed by R9 and penetratin [17,25,26,28,30-34,38]. The peptides pVEC, 
TP10, MAP and transportan showed higher cellular influx than Tat 48-60, penetratin and R9. 
Transportan mostly showed a higher cellular influx than TP10 [10,28]. Moreover, as a proof of 
concept, we investigated all manuscripts providing the quantitative data for cellular influx for the 186 
peptides and compiled for each peptide how the authors estimated (subjectively) their cell-
penetrating properties (see Table S3 of the Supplementary Information). In these studies, five 
classifications could be distinguished: no CPP, low CPP (described as low CPP, low efficient, low 
effective, slow, nearly unmeasurable), medium CPP (described as medium CPP, efficient, effective) 
and high CPP (described as high CPP, highly, extremely effective, extremely efficient, rapid). When 
the authors only described the peptide as cell-penetrating, without any scaling or subjective ranking, 
these peptides were classified as CPP. Next, the distribution of the CP-responses in the five different 
classes was evaluated using box-and-whisker plots (see Figure 1). The median CP-response increased 
over the different classes from no CPP over low CPP, medium CPP and CPP to high CPP, indicating 
that peptides having a high or low calculated CP-response were also estimated in the same way by 
the researchers. From Figure 1 can be concluded that the researchers who investigated peptide 80 
(MitP) were rather pessimistic when evaluating the uptake data: the authors concluded a medium 
cellular uptake, while a high CP-response was calculated. This comparative analysis thus 
demonstrated the validity of the CP-response, being indicative for the extent of cell-penetration of a 
peptide, as well as showed the use of this unified response during the evaluation of quantitative data 
for cellular uptake of peptides. 
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Figure 1. Distribution of the CP-responses in five different CPP classes as defined by the authors. The median 
CP-response increases from class no to high CPP, showing the validity of the CP-response to rank peptides 
according to their cell-penetrating properties. 
 
Exploration of the chemical space of cell-penetrating peptides 
To determine the chemical space of a set of 186 peptides, which were investigated for cell-
penetrating properties, a PCA and HCA analysis of their calculated descriptors was performed. The 
scores plot of the first and the second principal component (PC) of the calculated PCA model 
explained already 62.6% of the total variability (Table 3).  
Table 3. Summary of the PCA analysis of the original descriptors, describing the eigenvalues of the covariance 
matrix, the total variance explained (cumulative R²) and the predictive ability (cumulative Q²). 
Principal Component Eigenvalue Cumulative R² Cumulative Q² 
1 86.9 0.467 0.448 
2 29.5 0.626 0.602 
3 12.1 0.691 0.639 
4 11.6 0.753 0.701 
5 5.74 0.784 0.720 
6 5.16 0.812 0.743 
7 4.42 0.836 0.764 
8 3.53 0.854 0.781 
9 2.58 0.868 0.789 
10 2.17 0.880 0.797 
11 1.94 0.890 0.807 
 
Based on the dendrogram of the HCA analysis and the scores plot of the first two PCs of the PCA 
analysis, the 186 peptides were categorized into six main clusters, which could be subdivided into 
eight subclusters (Figure 2). 
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Figure 2. Scores plot of the first versus the second principal component of the PCA analysis of 186 peptides 
(represented by the black triangles). The six main clusters of peptides are indicated by a bold line, while the 
eight subclusters are encircled by a thin line. Along the principal axes, examples of descriptors strongly 
influencing the principal components are indicated as derived from the loadings plot.  
 
The loadings plot, which displays the relationship among the variables, can be used to explain 
interesting patterns in the scores plot, i.e. which variables or descriptors determine the observed 
clusters of peptides [24]. The loadings plot indicated that the first principle component (PC1) is 
mainly influenced by the mass, shape and connectivity of the peptides, while the second principle 
component (PC2) was determined by hydrophilicity and lipophilicity. In Figure 2, the peptides with 
high molecular weight (MW), surface area, molecular volume and number of hydrogen acceptor 
atoms were situated on the right along the horizontal axis and inherently these peptides had a higher 
number of peptide bonds (represented by the descriptors nRCONHR and C-040). The peptides on the 
right were also characterized by a more voluminous, complex and less compact structure. On the 
other side of the horizontal axis, the smaller, more symmetrical and compact peptides were located. 
On the PC2 axis, peptides mainly consisting of hydrophilic amino acids, like the basic arginine and 
lysine residues, represented by the high pI values of these peptides, were situated at the top. When 
descending to the bottom, the peptides turn more hydrophobic, indicated by higher log P values, 
hydration energy and BLI values (Kier Benzene Likeliness index), the latter describing the extent of 
molecular aromaticity.  
The light green cluster at the left in the scores plot represented short oligo-arginines (R3-R5), 
showing a very low median CP-response of 0.0769. The light blue subclusters contained cationic 
peptides, which differed in charge and peptide length (increasing from the left to the right). The light 
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blue dashed-dotted subcluster (e.g. SynB3 and polyomavirus Vp1), showed a low median CP-
response of 0.0392, while the dashed (e.g. R6, R7 and HATF3) and dotted (e.g. R9 and Tat 48-60) light 
blue subclusters had a mediocre cellular influx with median CP-responses of 0.323 and 0.464, 
respectively. The yellow and orange subclusters, which were centrally located in the PCA scores plot, 
formed mixed clusters, as they contained both cationic and amphipathic peptides. The pink and 
purple amphipathic subclusters had median CP-responses of 0.181 and 0.302, respectively. The 
yellow subcluster (e.g. pVEC and penetratin), orange subcluster (e.g. PasTat and M918) and the dark 
green subcluster (e.g. transportan and MPG) had the highest values for the median CP-response, 
ranging from 0.511 to 0.729 and 0.798, respectively. These peptides were cationic and/or 
amphipathic and are composed of 15-27 amino acids. Remarkably, the group of peptides, showing a 
high CP-response could be subdivided in two groups: those having a positive PC2 value, which were 
mainly arginine rich (yellow and orange subcluster) and those having a negative PC2 value (dark 
green subcluster), which were mainly lysine rich. Although it was previously stated that arginine 
residues are favorable over lysine for cellular influx [2], our data did not confirm this statement. 
Peptides showing the highest CP-response had a high charge density or show amphipathicity. The 
latter peptides were centrally located in the scores plot and were rich in sulfur-containing residues, 
especially methionine, as well as in aromatic amino acids.  
The hydrophobic peptides, which are alanine, glycine, leucine, proline and valine rich, were located 
at the bottom of the scores plot and showed a mediocre, but significant influx (median CP-response 
of 0.354). The peptides of the red cluster were highly charged and showed a high CP-response 
(median of 0.764). The cluster was mainly composed of oligo-arginines of more than 15 residues, 
which are known for their cellular toxicity [12]. The black cluster consisted of voluminous, high 
molecular weight peptides, i.a. some peptoid structures, showing a very low cellular influx (median 
CP-response of 0.166). 
As PC1 was mainly dominated by the molecular weight, the same PCA analysis was performed, but 
using all descriptors divided by the molecular weight in order to neutralize its MW size-effect, 
although some descriptors were already corrected for the MW. However, this modification of the 
descriptors did not provide additional information. The calculated PCA model resulted in similar 
clusters of CPPs (see Table S4 and Figure S1 of the Supplementary Information).  
 
Functional diversity of cell-penetrating peptides 
Using our newly defined CP-response and the calculated chemo-molecular descriptors of the 
peptides, a stepwise MLR model was constructed to predict the cell-penetrating ability of peptides. 
In order to find the descriptors most robustly influencing the CP-response, new datasets were 
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created by introducing a random response noise covering 20% of variability (MLR1 to MLR10). For 
these data sets, MLR analyses were performed allowing to identify the descriptors that significantly, 
based upon inclusion into the MLR model, and robustly influence the CP-response, i.e. descriptors 
which were withheld in more than half of the MLR-models (Table 4).  
Table 4. Overview of the most robust descriptors influencing the CP-responses in the 11 MLR data sets. 
 MLR MLR1 MLR2 MLR3 MLR4 MLR5 MLR6 MLR7 MLR8 MLR9 MLR10 Mean 
R² 0.621 0.589 0.493 0.515 0.619 0.617 0.508 0.587 0.525 0.572 0.615 0.569 
Adjusted 
R² 
0.577 0.545 0.458 0.478 0.578 0.572 0.471 0.542 0.487 0.532 0.567 0.528 
Descriptor Coefficients1 # 
B04[N-N] 0.175 0.285 0.287 0.298 0.228 0.154 0.183 0.251 0.203 0.305 0.187 11 
GATS5m 0.401 0.573 0.321 0.298 0.541 0.435 0.389 0.443 0.396 0.612 0.670 11 
G2e -0.184 -0.141 -0.186 -0.221 -0.205 -0.186 -0.218 -0.226 -0.215 -0.177 -0.181 11 
nCt 0.465 0.482 0.570 0.547 - 0.453 0.491 0.588 0.555 0.215 - 9 
nROR 0.244 0.198 - - 0.322 0.231 - - - 0.300 0.320 6 
T(N..S) 0.912 0.461 - - 0.897 0.940 - - - 0.799 0.607 6 
G3u -0.184 -0.137 - - -0.224 -0.183 - - - -0.190 - 5 
Mp 0.548 0.352 - - 0.525 0.553 - 0.307 - - - 5 
Mor15p -0.656 - - - -0.791 -0.673 - - - -0.366 -0.275 5 
Mor26m -0.319 - -0.202 -0.209 -0.361 -0.318 - - -0.191 -0.305 - 7 
GATS7e - - 0.922 1.066 - - 1.127 1.233 1.143 - - 5 
GATS7p - - -0.682 -0.761 - - -0.798 -0.944 -0.806 - - 5 
Mor16p - -0.316 -0.385 -0.419 - - -0.478 -0.482 -0.391 - -0.301 7 
Mor27m - - -0.410 -0.404 - - -0.327 -0.298 -0.387 - - 5 
Mor27e - - 0.248 0.291 - - 0.202 0.217 0.274 - - 5 
1For each model, the coefficients of the significant descriptors are indicated. 
 
In Table 5, the meaning of these robust descriptors influencing the cell-penetrating properties are 
listed.  
Table 5. Meanings of the robust descriptors influencing significantly the CP-response of peptides. 
Descriptor Meaning Class 
B04[N-N] Presence/absence of N-N  at topological distance 4 2D binary fingerprints 
GATS5m Geary autocorrelation - lag 5/weighted by atomic masses  2D autocorrelations 
G2e 
2st component symmetry directional WHIM index/weighted by 
atomic Sanderson electronegativities 
WHIM1 descriptors 
nCt Number of total tertiary C (sp3)  Functional group counts 
nROR Number of ethers (aliphatic)  Functional group counts 
T(N..S) Sum of topological distances between N..S  Topological descriptors 
G3u 
3rd component symmetry directional WHIM index/unweighted
  
WHIM descriptors 
Mp Mean atomic polarizability (scaled on Carbon atom)  
Constitutional 
descriptors 
Mor15p 3D-MoRSE - signal 15/weighted by atomic polarizabilities  3D-MoRSE² descriptors 
Mor26m 3D-MoRSE - signal 26/weighted by atomic masses 3D-MoRSE² descriptors 
GATS7e 
Geary autocorrelation - lag 7/weighted by atomic Sanderson 
electronegativities 
2D autocorrelations 
GATS7p Geary autocorrelation - lag 7/weighted by atomic polarizabilities 2D autocorrelations 
Mor16p 3D-MoRSE - signal 16/weighted by atomic polarizabilities 3D-MoRSE² descriptors 
Mor27m 3D-MoRSE - signal 27/weighted by atomic masses 3D-MoRSE² descriptors 
Mor27e 
3D-MoRSE - signal 27/weighted by atomic Sanderson 
electronegativities 
3D-MoRSE² descriptors 
1Weighted Holistic Invariant Molecular descriptors 
²3D-Molecular Representation of Structures based on Electron diffraction 
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The descriptor B04[N-N] is a 2D-binary fingerprint descriptor, representing the presence or absence 
of the specific atom pair N-N at a topological distance of four bonds. Our models indicated that the 
presence of such an N-N pair has a positive influence on the CP-response. When looking at the amino 
acid structures, this N-N bond at topological distance four is found in asparagine and histidine 
residues. The latter is a weak α-helix former and thus may be important to establish the secondary 
amphipathic structure of peptides [70]. The GATS5m, GATS7p and GATS7e descriptors are Geary 2D-
autocorrelation descriptors, which describe the topology of the peptide in association with atomic 
masses (m), polarizabilities (p) and Sanderson electronegativities (e). At specific path length (lag) five, 
the atomic masses have a high positive contribution to the cell-penetrating properties, while at lag 
seven, a positive (weighted by atomic Sanderson electronegativities) or negative (weighted by atomic 
polarizabilities) influence on our CP-response was observed. GATS7e shows the dispersion of 
electronegative atoms at a topological distance equal to seven bonds in a peptide, while the value of 
GATS7p shows the importance of atomic polarizabilities over the same topological distance. Peptides 
having high (GATS5m and GATS7e) or low (GATS7p) values of these descriptors, were rich in basic 
amino acids, arginine and lysine, as well as the aromatic amino acid tryptophan. 
3D-Molecule Representation of Structures based on Electron diffraction (3D-MoRSE) descriptors are 
3D-molecular descriptors derived from scattering transform functions, reflecting various 
physicochemical properties, like atomic polarizability (signals 15 and 16), atomic masses (signals 26 
and 27) and atomic electronegativity (signal 27) [71]. From these 3D-MoRSE descriptors could be 
derived that the position of these physicochemical properties in the 3D-space is crucial for cell-
penetrating properties. Based on these descriptors, a favorable cellular influx was predicted for the 
amphipathic and/or cationic subclusters of the PCA analysis, i.e. the dark green, pink, purple and 
yellow subclusters. Moreover, the peptides belonging to the dark green and yellow subclusters 
showed the highest median CP-response, which was also predicted based on their values of the 
robust 3D-MoRSE descriptors. 3D-descriptors characterizing the symmetry of the peptides also 
robustly influenced the CP-response: the symmetry-directional WHIM descriptors G2e (weighted by 
atomic Sanderson electronegativities) and G3u (unweighted) negatively influenced the cell-
penetrating properties, indicating that the cellular influx of peptides increased with decreasing 
peptide symmetry [71]. Peptides containing branched and hydrophobic amino acids, e.g. valine, 
leucine and isoleucine, as indicated by the descriptor nCt, accounting for the number of tertiary 
carbon atoms showed a higher CP-response. Also the T(N..S) descriptor referring to the presence of 
sulfur-containing amino acids, and the mean atomic polarizability (Mp) contributed positively to the 
cellular penetration. Methionine (α-helix former) as well as the hydrophobic amino acids (favor β 
strands) are important for establishing a secondary amphipathic structure. Finally, the nROR 
descriptor, which was an unexpected robust descriptor, also positively influenced the CP-response. 
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The cationic amphiphilic polyproline helices (CAPHs) contain such ether functions to link the 
hydrophobic and hydrophilic residues. Although the MLR analysis did not directly point to the 
importance of a positive charge for cellular uptake, the information contained in the robust 
descriptors indicated its influence as well as of a secondary amphipathic structure. 
 
4. EVALUATION OF THE CP-RESPONSE AND THE CHEMICAL SPACE OF 
CELL-PENETRATING PEPTIDES 
Studies of the cellular uptake of CPPs demonstrate a great variety in experimental conditions, as 
illustrated in Table 1. These differences in used techniques and operational parameters, are at least 
partly responsible for discrepancies in conclusions about the cellular uptake of certain CPPs, like e.g. 
the uptake mechanism. In Table S3, the available information on the mechanism of cellular uptake of 
our selected peptides is listed. There are three main mechanisms of cellular entry: (1) direct 
penetration, which can be subdivided into (a) inverted micelle formation, (b) pore formation, (c) 
carpet-like model, (d) membrane thinning and (e) nucleation zones. The second mechanism is (2) 
endocytosis, with subcategories (a) macropinocytosis, (b) dependent on coat proteins and (c) 
independent on coat proteins. Some publications also define a third mechanism: (3) energy-
dependent, but not endocytosis (exact mechanism not specified by authors) [2,12,72,73]. From Table 
S3 can be derived that the different studies on the uptake mechanism of CPPs show an inconsistency 
in cellular uptake mechanism. Cell-penetrating peptides use different mechanisms of entry, either 
simultaneously or as function of experimental factors, like the extracellular concentration, cell line, 
presence of a cargo, incubation time and temperature [2,42,44]. 
Clearly, there is an urgent need for harmonization of the experimental conditions in the 
investigations of cellular uptake of peptides, like other authors have already suggested in the past 
[18,20]. Especially, the use of a standard positive control or controls, e.g. penetratin, is 
recommended, as it allows to neutralize to some extent the differences in experimental conditions. 
Therefore, we defined a CP-response, a unified response which allows the comparison of 
experimental data of the cellular influx of peptides. Several assumptions were made, which cause, 
together with the existing experimental variations, some variability in our CP-response. Nevertheless, 
the hitherto described CPPs can be compared using this CP-response and new conclusions about the 
structure-activity modeling of these peptides can be drawn.   
As a first assumption, cell and label differences were neglected, as a wide range of cell lines and 
detection labels are used throughout the literature. It is clear that different cell lines have different 
membrane characteristics, influencing the used mechanism and quantity of cellular uptake of CPPs 
[17,22,25,27,30,32-34,37,38,40,41,43-45,53,55,56,58,64-67]. The correlation between the incubated 
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cell line and the cellular uptake properties of CPPs deserves a more thorough investigation, but was 
outside the scope of this study. We also assumed penetratin as a general positive control, because it 
is quite often used and is well characterized, being one of the first described CPPs. It was also 
necessary to correct the uptake responses for the incubation concentration, as there exists a clear 
relationship between the extra- and intracellular concentration of CPPs. Therefore, we assumed a 
simple linear relationship, justified by the fact that only a few studies have already investigated the 
internalization dependence on the extracellular peptide concentration, not allowing more complex 
models to be used. For most CPPs, there is indeed a correlation between the intracellular and the 
extracellular concentration [37,39,41,42,60]. On the other hand, some peptides, like R9, hLF and Tat 
47-57, show a sudden sharp increase in intracellular concentration, when a certain extracellular 
concentration is reached [41,42]. Still, for other peptides, the extracellular concentration needs to 
exceed a threshold concentration before cellular uptake takes place. Some authors explain this 
phenomenon by the fact that the uptake mechanism of CPPs depends on the extracellular 
concentration [42]. Moreover, Hällbrink et al. [74] showed that the uptake of CPPs may also be 
dependent on the peptide-to-cell ratio, as demonstrated for MAP and penetratin. Besides, some 
CPPs show toxic effects starting from a certain extracellular concentration [37,39]. Taking the above 
findings in consideration, we visualized the intracellular versus extracellular concentration curve for 
CPPs as a sigmoid (see Figure 3), characterized by a threshold value for influx, which was for all 
available peptide data about 1 µM. When the threshold is reached, the intracellular concentration 
increases in function of the extracellular concentration, followed by flattening of the curve until a 
plateau value for intracellular concentration is reached, possibly due to cell death. The threshold 
value for influx is CPP and cell line dependent. For most CPPs however, only one extracellular 
concentration is investigated, which makes it impossible to reconstruct the full sigmoid curve 
dependence. We applied a linear model, realizing that this approach is an over-simplification, leading 
to increased variability and bias. It is clear that studying the correlations between intracellular and 
extracellular concentration, would give more insights into the uptake mechanisms of the peptides, as 
well as into the toxicity profile.  
 
CHAPTER II – CHEMICAL-FUNCTIONAL DIVERSITY IN CELL-PENETRATING PEPTIDES 
  
 
54 
 
Figure 3. Supposed dependence of the intracellular CPP concentration on the extracellular concentration when 
performing cellular influx studies. 
Our data set contained peptides showing very low to high cellular influx (CP-response of 0.001378 to 
2.744), indicating that our data set covered a sufficiently wide range of CP-responses. Moreover, the 
ranking of the peptides based on the CP-responses, corresponds roughly with those found in the 
literature, when considering the most studied and compared CPPs. This indicates that our approach 
is a valuable quantitative way to assess CPP properties, which was also demonstrated by the 
evaluation of the distribution of the CP-responses in the five different classes of CPPs as defined by 
the authors. From Figure 1 can be derived that the medium CP-response increases over the different 
classes from no CPP to high CPP. Still there exists a clear overlap in CP-responses between the 
different classes. The lower whiskers of the distribution of the medium CPP, CPP and high CPP classes 
are extended to almost zero response, indicating that they also contain non- or low-penetrating 
peptides, according to our proposed CP-response. We evaluated the peptides composing these 
lowest values and concluded that they can often be explained by an incorrect descriptive conclusion 
of the authors. Possible reasons are that the classification was based on experiments without 
trypsinization, while also experiments with trypsinization of the cells were performed, or that much 
higher incubation concentrations than normally applied are used in order to reach cellular uptake, 
leading to low CP-responses as they are concentration corrected [17,51]. Nevertheless, this observed 
consistency strengthens the value of our CP-response.  
The exploration of the chemical space of the 186 peptides, investigated for cell-penetrating 
properties, confirmed some known features about CPPs, supporting our approach, but also revealed 
some new insights in the structural diversity of these peptides. The molecular weight, surface area, 
molecular volume, the number of hydrogen bond acceptors, hydrophobicity and charge determined 
the main clusters in the PCA analysis. These characteristics join with previous findings about 
important properties for cellular influx, i.a. z-scales used by Hällbrink et al. [19]. However, our PCA 
analysis indicated that also the shape and complexity of the structure differ within the group of CPPs. 
In the scores plot of the PCA analysis (Figure 2), there was a clear trend in symmetry, complexity and 
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compactness of the structure: extremes for these descriptors give low CP-responses for the peptides. 
From this exploration of the chemical space of CPPs, it can be derived that not only the constituent 
amino acids determine cell-penetrating properties but also their position. This contrasts the current 
general opinion that the 3D-structure is not significantly influencing the cellular uptake, except for 
the secondary amphipathic CPPs [6]. Moreover, our 3D-structures are calculated based on a 
theoretical phase, i.e. MM+ in vacuo optimized structures according to Hyperchem molecular 
mechanics, which is independent from its biological medium and interactions. 
The light green cluster in Figure 2 consists of oligo-arginines of up to five arginines and shows a very 
low to negligible CP-response, consistent with the conclusions of Mitchell et al. [12]. On the other 
hand, based on the characteristics of the clusters with the highest unified response, high density of 
positive charges and amphipathicity favor cellular uptake. The amphipathic peptides were located 
centrally in the scores plot of the PCA analysis and were characterized by a high extent of sulfur-
containing residues, as well as aromatic amino acids. These features are indeed important for 
establishing a secondary amphipathic structure. According to Chou and Fasman, methionine is a 
strong α-helix former, while the aromatic amino acids, phenylalanine and tryptophan favor the 
formation of β strands by contributing to hydrophobic interactions when establishing this secondary 
structure [70].  
Although MLR only captures a linear correlation between descriptors [21], it gives us valuable 
information about which descriptors significantly influence cellular uptake. By adding a random noise 
around our calculated CP-response, the descriptors most robustly influencing the CP-response, i.e. 
those descriptors which were incorporated in more than half of the obtained MLR models, were 
identified. This MLR analysis revealed that a positive charge, represented by the basic amino acids 
arginine and lysine, and an amphipathic structure are discriminating properties for cellular influx of 
peptides. We also identified the symmetry and the compactness of the peptide structure as 
determining. Furthermore, the 3D-MoRSE descriptors indicate that certain patterns in the molecular 
structure influence whether a peptide is efficiently cell-penetrating or not. This refers to an 
amphipathic structure, or more in general, to recurrent functional groups, like e.g. the guanidinium 
group of arginine. Indeed, based on the 3D-MoRSE descriptors, a favored cellular influx is predicted 
for the amphipathic peptides. The results of the MLR analysis correspond well with the identified 
important features for cellular uptake during the exploration of the chemical space of the 186 
peptides.  
Cell-penetrating peptides form a chemically diverse group of peptides, as we demonstrated during 
the PCA analysis, and are traditionally classified into three chemically different groups [6]: (1) cationic 
CPPs (C), which contain a stretch of positive charges and whose 3D-structure is not an amphipathic 
helix. (2) Amphipathic CPPs (A), which are characterized by a hydrophobic and hydrophilic part by 
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adopting a helix structure. Amphipathic peptides may have a cationic nature (AC) or their hydrophilic 
part can be neutral, anionic or polar (A). The (3) hydrophobic CPPs (H) are peptides containing only 
apolar residues, with low net charge or that have hydrophobic amino acid groups that are crucial for 
cellular uptake. Cationic CPPs may also have a hydrophobic (CH) or amphipathic nature (AC). In Table 
S3, the chemical classes of the individual peptides of our data set are listed and schematically 
visualized in Figure 4. Using this chemical classification method, there is a clear overlap 
demonstrated for the different classes, especially for the amphipathic-cationic peptides.  
We believe that our CP-response, as a more objective and quantitative measure for cellular 
penetration, will foster the discussion of the cellular uptake mechanisms, as well as the definition 
and the classification of the CPPs.  
 
Figure 4. Schematic representation of the CPP chemical classes from our data set. The number of peptides 
attributed to the different classes is indicated.  
 
5. CONCLUSIONS 
When gathering quantitative data for cellular influx of peptides, it was clear that harmonization of 
these studies is highly needed. By defining a CP-response, the quantitative evaluation of the cellular 
influx characteristics of 186 peptides was possible. This CP-response, together with chemo-molecular 
descriptors of the peptides, was used to explore the chemical-functional space of CPPs. Our study 
indicated that besides already reported CPP-determining features, like i.a. positive charge and 
amphipathicity, also the shape, complexity and compactness of the structures, play an import role 
for influx into the cell. As our CP-response is a more objective and quantitative measure for cellular 
penetration of peptides, it will help to classify these peptides, to unravel the different uptake 
mechanisms, as well as to establish a common evaluation tool. 
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SUPPLEMENTARY INFORMATION 
Table S1. Overview of the 186 (non-) CPPs, including their CP-response. 
Peptide 
ID 
Peptide name Sequence 
Number 
of AA 
CP-
response 
Ref.1 
1 pVEC LLIILRRRIRKQAHAHSK 18 1.318 
17, 25, 27, 
53, 66 
2 Tat 48-60 GRKKRRQRRRPPQ 13 0.221 
17, 26, 34, 
38, 66 
3 APH-1 (85-98) VFRFAYYKLLKKA 13 0.188 26 
4 APH-1 (236-246) LRSIQRSLLCK 11 0.039 26 
5 Nicastrin (38-53) RKIYIPLNKTAPCVR 15 0.345 26 
6 Nicastrin (414-434) RRPNQSQPLPPSSLQRFLRAR 21 0.016 26 
7 Nicastrin (616-635) RLPRCVRSTARLARALSPAF 20 0.031 26 
8 Presenilin-1 (97-109) VATIKSVSFYTRK 13 0.008 26 
9 Presenilin-1 (305-317) AQRRVSKNSKYNA 13 0.016 26 
10 D-pVEC lliilrrrirkqahahsk 18 0.824 7, 27, 53 
11 (KFF)3K KFFKFFKFFK 10 1.837 27 
12 Transportan GWTLNSAGYLLGKINLKALAALAKKIL 27 (4.357) 17, 28,  68 
13 TP10 AGYLLGKINLKALAALAKKIL 21 1.641 
28, 30, 32, 
34, 66 
14 MAP KLALKLALKALKAALKLA 18 1.716 
13, 17, 29, 
37, 53 
15 Syn B1 RGGRLSYSRRRFSTSTGR 18 0.063 17, 39 
16 Polyomavirus Vp1 APKRKSGVSK 10 0.028 17 
17 Bac1-15 RRIRPRPPRLPRPRP 15 0.035 17 
18 NF-ĸB VQRKRQKLMP 10 0.025 17 
19 SV40-T antigen PKKKRKV 7 0.028 17 
20 HATF3 ERKKRRRE 8 0.023 17 
21 hCT(9-32) LGTYTQDFNKFHTFPQTAIGVGAP 24 0.024 17 
22 HIV-1 Rev (34-50) TRQARRNRRRRWRERQR 17 1.460 17, 38, 56 
23 Integrin VTVLALGALAGVGVG 15 0.549 17 
24 DPV6 GRPRESGKKRKRKRLKP 17 0.073 17 
25 S413PV ALWKTLLKKVLKAPKKKRKV 20 0.781 17 
26 Pep-1 KETWWETWWTEWSQPKKKRKV 21 0.105 17 
27 MPG GALFLGWLGAAGSTMGAWSQPKKKRKV 27 1.065 17 
28 Poly-P (SAP) VRLPPPVLRPPPVLRPPP 18 0.027 17 
29 R7 RRRRRRR 7 0.395 
12, 16, 17, 
36 
30 R9 RRRRRRRRR 9 1.000 
17, 31, 33, 
41, 42, 47, 
63 
31 pVEC scrambled IAARIKLRSRQHIKLRHL 18 0.101 7, 17 
32 Tat 47-57 YGRKKRRQRRR 11 0.309 
30, 33, 42, 
58 
33 Tat 48-59 GRKKRRQRRRPP 12 0.192 31, 63 
34 M918 MVTVLFRRLRIRRACGPPRVRV 22 (7.158) 32 
35 Penetratin RQIKIWFQNRRMKWKK 16 1.000 33, 39, 44 
36 R11 RRRRRRRRRRR 11 0.211 34 
37 RL9 RRLLRRLRR 9 0.134 35 
38 RW9 RRWWRRWRR 9 1.301 35 
39 R7W RRRRRRRW 8 1.687 36 
40 VP22 NAKTRRHERRRKLAIER 17 0.161 38 
41 D-Syn B1 rggrlsysrrrfststgr 18 0.089 39 
42 Syn B3 RRLSYSRRRF 10 0.126 39 
43 D-Syn B3 rrlsysrrrf 10 0.185 39 
44 Syn B5 RGGRLAYLRRRWAVLGR 17 1.159 39 
45 ARF (1-22) MVRRFLVTLRIRRACGPPRVRV 22 1.641 40 
46 ARF (1-22) scrambled FVTRGCPRRLVARLIRVMVPRR 22 1.296 40 
47 ARF (2-14) VRRFLVTLRIRRA 13 0.950 40 
48 ARF (2-14) scrambled RVRILARFLRTRV 13 0.173 40 
49 ARF (19-31) RVRVFVVHIPRLT 13 1.382 40 
50 ARF (19-31) scrambled VIRVHFRLPVRTV 13 0.259 40 
51 hLF KCFQWQRNMRKVRGPPVSCIKR (disulfide 2-19) 22 0.952 41 
52 MAP (II) KALAALLKKLAKLLAALK 18 0.181 13 
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Peptide 
ID 
Peptide name Sequence 
Number 
of AA 
CP-
response 
Ref.1 
53 MAP (III) KLALKLALKALKAALK 16 0.115 13 
54 MAP (VII) KLALKLALKALQAALQLA 18 0.022 13 
55 MAP (VIII) KLALQLALQALQAALQLA 18 0.243 13 
56 MAP (XI) LKTLATALTKLAKTLTTL 18 0.177 13 
57 MAP (XIII) LKTLTETLKELTKTLTEL 18 0.052 13 
58 MAP (XV) RQIKIWFQNRRMKWKK 16 0.104 13 
59 KLA 1 KLALKLALKAWKAALKLA 18 0.085 13 
60 KLA 2 KLALKAALKAWKAAAKLA 18 0.008 13 
61 KLA 11 KITLKLAIKAWKLALKAA 18 0.025 13 
62 KLA 5 KIAAKSIAKIWKSILKIA 18 0.036 13 
63 KLA 12 KALAKALAKLWKALAKAA 18 0.079 13 
64 KLA 13 KLALKLALKWAKLALKAA 18 0.008 13 
65 KLA 14 KLLAKAAKKWLLLALKAA 18 0.015 13 
66 KLA 9 KLLAKAALKWLLKALKAA 18 0.023 13 
67 KLA 10 KALKKLLAKWLAAAKALL 18 0.115 13 
68 KLA 15 KLAAALLKKWKKLAAALL 18 0.120 13 
69 KLA 8 KALAALLKKWAKLLAALK 18 0.181 13 
70 TP10-1 AGYLLGPINLKALAALAKKIL 21 1.223 11 
71 TP10-2 AGYLLGKINLKPLAALAKKIL 21 0.749 11 
72 TP10-3 AAYLLAKINLKALAALAKKIL 21 1.243 11 
73 TP10-4 AGYLLGKINLRALAALARRIL 21 1.263 11 
74 TP10-5 AGYLLGKINLKKLAKL(Aib)KKIL2 21 2.141 11 
75 D-R9 rrrrrrrrr 9 1.389 12, 43 
76 MP INLKALAALAKKIL 14 0.570 45 
77 iMP inlkalaalakkil 14 (3.602) 45 
78 rMP LIKKALAALAKLNI 14 0.352 45 
79 riMP likkalaalaklni 14 0.288 45 
80 MitP INLKKLAKL(Aib)KKIL2 14 2.712 45, 46 
81 iMitP inlkklakl(Aib)kkil 14 2.272 45 
82 rMitP LIKK(Aib)LKALKKLNI 14 0.531 45 
83 riMitP likk(Aib)lkalkklni2 14 0.837 45 
84 Cyt c77-101 GTKMIFVGIKKKEERADLIAYLKKA 25 0.179 46 
85 Cyt c86-101 KKKEERADLIAYLKKA 16 0.006 46 
86 Cyt c79-92 KMIFVGIKKKEERA 14 0.013 46 
87 Cyt c79-88 KMIFVGIKKK 10 0.006 46 
88 Cyt c4-13 EKGKKIFIMK 10 0.013 46 
89 Cyt c5-13 KGKKIFIMK 9 0.069 46 
90 MTS AAVALLPAVLLALLAP 16 0.315 48 
91 P14LRR see fig. 1 reference 49 - (7.958) 49 
92 P11LRR see fig. 1 reference 49 - 1.623 49, 50 
93 (P10LRR-Gly)2-C5 see fig. 2 reference 50 - (84.034) 50 
94 (P10LRR-β-Ala)2-C5 see fig. 2 reference 50 - (66.648) 50 
95 (P10LRR-ABUA)2-C5 see fig. 2 reference 50 - (73.892) 50 
96 VPTLK VPTLK 5 0.002 51 
97 MAP(Aib) KL(Aib)LKL(Aib)LK(Aib)LKA(Aib)LKL(Aib)2 18 (125.240) 52 
98 sC18 GLRKRLRKFRNKIKEK 16 0.166 54 
99 hCT(18-32)-k7 
                                KFHTFPQTAIGVGAP                                                        
KKRKAPKKKRKFA  
28 0.183 54, 57 
100 N-E5L-hCT(18-32)-k7 
         GLLEALAELLEKFHTFPQTAIGVGAP                                                
KKRKAPKKKRKFA  
39 0.364 54 
101 N-E5L-sC18 GLLEALAELLEGLRKRLRKFRNKIKEK 27 0.150 54 
102 N-E5L-Tat 48-60 GLLEALAELLEGRKKRRQRRRPPQ 24 0.507 54 
103 FHV coat (35-49) RRRRNRTRRNRRRVR 15 (4.127) 56 
104 PasTat FFLIPKGGRKKRRQRRRPPQ 20 (4.426) 55 
105 BMV Gag (7-25) KMTRAQRRAAARRNRWTAR 19 0.288 56 
106 HTLV-II Rex (4-16) TRRQRTRRARRNR 13 0.288 56 
107 Human cJun (252-279) RIKAERKRMRNRIAASKSRKRKLERIAR 28 2.744 56 
108 Human cFos (139-164) KRRIRRERNKMAAAKSRNRRRELTDT 26 0.199 56 
109 
K-FGF 
(Kaposi fibroblast growth 
factor) 
AAVLLPVLLAAP 12 0.200 58 
110 
PreS2-TLM 
(PreS2-derived translocatory 
motif) 
PLSSIFSRIGDP 12 0.224 58 
 
CHAPTER II – CHEMICAL-FUNCTIONAL DIVERSITY IN CELL-PENETRATING PEPTIDES 
  
 
64 
Peptide 
ID 
Peptide name Sequence 
Number 
of AA 
CP-
response 
Ref.1 
111 
PTD4 
(Protein transduction 
domain 4) 
PIRRRKKLRRLK 12 0.658 58 
112 
α-peptide/β-peptoid 
chimera  2 
see fig. 1 reference 59 - 0.185 59 
113 
α-peptide/β-peptoid 
chimera 6 
see fig. 1 reference 59 - 2.040 59 
114 
α-peptide/β-peptoid 
chimera 8 
see fig. 1 reference 59 - 2.102 59 
115 hArg8 (Homoarginine8) see fig. 1 reference 59 - 0.464 59 
116 PenArg RQIRIWFQNRRMRWRR 16 1.810 60 
117 PenLys KQIKIWFQNKKMKWKK 16 0.041 60 
118 
aca-[Lys(Nys+)-aca]4-
Lys(Nys+) 
aca-[Lys(Nys+)-aca]4-Lys(Nys+)3 - 0.001 61 
119 
aca-[Lys(Nys+)-aca]6-
Lys(Nys+) 
aca-[Lys(Nys+)-aca]6-Lys(Nys+)3 - 0.005 61 
120 M511 FLGKKFKKYFLQLLK 15 0.599 62 
121 M551 KGKFQLYLKLKFKFL 15 0.240 62 
122 G53-1 IVIAKLKANLMCKTCRLAK 19 0.150 62 
123 G53-2 AIGVNYLVKFIKVIAIVIAKLKA 23 0.839 62 
124 
Kno ref. 63 
(Knotted-1 homeodomain 
third helix) 
KQIKINNWFINQRKRHWK 18 (7.358) 63 
125 R6/W3 RRWWRRWRR 9 0.910 63 
126 Phe6.14-penetratin RQIKIFFQNRRMKFKK 16 0.727 64 
127 Dodeca-penetratin RQIKIWFRKWKK 12 1.154 64 
128 
MG2d (Magainin 2 
analogue) 
GIGKFLHSAKKWGKAFVGQIMNC 23 0.798 65 
129 BF2d (Buforin 2 analogue) TRSSRAGLQWPVGRVHRLLRKGGC 24 0.953 65 
130 YTA2 YTAIAWVKAFIRKLRK 16 1.545 66 
131 K9 KKKKKKKKK 9 0.119 12 
132 H9 HHHHHHHHH 9 0.068 12 
133 O9 OOOOOOOOO 9 0.068 12 
134 R8 RRRRRRRR 8 0.639 12, 16 
135 R6 RRRRRR 6 0.194 12, 16 
136 R5 RRRRR 5 0.077 12, 16 
137 R4 RRRR 4 0.074 12 
138 R3 RRR 3 0.055 12 
139 D-R8 rrrrrrrr 8 1.577 12 
140 D-R7 rrrrrrr 7 1.071 12 
141 D-R6 rrrrrr 6 0.323 12 
142 D-R5 rrrrr 5 0.115 12 
143 D-R4 rrrr 4 0.098 12 
144 R15 RRRRRRRRRRRRRRR 15 1.345 12 
145 R20 RRRRRRRRRRRRRRRRRRRR 20 0.764 12 
146 R25 RRRRRRRRRRRRRRRRRRRRRRRRR 25 0.400 12 
147 R30 RRRRRRRRRRRRRRRRRRRRRRRRRRRRRR 30 0.109 12 
148 [Ala1]pVEC ALIILRRRIRKQAHAHSK 18 0.304 7 
149 [Ala2]pVEC LAIILRRRIRKQAHAHSK 18 0.507 7 
150 [Ala3]pVEC LLAILRRRIRKQAHAHSK 18 0.406 7 
151 [Ala4]pVEC LLIALRRRIRKQAHAHSK 18 0.659 7 
152 [Ala5]pVEC LLIIARRRIRKQAHAHSK 18 0.456 7 
153 [Ala6]pVEC LLIILARRIRKQAHAHSK 18 2.433 7 
154 [Ala7]pVEC LLIILRARIRKQAHAHSK 18 1.115 7 
155 [Ala8]pVEC LLIILRRAIRKQAHAHSK 18 2.129 7 
156 [Ala9]pVEC LLIILRRRARKQAHAHSK 18 0.760 7 
157 [Ala10]pVEC LLIILRRRIAKQAHAHSK 18 1.470 7 
158 [Ala11]pVEC LLIILRRRIRAQAHAHSK 18 1.774 7 
159 [Ala12]pVEC LLIILRRRIRKAAHAHSK 18 1.420 7 
160 [D-Ala13]pVEC LLIILRRRIRKQaHAHSK 18 1.825 7 
161 [Ala14]pVEC LLIILRRRIRKQAAAHSK 18 0.558 7 
162 [D-Ala15]pVEC LLIILRRRIRKQAHaHSK 18 1.115 7 
163 [Ala16]pVEC LLIILRRRIRKQAHAASK 18 1.521 7 
164 [Ala17]pVEC LLIILRRRIRKQAHAHAK 18 2.129 7 
165 [Ala18]pVEC LLIILRRRIRKQAHAHSA 18 2.079 7 
166 retro-pVEC KSHAHAQKRIRRRLIILL 18 0.406 7 
167 Ap1 AQIKIWFQNRRMKWKK 16 0.289 9 
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Peptide 
ID 
Peptide name Sequence 
Number 
of AA 
CP-
response 
Ref.1 
168 Ap2 RAIKIWFQNRRMKWKK 16 1.333 9 
169 Ap3 RQAKIWFQNRRMKWKK 16 0.111 9 
170 Ap4 RQIAIWFQNRRMKWKK 16 0.511 9 
171 Ap5 RQIKAWFQNRRMKWKK 16 0.244 9 
172 Ap6 RQIKIAFQNRRMKWKK 16 0.222 9 
173 Ap7 RQIKIWAQNRRMKWKK 16 0.089 9 
174 Ap8 RQIKIWFANRRMKWKK 16 0.778 9 
175 Ap9 RQIKIWFQARRMKWKK 16 0.978 9 
176 Ap10 RQIKIWFQNARMKWKK 16 0.400 9 
177 Ap11 RQIKIWFQNRAMKWKK 16 0.242 9 
178 Ap12 RQIKIWFQNRRAKWKK 16 0.644 9 
179 Ap13 RQIKIWFQNRRMAWKK 16 0.378 9 
180 Ap14 RQIKIWFQNRRMKAKK 16 0.356 9 
181 Ap15 RQIKIWFQNRRMKWAK 16 0.411 9 
182 Ap16 RQIKIWFQNRRMKWKA 16 0.444 9 
183 SAP (E) VELPPPVELPPPVELPPP 18 0.007 67 
184 
Eng 
(Engrailed-2 homeodomain 
third helix) 
SQIKIWFQNKRAKIKK 16 1.235 69 
185 
Hox 
(HoxA-13 homeodomain 
third helix) 
RQVTIWFQNRRVKEKK 16 0.500 69 
186 
Kno ref. 69 
(Knotted-1 homeodomain 
third helix) 
KQINNWFINQRKRHWK 16 (11.118) 69 
Peptides whose unified response is an (extreme) outlier are indicated in italic. Their CP-responses were not considered during data 
evaluation. 
1References are listed in the reference list of this chapter. 
2Aib = alpha amino-isobutyric acid. 
3Aca = NH2(CH2)5CO-; Lys(Nys+) = Redox amino acid = Lys with 1,4-dihydrotriognelline side chain. 
 
 
Table S2. List of CPPs of which CP-response is an outlier. 
Peptide ID Peptide Name Reference Details 
12 Transportan 17 
In reference 17, transportan showed higher cell-specificity for 
HeLa cells, resulting in a higher response for cellular influx in 
comparison with other results for transportan. 
34 M918 32 
In the quantitative uptake assay, M918 showed a 7 times 
higher influx than penetratin. 
91 P14LRR 49 
P14LRR showed an about 20 times higher uptake than Tat 47-
57, the positive control. 
93 (P10LRR-Gly)2-C5 50 The dimeric cationic amphiphilic polyproline helices showed 
an about 200 times higher uptake responses than the positive 
control Tat 47-57. 
94 (P10LRR-β-Ala)2-C5 50 
95 (P10LRR-ABUA)2-C5 50 
97 MAP(Aib) 52 
The internal positive control MAP showed a much lower 
influx response in the tested A549 cells (cfr. cell-specificity). 
103 FHV Coat (35-49) 56 
FHV coat (35-49) showed a 21 times higher cellular uptake 
than the positive control Tat 48-60. 
104 PasTat 55 
PasTat has a 20 times higher uptake than the positive control 
Tat. 
124 Kno (ref 63) 63 
Kno has a 7 times higher uptake than the positive control 
penetratin. 
186 Kno (ref 69) 69 
Kno has a 10 times higher uptake than the positive control 
penetratin. 
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Table S3. Classification of (non-) CPPs based on chemical class, literature data and their uptake mechanisms. 
Peptide 
ID 
Peptide name 
Chemical 
class1 
CP-
response 
Ref.2 
Literature 
evaluation3 
Comment 
Uptake 
mechanism4 
Comment 
1 pVEC AC 1.318 
17 High CPP - 2 Unspecified 
25 CPP ≥ penetratin 1 and 2 Unsure 
27 CPP 
> (KFF)3K and 
penetratin 
Not available - 
53 CPP ≥ MAP, > penetratin Not available - 
66 CPP 
= YTA2, > Tat 48-60, 
TP10, penetratin 
1 and 2  Unspecified 
2 Tat 48-60 C 0.221 
17 Medium CPP - 2 Unspecified 
26 CPP 
< penetratin, APH (85-
98), nicastrin (38-53) 
2a - 
34 CPP 
= TP10  
< penetratin < R11 
2b - 
38 CPP 
> VP22, < HIV Rev (34-
50) and penetratin 
2a - 
66 CPP 
= TP10, > Tat 48-60,  
< pVEC and YTA2 
1 and 2  Unspecified 
3 APH-1 (85-98) AU (AC) 0.188 26 CPP  
> Tat 48-60,  
< penetratin and 
nicastrin (38-53) 
2a - 
4 APH-1 (236-246) AU (AC) 0.039 26 No CPP - 
Not 
applicable 
- 
5 Nicastrin (38-53) AU (AC) 0.345 26 CPP  
> Tat 48-60, 
< penetratin and APH 
(85-98) 
2a - 
6 Nicastrin (414-434) AU (C) 0.016 26 No CPP - 
Not 
applicable 
- 
7 Nicastrin (616-635) AU (AC) 0.031 26 No CPP - 
Not 
applicable 
- 
8 Presenilin-1 (97-109) AU (AC) 0.008 26 No CPP - 
Not 
applicable 
- 
9 
Presenilin-1 (305-
317) 
AU (AC) 0.016 26 No CPP - 
Not 
applicable 
- 
10 D-pVEC AC 0.824 
7 CPP ≈ pVEC 2b > 2a - 
27 CPP  ≥ pVEC Not available - 
53 CPP  ≥ pVEC Not available - 
11 (KFF)3K AU (AC) 1.837 27 CPP 
Less efficient than 
pVEC because of 
degradation 
Not available - 
12 Transportan AC (4.357) 
17 High CPP - 2 Unspecified 
28 CPP  > TP10 
Not 
available 
- 
68 CPP - 1 Unspecified 
13 TP10 AC 1.641 
28 CPP  < transportan Not available - 
30 CPP 
> penetratin >> Tat 47-
57 
Not available - 
32 CPP < M918 2a and 2b - 
34 CPP 
= Tat 48-60, < 
penetratin < R11 
Not available - 
66 CPP 
= penetratin, > Tat 48-
60, < pVEC and YTA2 
1 and 2 Unspecified 
14 MAP AC 1.716 
13 CPP - 1 and 2 - 
17 High CPP - 2  Unspecified 
29 CPP - 1 and 2  Unspecified 
37 CPP - 1 and 2 Unsure 
53 CPP ≥ pVEC, > penetratin Not available - 
15 Syn B1 AC 0.063 
17 Medium CPP - 2  Unspecified 
39 CPP - 2c - 
16 Polyomavirus Vp1 AU (C) 0.028 17 Low CPP 
Nearly unmeasurable 
uptake 
2 Unspecified 
17 Bac1-15 AU (C) 0.035 17 Medium CPP - 2 Unspecified 
18 NF-ĸB C 0.025 17 Low CPP 
Nearly unmeasurable 
uptake 
2 Unspecified 
19 SV40-T antigen C 0.028 17 Low CPP 
Nearly unmeasurable 
uptake 
2 Unspecified 
20 HATF3 C 0.023 17 Low CPP 
Nearly unmeasurable 
uptake 
2 Unspecified 
21 hCT(9-32) A 0.024 17 Low CPP 
Nearly unmeasurable 
uptake 
2 Unspecified 
22 HIV-1 Rev (34-50) C 1.460 
17 High CPP - 2  Unspecified 
38 CPP 
> penetratin > Tat 48-
60 > VP22 
2a - 
56 CPP - Not available - 
23 Integrin H 0.549 17 Medium CPP - 2 Unspecified 
24 DPV6 C 0.073 17 Medium CPP - 2  Unspecified 
25 S413PV AC 0.781 17 High CPP - 2  Unspecified 
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26 Pep-1 AC 0.105 17 Medium CPP - 2  Unspecified 
27 MPG AC 1.065 17 Medium CPP - 2  Unspecified 
28 Poly-P (SAP) AC 0.027 17 Low CPP 
Nearly unmeasurable 
uptake 
2 Unspecified 
29 R7 C 0.395 
12 CPP > R6, < R8-9 3 - 
16 CPP  > R6, < R8-9 Not available - 
17 High CPP - 2 Unspecified 
36 CPP < R7W 1 and 2  
Unspecified,  
2 = dominant 
mechanism 
30 R9 C 1.000 
17 High CPP - 2 Unspecified 
31 CPP - Not available - 
33 CPP - 2 Unspecified 
35 High CPP 
One of the most 
efficient known CPPs 
1 and 2 Unspecified 
41 High CPP Rapid 1e and 2 Unspecified 
42 CPP - 
1e, 2a and 
2b 
- 
43 CPP - 1 < 2 Unspecified 
47 CPP - Not available - 
63 CPP - Not available - 
31 pVEC scrambled AU 0.101 
7 Low CPP << pVEC , not efficient 2b > 2a - 
17 Medium CPP - 2 Unspecified 
32 Tat 47-57 C 0.309 
30 CPP << penetratin < TP10 1 and 2 Unspecified 
33 CPP - 2 Unspecified 
42 CPP - 
1e, 2a and 
2b 
- 
58 CPP > K-FGF and PreS2-TLM Not available - 
33 Tat 48-59 C 0.192 
31 CPP < penetratin < R9 Not available - 
63 CPP - Not available - 
34 M918 AC (7.158) 32 High CPP 
Excellent novel CPP, > 
penetratin and TP10 
2a - 
35 Penetratin C 1.000 
17 High CPP - 2  Unspecified 
29 CPP - 2 Unspecified 
32 CPP - 2a and 2b - 
33 CPP - 2  Unspecified 
39 CPP - 2c - 
42 CPP - 
1e, 2a and 
2b 
- 
44 CPP - 1 and 2 Unspecified 
60 CPP - 2a - 
64 CPP - 2b - 
36 R11 C 0.211 34 CPP  
> penetratin  > Tat 48-
60, TP10 
Not available - 
37 RL9 AC 0.134 35 Low CPP Poor 1 and 2 Unspecified 
38 RW9 AC 1.301 35 High CPP 
One of the most 
efficient known CPPs 
1 and 2 Unspecified 
39 R7W C 1.687 36 CPP Efficient 1 and 2 
Unspecified,  
2 = dominant 
40 VP22 AU (C) 0.161 38 CPP  
< Tat 48-60 < 
penetratin <  HIV Rev 
(34-50) 
2a - 
41 D-Syn B1 AC 0.089 39 CPP - 2c - 
42 Syn B3 AU (C) 0.126 39 CPP - 2c - 
43 D-Syn B3 AU (C) 0.185 39 CPP - 2c - 
44 Syn B5 AU (AC) 1.159 39 CPP - 2c - 
45 ARF (1-22) AC 1.641 40 High CPP ≈ TP10 2b - 
46 ARF (1-22) scrambled AU 1.296 40 High CPP ≈ TP10 2b - 
47 ARF (2-14) AC 0.950 40 High CPP ≈ TP10 Not available - 
48 ARF (2-14) scrambled AU 0.173 40 Low CPP - Not available - 
49 ARF (19-31) AC 1.382 40 High CPP ≈ TP10 Not available - 
50 
ARF (19-31) 
scrambled 
AU 0.259 40 Low CPP - Not available - 
51 hLF AC 0.952 41  High CPP Rapid 1e and 2 2 unspecified 
52 MAP (II) AC 0.181 13 CPP - 1 and 2 Unspecified 
53 MAP (III) AC 0.115 13 CPP  ≈ MAP 1 and 2 Unspecified 
54 MAP (VII) AC 0.022 13 Low CPP Slow 1 and 2 Unspecified 
55 MAP (VIII) A 0.243 13 CPP  > MAP 1 and 2 Unspecified 
56 MAP (XI) AC 0.177 13 CPP  ≈ MAP 1 and 2 Unspecified 
57 MAP (XIII) A 0.052 13 CPP  ≈ MAP 1 and 2 Unspecified 
58 MAP (XV) AC 0.104 13 CPP  ≈ MAP 1 and 2 Unspecified 
59 KLA 1 AC 0.085 13 CPP - 1 and 2 Unspecified 
60 KLA 2 AC 0.008 13 Low CPP Slow 1 and 2 Unspecified 
61 KLA 11 AC 0.025 13 Low CPP Slow 1 and 2 Unspecified 
62 KLA 5 AC 0.036 13 Low CPP Slow 1 and 2 Unspecified 
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63 KLA 12 AC 0.079 13 CPP - 1 and 2 Unspecified 
64 KLA 13 AC 0.008 13 Low CPP Slow 1 and 2 Unspecified 
65 KLA 14 AC 0.015 13 Low CPP Slow 1 and 2 Unspecified 
66 KLA 9 AC 0.023 13 Low CPP Slow 1 and 2 Unspecified 
67 KLA 10 AC 0.115 13 CPP - 1 and 2 Unspecified 
68 KLA 15 AC 0.120 13 CPP - 1 and 2 Unspecified 
69 KLA 8 AC 0.181 13 CPP - 1 and 2 Unspecified 
70 TP10-1 AC 1.223 11 CPP  < TP10 1d - 
71 TP10-2 AC 0.749 11 CPP < TP10 1d - 
72 TP10-3 AC 1.243 11 CPP < TP10 1d - 
73 TP10-4 AC 1.263 11 CPP < TP10 1d - 
74 TP10-5 AC 2.141 11 CPP > TP10 1d - 
75 D-R9 C 1.389 
12 CPP Effective, (> (D-)R6-8) 3 - 
43 CPP < R9 1 > 2 Unspecified 
76 MP AC 0.570 45 Low CPP Low efficient 1 Unspecified 
77 iMP AC (3.602) 45 High CPP 
Highly efficient,  
(> MitP, penetratin) 
1 Unspecified 
78 rMP AC 0.352 45 Low CPP Low efficient 
Not 
applicable 
- 
79 riMP AC 0.288 45 Low CPP Low efficient 
Not 
applicable 
- 
80 MitP AC 2.712 
45 Medium CPP Efficient 1 Unspecified 
46 CPP - Not available - 
81 iMitP AC 2.272 45 CPP  
Strong propensity for 
cell penetration 
Not available - 
82 rMitP AC 0.531 45 Low CPP Low efficient Not available - 
83 riMitP AC 0.837 45 Low CPP Low efficient Not available - 
84 Cyt c77-101 AU (C) 0.179 46 High CPP 
Extremely/very 
efficient 
Not available - 
85 Cyt c86-101 AU (C) 0.006 46 CPP - Not available - 
86 Cyt c79-92 AU (C) 0.013 46 Not available - Not available - 
87 Cyt c79-88 AU (C) 0.006 46 Not available - Not available - 
88 Cyt c4-13 AU (C) 0.013 46 Not available - Not available - 
89 Cyt c5-13 AU (C) 0.069 46 Not available - Not available - 
90 MTS H 0.315 48 CPP - Not available - 
91 P14LRR AC (7.958) 49 High CPP 
Highly efficient class of 
CPPs 
1 Unspecified 
92 P11LRR AC 1.623 
49 High CPP 
Highly efficient class of 
CPPs 
1 and 2 Unspecified 
50 CPP - 1 and 2 Unspecified 
93 (P10LRR-Gly)2-C5 AC (84.034) 50 CPP  
Uptake far superior to 
P11LRR and Tat 47-57 
1 and 2 Unspecified 
94 (P10LRR-β-Ala)2-C5 AC (66.648) 50 CPP  
Uptake far superior to 
P11LRR and Tat 47-57 
1 and 2 Unspecified 
95 (P10LRR-ABUA)2-C5 AC (73.892) 50 CPP  
Uptake far superior to 
P11LRR and Tat 47-57 
1 and 2 Unspecified 
96 VPTLK CH 0.002 51 CPP - Unknown - 
97 MAP(Aib) AC (125.240) 52 High CPP - 
Not 
available 
- 
98 sC18 AC 0.166 54 High CPP Highly efficient 1 and 2 Unspecified 
99 hCT(18-32)-k7 AU 0.183 
54 CPP - 2 Unspecified 
57 Medium CPP Effective Not available - 
100 N-E5L-hCT(18-32)-k7 AU 0.364 54 CPP 
Faster and efficienter 
than hCT(18-32)-k7 
Unclear - 
101 N-E5L-sC18 AC 0.150 54 CPP 
Faster and efficienter 
than sC18 
Unclear - 
102 N-E5L-Tat 48-60 AU (C) 0.507 54 CPP  
Faster and efficienter 
than Tat 48-60 
Unclear - 
103 FHV coat (35-49) C (4.127) 56 High CPP 
High efficient CPP and 
superior cellular uptake 
> Tat 48-60 
2a - 
104 PasTat C (4.426) 55 CPP - 
Not 
available 
- 
105 BMV Gag (7-25) C 0.288 56 CPP - Not available - 
106 HTLV-II Rex (4-16) C 0.288 56 CPP - Not available - 
107 
Human cJun (252-
279) 
C 2.744 56 CPP - Not available - 
108 
Human cFos (139-
164) 
C 0.199 56 CPP - Not available - 
109 
K-FGF 
(Kaposi fibroblast 
growth factor) 
H 0.200 58 CPP 
< arginine-rich 
peptides: Tat 47-57, 
penetratin and PTD4 
Not available - 
110 
PreS2-TLM 
(PreS2-derived 
translocatory motif) 
A 0.224 58 CPP 
< arginine-rich 
peptides: Tat 47-57, 
penetratin and PTD4 
Not available - 
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111 
PTD4 
(Protein transduction 
domain 4) 
C 0.658 58 CPP 
> peptides: K-FGF and 
PreS2-TLM 
Not available - 
112 
α-peptide/β-peptoid 
chimera  2 
AU 0.185 59 Medium CPP  
Possesses efficient 
cellular uptake 
properties  superior to 
well-described CPPs,   
≈ Tat 47-57 
1 and 2 Unspecified 
113 
α-peptide/β-peptoid 
chimera 6 
AU 2.040 59 High CPP 
Possesses efficient 
cellular uptake 
properties superior to 
well-described CPPs,   
> Tat 47-57 
1 and 2 Unspecified 
114 
α-peptide/β-peptoid 
chimera 8 
AU 2.102 59 High CPP 
Possesses efficient 
cellular uptake 
properties superior to 
well-described CPPs,  
> Tat 47-57 
1 and 2 Unspecified 
115 
hArg8 
(Homoarginine8) 
C 0.464 59 Medium CPP 
Possesses efficient 
cellular uptake 
properties superior to 
well-described CPPs,   
≈ Tat 47-57 
1 and 2 Unspecified 
116 PenArg C 1.810 60 CPP > penetratin > PenLys 2a - 
117 PenLys C 0.041 60 CPP < penetratin < PenArg 2a - 
118 
aca-[Lys(Nys+)-aca]4-
Lys(Nys+) 
AU 0.001 61 No CPP - 
Not 
applicable 
- 
119 
aca-[Lys(Nys+)-aca]6-
Lys(Nys+) 
AU 0.005 61 Low CPP - Not available - 
120 M511 AU (AC) 0.599 62 CPP - Not available - 
121 M551 AU (C) 0.240 62 CPP - Not available - 
122 G53-1 AU (AC) 0.150 62 Low CPP - Not available - 
123 G53-2 AU (AC) 0.839 62 CPP - Not available - 
124 
Kno ref. 61 
(Knotted-1 
homeodomain third 
helix) 
C (7.358) 63 CPP - 
Not 
available 
- 
125 R6/W3 AC 0.910 63 CPP - Not available - 
126 Phe6.14-penetratin AU (C) 0.727 64 CPP < penetratin 2b - 
127 Dodeca-penetratin AU (AC) 1.154 64 CPP ≈ penetratin 2b - 
128 
MG2d (Magainin 2 
analogue) 
AC 0.798 65 CPP - 1b - 
129 
BF2d (Buforin 2 
analogue) 
AC 0.953 65 CPP - Not available - 
130 YTA2 AC 1.545 66 CPP 
= pVEC, > Tat 48-60, 
TP10, penetratin 
1 and 2 Unspecified 
131 K9 C 0.119 12 Low CPP Not effective Not available - 
132 H9 C 0.068 12 Low CPP Not effective Not available - 
133 O9 C 0.068 12 Low CPP Not effective Not available - 
134 R8 C 0.639 
12 Medium CPP 
Effective CPP (> R6-7,  
< R9) 
3 - 
16 CPP  > R6-7, < R9 Not available - 
135 R6 C 0.194 
12 Medium CPP  Effective CPP, < R7-9 3 - 
16 CPP < R7-9 Not available - 
136 R5 C 0.077 
12 Low CPP Not effective CPP Not available - 
16 No CPP - 
Not 
applicable 
- 
137 R4 C 0.074 12 Low CPP Not effective CPP Not available - 
138 R3 C 0.055 12 Low CPP Not effective CPP Not available - 
139 D-R8 C 1.577 12 Medium CPP 
Effective CPP, > (D-)R6-
7, < (D-) R9 
3 - 
140 D-R7 C 1.071 12 Medium CPP 
Effective CPP, > (D-)R6, 
< (D-) R8-9 
3 - 
141 D-R6 C 0.323 12 Medium CPP 
Effective CPP, < (D-)R7-
9 
3 - 
142 D-R5 C 0.115 12 Low CPP Not effective CPP Not available - 
143 D-R4 C 0.098 12 Low CPP Not effective CPP Not available - 
144 R15 C 1.345 12 Medium CPP 
Effective CPP, > R6-9, 
but toxic 
3 - 
145 R20 C 0.764 12 Medium CPP 
Effective CPP, < R9, 
R15, but toxic 
3 - 
146 R25 C 0.400 12 Low CPP 
Not effective CPP, < 
R7, R9, R15, but toxic 
Not available - 
147 R30 C 0.109 12 Low CPP Not effective CPP Not available - 
148 [Ala1]pVEC AC 0.304 7 CPP  Significant < pVEC 2b > 2a - 
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149 [Ala2]pVEC AC 0.507 7 CPP Significant < pVEC 2b > 2a - 
150 [Ala3]pVEC AC 0.406 7 CPP Significant < pVEC 2b > 2a - 
151 [Ala4]pVEC AC 0.659 7 CPP Significant < pVEC 2b > 2a - 
152 [Ala5]pVEC AC 0.456 7 CPP Significant < pVEC 2b > 2a - 
153 [Ala6]pVEC AC 2.433 7 CPP Significant > pVEC 2b > 2a - 
154 [Ala7]pVEC AC 1.115 7 CPP ≈ pVEC 2b > 2a - 
155 [Ala8]pVEC AC 2.129 7 CPP Significant > pVEC 2b > 2a - 
156 [Ala9]pVEC AC 0.760 7 CPP Significant > pVEC 2b > 2a - 
157 [Ala10]pVEC AC 1.470 7 CPP ≈ pVEC 2b > 2a - 
158 [Ala11]pVEC AC 1.774 7 CPP ≈ pVEC 2b > 2a - 
159 [Ala12]pVEC AC 1.420 7 CPP ≈ pVEC 2b > 2a - 
160 [D-Ala13]pVEC AC 1.825 7 CPP ≈ pVEC 2b > 2a - 
161 [Ala14]pVEC AC 0.558 7 CPP Significant > pVEC 2b > 2a - 
162 [D-Ala15]pVEC AC 1.115 7 CPP ≈ pVEC 2b > 2a - 
163 [Ala16]pVEC AC 1.521 7 CPP ≈ pVEC 2b > 2a - 
164 [Ala17]pVEC AC 2.129 7 CPP Significant > pVEC 2b > 2a - 
165 [Ala18]pVEC AC 2.079 7 CPP ≈ pVEC 2b > 2a - 
166 retro-pVEC AC 0.406 7 CPP Significant > pVEC 2b > 2a - 
167 Ap1 C 0.289 9 Low CPP < penetratin Unclear - 
168 Ap2 C 1.333 9 CPP  > penetratin Unclear - 
169 Ap3 C 0.111 9 Low CPP < penetratin Unclear - 
170 Ap4 C 0.511 9 Low CPP < penetratin Unclear - 
171 Ap5 C 0.244 9 Low CPP < penetratin Unclear - 
172 Ap6 C 0.222 9 Low CPP < penetratin Unclear - 
173 Ap7 C 0.089 9 Low CPP < penetratin Unclear - 
174 Ap8 C 0.778 9 CPP ≈ penetratin Unclear - 
175 Ap9 C 0.978 9 CPP ≈ penetratin Unclear - 
176 Ap10 AC 0.400 9 Low CPP < penetratin Unclear - 
177 Ap11 C 0.242 9 Low CPP < penetratin Unclear - 
178 Ap12 C 0.644 9 CPP  < penetratin Unclear - 
179 Ap13 C 0.378 9 Low CPP < penetratin Unclear - 
180 Ap14 C 0.356 9 Low CPP < penetratin Unclear - 
181 Ap15 C 0.411 9 Low CPP < penetratin Unclear - 
182 Ap16 C 0.444 9 Low CPP < penetratin Unclear - 
183 SAP (E) A 0.007 67 Low CPP Not highly efficient 2b - 
184 
Eng 
(Engrailed-2 
homeodomain third 
helix) 
C 1.235 69 CPP - Not available - 
185 
Hox 
(HoxA-13 
homeodomain third 
helix) 
C 0.500 69 CPP - Not available - 
186 
Kno ref. 67 
(Knotted-1 
homeodomain third 
helix) 
C (11.118) 69 High CPP High uptake efficiency 
Not 
available 
- 
Peptides whose unified response is an (extreme) outlier are indicated in italic. Their CP-responses were not considered during data 
evaluation. 
1Chemical classes of CPPs: A = amphipathic, C = cationic, H = hydrophobic, AC = intersection amphipathic-cationic, CH = intersection 
cationic-hydrophobic and AU = author unclassified. If AU, the recommended chemical class, according to ref. 6, is indicated between 
brackets.  
2References are listed in the reference list of this chapter. 
3Literature evaluation = how the authors of the study estimated the cellular influx capacity of the investigated peptides: no, low, medium 
or high CPP. CPP alone means not specified by the authors. 
41 = direct penetration with 1a = inverted micelles, 1b = pore formation, 1c = carpet like model, 1d = membrane thinning and 1e = uptake 
through nucleation zones; 2 = endocytosis with 2a = macropinocytosis, 2b = endocytosis dependent on coat proteins (clathrin, caveolae or 
lipid raft mediated) and 2c = endocytosis independent on coat proteins; 3 = energy-dependent mechanism, but not endocytosis (not 
further specified by authors) [according to ref. 2,12,72,73]. 
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Table S4. Summary of the PCA analysis of the descriptors divided by the molecular weight, describing the 
eigenvalues of the covariance matrix, the total variance explained (cumulative R²) and the predictive ability 
(cumulative Q²). 
Principal Component Eigenvalue Cumulative R² Cumulative Q² 
1 73.7 0.396 0.371 
2 41.8 0.621 0.596 
3 12.7 0.689 0.655 
4 8.28 0.734 0.678 
5 7.95 0.777 0.715 
6 6.27 0.810 0.749 
7 4.44 0.834 0.771 
8 3.18 0.851 0.781 
9 2.75 0.866 0.792 
10 2.53 0.880 0.803 
11 2.08 0.891 0.807 
12 1.62 0.900 0.803 
13 1.44 0.907 0.807 
 
 
Figure S1. Scores plot of the first versus the second principal component of the PCA analysis of 186 peptides 
after dividing their descriptors by the molecular weight. The colors of the clusters correspond with the clusters 
found in the scores plot of the PCA analysis using the original descriptors (Figure 2). For each cluster, some 
examples of peptides are indicated. 
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CHAPTER III 
 
CLASSIFICATION OF 
PEPTIDES  
ACCORDING TO THEIR 
BLOOD-BRAIN BARRIER 
INFLUX 
  
 
 
“The end of our exploring will be to arrive at where we started  
and to know the place for the first time.” 
 
Thomas Stearns Eliot 
(°1888 - †1965, American essayist and poet) 
 
 
 
 
 
 
 
Parts of this chapter were published: 
 
Stalmans S, Gevaert B, Wynendaele E, Nielandt J, De Tré G, Peremans K, Burvenich C, De 
Spiegeleer B. Classification of Peptides According to Their Blood-Brain Barrier Influx. Protein 
Peptide Lett. 2015; 22: 768-775. 
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ABSTRACT 
An increasing number of studies demonstrate the ability of peptides to cross the blood-brain 
barrier (BBB), opening perspectives for a new class of therapeutics for central nervous system 
diseases. However, information on the BBB transport of peptides suffers from a wide variety in 
used methods and experimental set-ups. Therefore, it is currently difficult, if not impossible, to 
classify peptides according to their BBB influx characteristics. To allow direct comparison of BBB 
influx results of peptides, we introduce a classification method and unified response for BBB influx 
transport of peptides. First, the results of BBB influx response types (i.e. Kin (MTR), Kin (Perfusion), 
Pin vitro and Pin vivo), which quantitatively express brain influx, were classified into five classes of BBB 
influx magnitude based on the distribution of these results for the individual response types. Then, 
these classes were converted to a BBBin-response, representing a scaled value ranging from zero 
(no influx) to ten (high influx), independent from the BBB influx response type from which it was 
derived. This unified response can immediately be applied for new BBB influx results of peptides 
and represents a ballpark figure for BBB influx allowing direct comparison and ranking of peptides 
independent of the response type.  
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CHAPTER III 
CLASSIFICATION OF PEPTIDES ACCORDING 
TO THEIR BLOOD-BRAIN BARRIER INFLUX 
Main focus in this chapter: 
 To introduce a classification method and unified response, BBBin, for the BBB influx properties 
of peptides. 
 To present possible applications of this classification system for peptides. 
 
1. BLOOD-BRAIN BARRIER TRANSPORT OF PEPTIDES 
Peptide drugs are exponentially gaining interest from the pharmaceutical industry, with already more 
than one hundred commercialized peptide drugs. Peptides fill the gap between small molecules and 
protein biologics, which currently are the two main classes of successful drugs. Therefore, peptides 
combine the advantages of both drug classes, i.e. the high specificity of the protein biologics for in 
vivo targets, causing high potency and few side-effects, and the smaller size, making them more 
accessible and cheaper to manufacture [1]. However, the widespread therapeutic applicability of 
peptides is limited due to their undesirable physicochemical properties, such as higher molecular 
weight and hydrophilicity compared to small molecules. These properties, together with their poor in 
vivo stability and rapid (renal) clearance, cause a low bioavailability, poor membrane permeability, 
short half-life and potential immunogenicity [1-3]. Several strategies are being applied to engineer 
the peptides in order to overcome these problems, making peptide therapeutics one of the fastest 
growing segments in the pharmaceutical industry [2-4].  
Current marketed small molecules for the treatment of central nervous system (CNS) disorders, like 
schizophrenia, anxiety, depression and autism, suffer from serious side effects and significant efficacy 
limitations. Moreover, the development of safer and more effective therapies for these psychiatric 
disorders has slowed down [5-7]. Because of their high specificity and potency, peptides are 
promising therapeutics for CNS disorders [5]. Historically, peptides were believed not to reach the 
brain parenchyma, but in the 1970s the first reviews were published in which the ability of peptides 
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to cross the blood-brain barrier (BBB) was demonstrated [8,9]. Since then, numerous studies have 
described the BBB transport of peptides [9,10]. Brainpeps, the BBB peptide database, was 
constructed to collect these quantitative BBB transport data of peptides which are scattered in 
literature [11]. A multitude of methods and experimental protocols is used to assess the BBB 
behavior of peptides, impeding the comparison, ranking or classification of peptides according to 
their BBB influx characteristics. Moreover, very few BBB transport studies of peptides incorporate 
control compounds, considered as system suitability tests (SST) allowing standardization. In the 
literature, inulin, sucrose and bovine serum albumin (BSA), as vascular markers which do not cross 
the BBB, are most frequently proposed [12]. On the other hand, a positive control as SST is lacking in 
the majority of the BBB transport studies. This makes meaningful quantitative comparisons between 
influx properties very difficult, if not, impossible. Therefore, it was strongly suggested to include also 
a positive BBB permeability peptide in the experiments and dermorphin has been suggested to fulfill 
this role, being a universally available, well-characterized, pure, stable and easily-labeled peptide 
[11]. This standardization procedure would allow easier comparison of data between different 
research groups and methods as the correction of BBB transport results by the controls compensates 
for experimental differences. Clearly, there is a need for one universal measure for BBB influx 
transport of peptides. Therefore, we present here a classification method and unified response, 
BBBin, which is a ballpark figure for BBB influx of peptides, using a straightforward calculation 
method. Our BBB influx classification and BBBin-response are an elegant way to compare peptides 
regarding their overall BBB influx behavior and transcends the differences in experimental set-up and 
techniques.  
 
2. CLASSIFICATION METHOD FOR BLOOD-BRAIN BARRIER INFLUX 
DATA OF PEPTIDES 
BBB influx data 
All data were gathered from the most recent Brainpeps database (http://brainpeps.ugent.be), which 
contains quantitative data of BBB transport of peptides available in literature [11]. Four different 
response types, expressing quantitatively BBB influx, were selected based on the availability of more 
than three experimental results. Reported negative response values were converted to zero, i.e. its 
physical-theoretical boundary. In total, 115 peptides were included in this study, containing up to 55 
amino acids in their sequence. This arbitrary cut-off point for peptides is somewhat higher than the 
mostly used (arbitrary) cut-off of 50 amino acids applied throughout the literature in order to include 
borderline cases.  
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The original studies reporting the selected BBB influx responses can be found in the Brainpeps 
database and are not listed in the reference list. The used identification numbers of the peptides 
correspond with those in Brainpeps.  
Method for classification and calculation of BBBin-response 
To define a BBBin-response, the available data for the different selected BBB influx response types 
were evaluated by a box-and-whisker plot using SPSS Statistics 22 (IBM, Brussels, Belgium). This 
software was also used to calculate the 25, 50 and 75 percentiles, of which the weighted average 
percentiles were used in this study. Based on these percentiles and whiskers, reflecting the 
distribution of the experimental data for a specific influx response, the data were classified into five 
BBB influx classes: very low (lowest value – 25 percentile), low (25 – 50 percentile), medium (50 – 75 
percentile), high (75 percentile – higher whisker) and very high influx (> higher whisker). The five-
cluster principle represents a simple, but sufficiently detailed classification system. The classes were 
assigned a response score, BBBin, as follows (between brackets the BBBin-range is indicated for a 
class): class 1 = score 1 [0,2]; class 2 = score 3 ]2,4]; class 3 = score 5 ]4,6]; class 4 = score 7 ]6,8] and 
class 5 = score 9 ]8,10]. Several BBBin data were sometimes available for one peptide, as well as 
within the same influx response as from different influx response types. Therefore, an overall BBBin-
response was calculated, which was obtained by calculating the median BBBin-response of the 
peptide within each response type. Then, the median BBBin-response was calculated over all BBB 
influx response types available for the peptide. The median was preferred over the mean, being less 
sensitive to outliers. 
 
Evaluation of classification 
The approach to classify and score the peptides according to their BBBin-intensity was evaluated by 
comparing our result with the appreciation of the BBB transport by the authors who investigated the 
peptides. A positive correspondence was concluded in case of the same classification or only one 
class difference. If there was more than one class difference, a negative correspondence was 
reported. When authors only concluded the peptide crossed the BBB or if the BBB transport was 
described to be significantly higher than the vascular marker, without any more appreciation details, 
this was interpreted as low to medium BBB influx. 
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3. BBBIN, AN INDEPENDENT MEASURE FOR BLOOD-BRAIN BARRIER 
INFLUX OF PEPTIDES 
Influx responses 
The unidirectional influx rate (Kin), represents the influx rate of peptides that are relatively stable in 
blood and slowly cross the BBB [10]. Kin actually represents the clearance of blood from the peptides 
after a single passage of the brain, expressed in units of volume per time [11]. Two Kin responses can 
be distinguished: Kin (MTR) obtained by performing a multiple time regression (MTR) experiment 
after intravenous injection (n = 76) and Kin (Perfusion) obtained by performing an in situ brain 
perfusion experiment (n = 21). Two permeability responses were included as well, representing the 
rate at which a peptide moves from blood to the brain with units of distance per time [11]. Both in 
vitro (n = 44) and in vivo (n = 6) BBB permeability (P) data were available: all Pin vitro data were 
acquired using a brain microvessel endothelial cell culture model (BMEC), while Pin vivo data were 
calculated after in situ brain perfusion experiments in rats. An overview of the data is given in the 
Supplementary Information (Table S1-S4). During a MTR experiment, peptides are intravenously 
injected and the solute concentration or radioactivity is determined at different time points in brain 
and serum. The same measurements are performed during the in situ brain perfusion method, but a 
perfusion fluid replaces the animal’s circulating blood. The peptide, at a known concentration, is 
perfused into the carotid artery for a defined time interval and directly delivered to the brain via the 
perfusion fluid. During both in vivo methods, the BBB system is intact, which is a general advantage 
compared to the in vitro methods. The use of a perfusion buffer during the in situ brain perfusion 
method allows to control constituting components, which simplifies data interpretation, e.g. less 
metabolization of peptides due to absence of metabolizing enzymes in the perfusion fluid. However, 
the MTR method represents the “golden standard” for evaluating the BBB transport of peptides [12]. 
Thus, each of the four selected BBB influx responses is looking at BBB influx from a slightly different 
viewpoint and hence giving a slightly different information aspect.  
 
Classification and calculation of BBBin-response 
For each of the selected BBB influx response types, the data distribution was evaluated using a box-
and-whisker plot. In Figure 1, the classification of the Kin (Perfusion) data is presented.  
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Figure 1. Classification of the BBB influx data.  
The classification of the Kin (Perfusion) data are presented as an example. At the top, the box-and-whisker plot 
of the Kin (Perfusion) data is shown and data were classified into five BBB influx classes based on the 25, 50 and 
75 percentiles as well as the lower and higher whisker. Peptides with outlying Kin (Perfusion) data constitute 
class 5. Then, BBB influx classes were converted to the BBBin-response by attributing the mid-value of the 
corresponding BBBin-range of the obtained BBB influx class, illustrated in the lower part of the figure. 
 
Five BBB influx classes, ranging from very low over medium to very high BBB influx, were calculated, 
with class 1 to 4 were determined by the 25, 50 and 75 percentiles as well as the lower and higher 
whisker. BBB influx class 5 comprised the peptides with outlying BBB influx data (Figure 1). In Table 1, 
the limits of the five classes are listed for each influx response type. This table was used to classify 
peptides based on their BBB influx properties and can be used to classify newly obtained BBB 
transport data. The classification of the individual peptides can be found in the Supplementary 
Information (Table S1-S4). 
Table 1. Classification of peptides based on BBB influx response data.  
The ranges of the different BBB influx classes are determined by the calculated 25, 50 and 75 percentiles as 
well as the lower and higher whiskers calculated for the data of each individual BBB influx response type.  
Class 5 contains all data above the higher whisker, i.e. the outlying values. 
BBB influx 
response  
type 
Number of 
peptides 
Class 1 
Very low 
influx 
Class 2 
Low influx 
Class 3 
Medium 
influx 
Class 4 
High influx 
Class 5 
Very high 
influx 
Unit 
Kin 
(MTR) 
76 [0; 1.8310-4] 
]1.8310-4; 
3.7810-4] 
]3.7810-4; 
9.3710-4] 
]9.3710-4; 
2.1010-3] 
]2.1010-3; [ ml/(g × min) 
Kin 
(Perfusion) 
21 [0; 9.3010-4] 
]9.3010-4; 
2.3410-3] 
]2.3410-3; 
4.3210-3] 
]4.3210-3; 
1.2510-2] 
]1.2510-2; [ ml/(g × min) 
Pin vitro 44 [0; 1.7410-5] 
]1.7410-5; 
3.4410-5] 
]3.4410-5; 
8.2110-5] 
]8.2110-5; 
1.5310-4] 
]1.5310-4; [ cm/s 
Pin vivo 6 [0; 4.7510-8] 
]4.7510-8; 
9.5010-8] 
]9.5010-8; 
4.3410-7] 
]4.3410-7; 
5.6510-7] 
]5.6510-7; [ cm/s 
 
For 15 peptides, BBB influx data were available for more than one BBB influx response type (Table 2). 
It concerns peptides already extensively investigated for their BBB transport properties. Five of these 
peptides, i.e. exendin-4, adrenomedullin, endomorphin-2, biphalin and urocortin II, showed 
divergent classification based on the different BBB influx response types, i.e. the classification range 
was more than one class. For exendin-4, adrenomedullin, biphalin and urocortin II, the range of 
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classification based on the different BBB influx responses was two classes (indicated as “+/-“ in Table 
2). An important discrepancy between the techniques used to obtain the BBB influx responses of 
exendin-4, adrenomedullin and urocortin II, is that during MTR, peptides are intravenously injected, 
causing an increased possibility of metabolization and protein binding. In contrast, during in situ 
brain perfusion studies, peptides are perfused in serum-free buffers. Thus differences in 
methodologies used in the different BBB influx response types explain deviating classification.  
There is only one peptide with a classification range greater than two (indicated as “-“ in Table 2), i.e. 
endomorphin-2, which showed a higher classification based on the Kin (MTR) data (i.e. 4) compared 
to Pin vitro data (i.e. 1). In the study of endomorphin-2 where the MTR method was used to 
characterize the BBB transport properties, the proposed control peptide dermorphin was 
investigated as well, allowing to “standardize” the experimental values [13]. We thus compared the 
dermorphin Kin results obtained in that study with the overall Kin results obtained, and observed a 
significantly higher Kin result for dermorphin in the concerned study (i.e. 2.2·10-3 ml/(g × min)) 
compared to the other values reported (range from 1.6·10-4 ml/(g × min) to 3.6·10-4 ml/(g × min), 
with a median value of 2.7·10-4 ml/(g × min)) [values from Brainpeps database]. Thus, the higher 
result of dermorphin in the concerned study (class 5 compared to class 1 or 2 for other results) 
indicates that the obtained BBB influx data are generally higher, which might be due to biological 
factors like increased stress or older age of the mice. This illustrates one of the applications of our 
classification method of BBB influx data of peptides: it allows the evaluation of obtained 
experimental data on the BBB transport of peptides and the comparison with other already available 
data. 
Table 2. Correspondence of classification of peptides based on their BBB influx properties for which data are 
available for more than one type of BBB influx responses. A positive correspondence (+) is concluded if the 
classification range was ≤ 1. If the classification range is 2 classes, the correspondence is indicated as “+/-“ and 
if the classification range was ≥ 3, a negative correspondence (-) is concluded. 
Peptide name 
BBB influx class 
Correspond? 
Kin (MTR) Kin (Perfusion) Pin vitro Pin vivo 
PACAP 38 5 5 - - + 
VIP 3 2 - - + 
Exendin-4 3 5 - - +/- 
F13, Y19-MCH 1 1 - - + 
Adrenomedullin 3 1 - - +/- 
Urocortin I 1 1 - - + 
[Tyr10] Secretin-27 4 3 - - + 
Endomorphin-2 4 - 1 - - 
Biphalin - 2 4 3 +/- 
DPDPE - 2 3 - + 
Urocortin II 3 5 - - +/- 
Peptide YY 3 2 - - + 
p-[Cl-Phe4’4’] 
biphalin 
- 3 4 4 + 
CTAP 1 2 - - + 
Insulin detemir 1 1 - - + 
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To obtain a response type-independent overall measure for BBB influx of peptides, the BBB influx 
classes were converted to a BBBin-response, which is a scaled value estimating the BBB influx 
properties of peptides, ranging from zero (no influx) to ten (high influx). This BBBin-response could be 
calculated for each peptide enabling direct comparison of peptides regarding their blood-to-brain 
transport characteristics. The conversion from class to BBBin-response is given in Figure 1. In the 
Supplementary Information (Table S5), the overall BBBin-responses of the included peptides are 
listed. Although MTR is currently the “golden standard” method for evaluation of the BBB influx of 
peptides, it is currently not clear how much weight has to be justifiably attributed to Kin (MTR) 
compared to the other BBB influx response types. Therefore, at this moment, the contribution of the 
different response types to the overall BBBin-response was not weighed. 
 
Evaluation of the classification 
For two-thirds (n = 10) of the peptides having data available for more than one influx response type 
(n = 15), the classification based on these different response types corresponded well, indicating the 
appropriateness of the classification. Moreover, our BBB influx classification of peptides was verified 
by comparing our result with the appreciation by the original authors, which is visualized in Figure 2.  
 
Figure 2. Evaluation of correspondence between BBB influx classes and appreciation by the original authors.  
A positive correspondence was attributed if the authors concluded the same classification, allowing one class 
difference. If the calculated influx class and the estimation of the authors differed more than one influx class, a 
negative correspondence was concluded. 
 
The comments of the authors on the individual BBB influx response data are listed in the 
Supplementary Information (Table S1-S4). This cross-verification indicated a 75% correspondence 
between our classification method, based on all available BBB influx responses for peptides, and the 
appreciation of the BBB influx of the peptides by the authors who investigated the peptides. The 
observed 75% correspondence between our classification method and the authors’ conclusions thus 
justified our classification approach. 
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Application of the BBBin-response  
In the selected data set, seven groups of peptides could be identified based on their biological 
functionality. In Figure 3, the distribution of the BBBin-response within these different groups is 
visualized.  
 
Figure 3. Distribution of the BBBin-responses, visualized using a box-and-whisker plot, in the seven groups of 
peptides identified in the investigated data set based on their biological function. The number of peptides per 
group are indicated under the box-and-whisker plots. 
 
The PACAP/glucagon/VIP/secretin family showed the highest BBB influx (median high BBB influx). 
This group of peptide hormones is widely distributed in the body, but especially in the brain and gut 
and displays pleiotropic physiological functions, i.a. neurotransmitter, neuromodulatory and 
neurotrophic properties [14]. The high median BBBin-response indicates that peripherally synthesized 
peptides can reach the brain as well, which also has therapeutic implications [14]. The antimicrobial 
(AMP) and cell-penetrating peptides (CPP), which are rich in basic arginine and/or lysine residues, 
had a median medium BBB influx [15,16]. Cationization of peptides has already been demonstrated 
to improve brain uptake, as the positive charges enable to use an adsorptive-mediated transcytosis 
mechanism to cross the BBB [17].  However, we could not demonstrate a saturable influx mechanism 
for CPPs when we investigated their BBB transport characteristics of five representative peptides, 
which is further elaborated in Chapter V. For the opioid peptides, which can alleviate centrally 
mediated pain, a low median BBBin-response was calculated. This result was expected as these 
peptides suffer from a low brain influx and significant efflux out of the brain due to their structural 
characteristics, resulting in poor net BBB transport [18]. Several strategies are now explored to 
enhance their brain influx [18]. The food ingestion peptides also show a low median brain influx. This 
group of peptides is involved in the regulation of feeding. Some of these peptides enter the brain 
using a simple passive diffusion, while others use a saturable transport system. Due to their 
regulatory function, this transport system can be influenced by fluctuations in blood levels of 
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nutrients, resulting in a varying extent of brain influx [19]. Finally, the somatostatin analogs had a 
very low median brain influx, which can be explained by a serum-related factor, like protein-binding 
or an aggregation-promoting factor limiting the brain influx of these peptides [20]. 
When the distribution of the BBBin-response was evaluated in function of the used transport type to 
cross the BBB, there was no difference determined between the peptides using a saturable or non-
saturable mechanism (Figure 4).  
 
Figure 4. BBBin-response distribution in function of used transport type to cross the BBB. The number of 
peptides per transport type group are indicated under the box-and-whisker plots. 
 
4. APPLICATION OF THE CLASSIFICATION METHOD AND BBBIN-
RESPONSE 
Historically, peptides were believed not to cross the BBB as a result of the unsuitability of the 
traditional techniques, like the brain uptake index (BUI) which is not sensitive enough to measure the 
influx of the slowly BBB-penetrating peptides [21]. However, during the last decades, numerous 
studies have demonstrated the ability of peptides to overcome the BBB [22-25]. Currently, a variety 
of methods is used to describe the BBB influx properties of peptides, which are numerically 
expressed using different BBB influx response types. Moreover, in most BBB transport studies, a 
negative and/or positive control are not included, making it very difficult, if not impossible, to 
globally compare the brain influx of peptides [11]. To overcome this problem, we introduced a 
classification system and unified response, BBBin. Four different BBB influx response types, for which 
at least three quantitative data were available, were used. These influx responses were obtained 
using different techniques, have different units and are not directly inter-comparable. Based on their 
distribution, visualized using a box-and-whisker plot, each response type was classified into five BBB 
influx classes ranging from very low to very high BBB influx. Next to this classification, a more 
quantitative approach is useful, for example when the same peptide was investigated using different 
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techniques and an overall but simple BBB influx measure is required. Therefore, the resulting classes 
were converted to a BBBin-response, which is a scaled value ranging between zero (no influx) to ten 
(very high influx), allowing to calculate an overall brain influx response independent from the influx 
response type from which it was derived.  
Our approach was verified by demonstrating a 75% correspondence between our classification and 
the qualitative appreciation by the authors who performed the experiments. Figure 2 shows that the 
correspondence between our classification method and the estimation by the authors is high for 
class 2 and 3. However, the predictive power is much poorer for the other three BBB influx classes, 
explained by the fact that a negative correspondence was mostly attributed when the authors did 
not estimate the brain influx properties of the investigated peptides, which we ourselves interpreted 
that as class 2 or 3 without allowing any class difference. Therefore, we estimate this cross-
verification method, although being rather qualitative and to some extent subjective, valuable. The 
obtained correspondence indicates that our conclusions are in line with the opinion of the authors, 
based on their scientific experience. For two-thirds of the peptides for which quantitative data were 
available for more than one BBB influx response type, the classification corresponded well, i.e. only 
one class difference. For other peptides, the deviating classification could be explained by differences 
in experimental factors, illustrating the use of the BBBin-response during the evaluation of 
quantitative data for BBB influx of peptides. 
Inherent to any data reduction technique, the use of this classification and the unified BBBin-response 
includes a loss of details on the BBB transport, e.g. clearance versus permeability or peptide serum 
stability, serum protein binding or the presence of an efflux out of the brain, all influencing the net 
brain influx [26]. The overall BBBin-response also misses the interpretational aspects which are 
included in the individual BBB influx responses. However, our brain influx classification and BBBin-
response permit direct comparison of the overall BBB influx characteristics of peptides, despite 
different methods being used. Moreover, it is the first time that a ready-to-use response is proposed: 
researchers can classify and calculate the BBBin-response for newly investigated peptides by fitting 
their results in Table 1. This approach can be applied to other techniques and related BBB transport 
responses if sufficient data are available. For example, future recalculation of the classification 
system might be beneficial for the Pin vivo response, for which only six data were available during this 
study. Seen the availability of a considerable amount of data for the other three selected influx 
response types (n ≥ 21), we consider them more robust in time. The current awareness of the value 
of publishing negative research outcomes will also prevent the evolution to positively biased 
quantitative data for BBB influx of peptides, ultimately influencing the BBBin classification study of 
peptides [27].   
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The BBBin-response offers a framework to discuss and benchmark the brain influx the BBB transport 
results of peptides in a broader perspective. For example, for PACAP 38, a 30% faster influx into the 
brain was demonstrated than for PACAP 27 [28]. These conclusions can be nuanced by our 
classification system, which indicates that both peptides show a very high influx into the brain.   
The scope of this study was not to provide new insights in the mechanisms that influence the BBB 
influx properties of peptides. However, the BBB influx class, a categorical value, and the BBBin-
response, a continuous value, can be used to further explore the brain influx of peptide. For example, 
seven different biological functionalities were identified for the investigated peptides. We observed 
differences in median BBBin-response between these functionally different groups of peptides. The 
high median BBBin-response of the PACAP/glucagon/VIP/secretin family indicates that the 
peripherally synthetized peptides can reach the brain, while the low median BBBin-response of the 
opioid peptides indicates that structural modifications are needed to ensure efficient pain therapy. 
However, poor BBB penetration does not necessarily means no biological effect, as was 
demonstrated for cyclo(His-Pro). This peptide showed a very low brain influx rate, but a sufficient 
amount of the peptide reached the brain parenchyma, i.e. 0.01% of the injected dose per gram 
tissue, to reverse alcohol-induced narcosis [19,29]. No difference was observed in distribution of 
BBBin-responses between peptides using a saturable or non-saturable transport system. This was 
unexpected as peptides using a saturable transport system generally show a higher net transfer 
across the BBB compared to those that cross the BBB by passive diffusion [22]. However, to draw 
substantiated conclusions on the BBBin distribution of peptides having different biological functions, 
a larger data set is needed. Still, the comparison of the BBBin for functionally different peptides is an 
illustrative example for the application of our classification method within the constraints of the 
current limited data set.  
 
5. CONCLUSIONS 
Currently, data on BBB influx properties of peptides suffer from inconsistencies with regards to used 
techniques and influx response types, making it difficult to directly and objectively compare the BBB 
influx properties of peptides. The introduced BBB influx classification system and derived BBBin-
response, a scaled value ranging between zero and ten, allow ranking of peptides based on their BBB 
influx characteristics despite differences in experimental set-up. This unified response opens 
perspectives to further unravel the transport mechanism and to determine required structural 
features for BBB transport of peptides. 
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SUPPLEMENTARY INFORMATION  
Table S1: Classification Kin (MTR) data. 
 
Lower limit 
(ml/(g × min)) 
Upper limit 
(ml/(g × min))  
BBB 
influx 
response  
   Class 1 0.00E+00 1.83E-04 included 1 
    Class 2 1.83E-04 3.78E-04 included 3 
    Class 3 3.78E-04 9.37E-04 included 5 
    Class 4 9.37E-04 2.10E-03 included 7 
    Class 5 2.10E-03 ∞ 
 
9 
    
ID Peptide Name 
Kin (MTR) 
(ml/(g × min)) 
BBB 
influx 
class 
BBB 
influx 
response 
PubID 
(Brainpeps) 
Comment author 
Correspond
? 
6 
Vapreotide;  
RC-160 
9.23E-05 1 1 11 
The entry rates were 
generally low. 
+ 
7 CRH 2.24E-04 2 3 24 
Influx into brain was slower 
than UCN II, which crossed 
the BBB at a moderate rate. 
+ 
8 PACAP 27 2.13E-03 5 9 30 
Enters brain at a modest 
rate. 
- 
9 PACAP 38 2.86E-03 5 9 30 
Faster than PACAP-27 which 
enters at modest rate. 
- 
10 VIP 4.00E-04 3 5 22 Moderate rate of uptake. + 
11 Neuropeptide Y 1.94E-04 2 3 33 
NPY entered brain 
significantly higher than the 
albumin control; slightly 
higher influx than cHP. 
+ 
14 Orexin A 3.09E-04 2 3 35 Rapidly enters the brain. - 
16 Exendin-4 4.62E-04 3 5 39 Entry at a fast rate. + 
17 F13,Y19-MCH 5.20E-05 1 1 34 
P-T-MCH does not 
significantly cross the BBB, 
probably because of its 
binding to serum proteins. 
+ 
21 Adrenomedullin 5.83E-04 3 5 37 
Much faster than albumin 
(vascular control). 
+ 
22 Urocortin-I 1.68E-04 1 1 38, 18 
Urocortin I does not 
significantly penetrate the 
BBB. 
+ 
22 Urocortin-I 0.00E+00 1 1 113 
Adult mice did not transport 
urocortin across BBB. 
+ 
23 Insulin 3.46E-04 2 3 32 Slow influx. + 
23 Insulin 8.66E-04 3 5 129 Insulin crosses the BBB. + 
23 Insulin 6.88E-04 3 5 129 Insulin crosses the BBB. + 
25 Ghrelin 3.24E-04 2 3 31 Influx, but not estimated. + 
27 Amylin 9.54E-04 4 7 32 Crosses BBB. - 
27 Amylin 8.99E-04 3 5 126 Amylin crosses the BBB. + 
28 [Tyr10] Secretin-27 9.49E-04 4 7 77 
SA was taken up by brain at 
a modest rate of 0.9-1.5 
µl/(g x min). 
+ 
31 Endomorphin-1 1.06E-03 4 7 97 High influx constant rates. + 
32 Endomorphin-2 1.14E-03 4 7 97 High influx constant rates. + 
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ID Peptide Name 
Kin (MTR) 
(ml/(g × min)) 
BBB 
influx 
class 
BBB 
influx 
response 
PubID 
(Brainpeps) 
Comment author Correspond? 
47 
Pancreatic 
Polypeptide 
1.15E-03 4 7 47 Able to cross BBB. - 
55 
Epidermal Growth 
Factor 
2.02E-03 4 7 54 
EGF crosses the BBB 
rapidly. 
+ 
57 
[Met(O)67]CART-
(55-102) 
5.10E-04 3 5 58 Rapid rate of entry. + 
58 
Mahogany (1377-
1428) 
5.53E-04 3 5 60 Crosses BBB. + 
59 Urocortin II 5.91E-04 3 5 24 Moderate rate of uptake. + 
66 Peptide YY (3-36) 4.90E-04 3 5 41 
Similar rate to leptin. Based 
on our classification 
method, leptin and PYY 
belong to the same class 
(data leptin not included in 
this study). 
+ 
74 CTAP 0.00E+00 1 1 97 Very low to no influx. + 
83 cHP 1.80E-04 1 1 58 
cHP has the slowest Ki of a 
group of peptides involved 
in food ingestion. 
+ 
83 cHP 1.79E-04 1 1 104 
The rate of entry of cHP 
was low in comparison with 
other peptides. 
+ 
93 DAMGO 4.00E-04 3 5 97 Very low to no influx. - 
100 TAPA 2.65E-04 2 3 95 
Influx similar to sucrose 
which is slightly permeable 
for normal BBB. 
+ 
104 TAPS 1.80E-04 1 1 97 Very low to no influx. + 
105 TAPP 1.12E-03 4 7 97 High influx constant rates. + 
106 CTOP 2.40E-04 2 3 97 Very low to no influx. + 
110 Dermorphin 2.18E-03 5 9 97 Very high influx into brain. + 
110 Dermorphin 1.90E-04 2 3 114 
Positive control, shows 
influx. 
+ 
110 Dermorphin 3.50E-04 2 3 120 
Positive control, shows 
influx. 
+ 
110 Dermorphin 1.60E-04 1 1 120 
Positive control, shows 
influx. 
- 
110 Dermorphin 3.56E-04 2 3 120 
Positive control, shows 
influx. 
+ 
113 Obestatin (mouse) 1.86E-03 4 7 8 
Extremely fast influx into 
the brain. 
+ 
114 P41 3.68E-04 2 3 102 
Slower influx properties 
(based in initial Kin data). 
+ 
115 P42 2.49E-04 2 3 102 
Slower influx properties 
(based in initial Kin data). 
+ 
116 P43 0.00E+00 1 1 102 
Rapid and high influx 
(based on initial Kin data, 
here Kin,SS reported). 
- 
117 Sb-Aba 4.46E-04 3 5 102 
Rapid and high influx 
(based on initial Kin data, 
here Kin,SS reported). 
+ 
121 Api88 3.70E-04 2 3 98 Small but significant influx. + 
122 Apidaecin Api137 7.30E-04 3 5 114 Influx, no estimation. - 
130 
Agouti-Related 
Protein (83-132) 
5.70E-05 1 1 64 
AgRP(83-132) crosses BBB 
very slowly. 
+ 
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ID Peptide Name 
Kin (MTR) 
(ml/(g × min)) 
BBB 
influx 
class 
BBB 
influx 
response 
PubID 
(Brainpeps) 
Comment author Correspond? 
131 RC-121 4.01E-05 1 1 11 
The entry rates were 
generally low; entry rate 
was near the value 
generally found for 
albumin. 
+ 
132 RC-161 2.32E-04 2 3 11 
The entry rates were 
generally low. 
+ 
134 
(3-methyl-His²) 
Thyrotropin-
releasing 
hormone 
1.15E-03 4 7 89 
Significantly higher than 
sucrose and similar to 
previously reported small 
peptides (medium to high 
influx). 
- 
135 SKB P5 1.46E-04 1 1 102 
Rapid and high influx 
(based on initial Kin data, 
here Kin,SS reported). 
- 
136 AN110 3.43E-04 2 3 102 
Rapid and high influx 
(based on initial Kin data, 
here Kin,SS reported). 
- 
139 ADAB 5.15E-05 1 1 105 
Slower rate of influx than 
TAPA (class 2), slow onset 
of antinociceptive effect. 
+ 
140 ADAMB 2.90E-05 1 1 105 
Slower rate of influx than 
TAPA (class 2), slow onset 
of antinociceptive effect. 
+ 
141 cationic AVP4-9 3.10E-04 2 3 106 
cAVP4-9 is effectively 
transported across BBB. 
+ 
154 Oncocin 4.40E-04 3 5 114 Influx, no estimation. + 
155 Drosocin 8.60E-04 3 5 114 Influx, no estimation. - 
156 Drosocin Pro5Hyp 3.70E-04 2 3 114 Influx, no estimation. + 
157 LinS 4.50E-04 3 5 115 
Have favorable initial brain 
influx rates. 
+ 
158 LinNMe 1.70E-04 1 1 115 
Have favorable initial brain 
influx rates. 
- 
159 CycS 1.10E-04 1 1 115 
Have favorable initial brain 
influx rates. 
- 
160 CycNMe 3.10E-04 2 3 115 
Have favorable initial brain 
influx rates. 
+ 
168 SynB3 8.20E-04 3 5 120 High influx into brain. + 
169 Tat 47-57 1.13E-03 4 7 120 High influx into brain. + 
170 pVEC 6.05E-03 5 9 120 Very high influx into brain. + 
171 Transportan 10 1.14E-04 1 1 120 Low influx rate. + 
172 TP10-2 3.59E-04 2 3 120 Low influx rate. + 
173 
D-[Ala1]-peptide 
T-amide 
1.13E-03 4 7 121 
Crosses the BBB to a 
significantly greater extent 
than albumin. 
- 
173 
D-[Ala1]-peptide 
T-amide 
2.50E-03 5 9 121 
Crosses the BBB to a 
significantly greater extent 
than albumin. 
- 
173 
D-[Ala1]-peptide 
T-amide 
2.92E-03 5 9 121 
Crosses the BBB to a 
significantly greater extent 
than albumin. 
- 
173 
D-[Ala1]-peptide 
T-amide 
2.50E-03 5 9 121 
Crosses the BBB to a 
significantly greater extent 
than albumin. 
- 
174 
Neurotensin8-13 
analog 
5.12E-04 3 5 122 
NT1 crosses the BBB. Kin in 
lower half of the range of 
Kin's of other peptides. 
+ 
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ID Peptide Name 
Kin (MTR) 
(ml/(g × min)) 
BBB 
influx 
class 
BBB 
influx 
response 
PubID 
(Brainpeps) 
Comment author Correspond? 
186 MIF-1 2.37E-02 5 9 125 
One of the highest blood to 
brain rate of influx found 
for a peptide. 
+ 
187 β-Amyloid1-28 3.86E-04 3 5 130 
β-Amyloid1-28 entered brain 
slowly. 
+ 
216 Insulin detemir 0.00E+00 1 1 137 
Insulin detemir not 
transported across BBB. 
+ 
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Table S2: Classification Kin (Perfusion) data. 
  
Lower limit 
(ml/(g × min)) 
Upper limit 
(ml/(g × min)) 
  
BBB 
influx 
response 
   
Class 1 0.00E+00 9.30E-04 included 1 
    
Class 2 9.30E-04 2.34E-03 included 3 
    
Class 3 2.34E-03 4.32E-03 included 5 
    
Class 4 4.32E-03 1.25E-02 included 7 
    
Class 5 1.25E-02 ∞   9 
    
ID Peptide Name 
Kin (Perfusion) 
(ml/(g × min)) 
BBB 
influx 
class 
BBB 
influx 
response 
PubID 
(Brainpeps) 
Comment author Correspond? 
9 PACAP 38 1.53E-02 5 9 30 Fast influx. + 
10 VIP 2.16E-03 2 3 22 Moderate rate of uptake. + 
16 Exendin-4 1.90E-02 5 9 39 
Exendin-4 crossed directly 
the BBB at fast rate. 
+ 
17 F13, Y19-MCH 5.94E-04 1 1 34 
P-T-MCH does not 
significantly cross the BBB 
probably because of its 
binding to serum proteins.  
+ 
21 Adrenomedullin 6.76E-04 1 1 37 
Much faster than albumin 
(vascular control). 
- 
22 Urocortin-I 8.60E-04 1 1 18 
Urocortin I does not 
significantly penetrate the 
BBB. 
+ 
28 [Tyr10] Secretin-27 2.73E-03 3 5 77 
SA was taken up by brain at 
a modest rate of 0.9-1.5 
µl/(g x min). 
+ 
37 Biphalin 2.34E-03 2 3 91 
Influx significantly greater 
than sucrose. 
+ 
38 DPDPE 1.46E-03 2 3 87 
Brain uptake of DPDPE was 
significantly greater than 
sucrose, a vascular marker. 
+ 
40 SAM 995 1.00E-03 2 3 26 Enters brain. + 
41 SAM 1095 2.20E-03 2 3 26 
Enters brain ( x faster than 
peptide 40). 
+ 
59 Urocortin II 2.02E-02 5 9 24 High influx rate. + 
61 LHRH 1.25E-02 4 7 66 
The results indicate that 
there is a bidirectional 
transport across the BBB. 
- 
64 
Des-Octanoyl 
Ghrelin 
5.73E-04 1 1 31 Influx, but not estimated. - 
66 Peptide YY (3-36) 2.34E-03 2 3 41 
Similar rate to leptin (no 
data available). Thus influx 
into the brain. 
+ 
69 
p-[Cl-Phe4’4’] 
biphalin 
3.39E-03 3 5 91 
Influx significantly greater 
than sucrose. 
+ 
74 CTAP 1.61E-03 2 3 69 
Greater amounts of 
radioactivity were detected 
in the brain for CTAP than 
inulin. 
+ 
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ID Peptide Name 
Kin (Perfusion) 
(ml/(g × min)) 
BBB 
influx 
class 
BBB 
influx 
response 
PubID 
(Brainpeps) 
Comment author Correspond? 
177 
Arginine 
Vasopressin 
2.37E-03 3 5 127 
Transfer rate 10 times 
higher than sucrose. 
+ 
185 N-Tyr-MIF-1 4.44E-03 4 7 139 
Entry rate significantly 
higher than the vascular 
marker albumin. 
- 
216 Insulin detemir 0.00E+00 1 1 137 
Insulin detemir not 
transported across BBB. 
+ 
217 Ziconotide 4.20E-03 3 5 138 
Brain uptake statistically 
greater than inulin. Brain 
amounts of Ziconotide are 
low. 
+ 
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Table S3: Classification Pin vitro data. 
  
Lower limit 
(cm/s) 
Upper limit 
(cm/s) 
  
BBB 
influx 
response 
    
Class 1 0.00E+00 1.74E-05 included 1 
     
Class 2 1.74E-05 3.44E-05 included 3 
     
Class 3 3.44E-05 8.21E-05 included 5 
     
Class 4 8.21E-05 1.53E-04 included 7 
     
Class 5 1.53E-04 ∞   9 
     
ID Peptide Name P (cm/s) 
BBB 
influx 
class 
BBB 
influx 
response 
PubID 
(Brainpeps) 
Comment author Correspond? 
18 Deltorphin I 3.79E-05 3 5 132 
Able to cross the in vitro 
BBB. Deltorphin I has 
higher permeability 
compared to majority of 
analogues. 
+ 
19 Deltorphin II 3.92E-05 3 5 132 
Able to cross the in vitro 
BBB. Deltorphin I has 
higher permeability 
compared to majority of 
analogues. 
+ 
29 [Met5] Enkephalin 2.00E-05 2 3 27 
Rapidly degradated in 
plasma. Inhibition of 
endothelial cell peptidases 
increased significantly the 
permeability. 
+ 
29 [Met5] Enkephalin 7.74E-05 3 5 29 
Rapidly degraded in 
plasma, inhibition of 
endothelial cell peptidases 
allows calculation of P. 
Influx not estimated.  
+ 
32 Endomorphin-2 7.84E-06 1 1 101 
Influx of EM-2 and analogs 
into brain is low but 
significantly higher than 
sodium fluorescein. 
+ 
32 Endomorphin-2 5.32E-05 3 5 135 
Endomorphin traverses the 
in vitro BBB. 
+ 
37 Biphalin 9.17E-05 4 7 91, 29 Significant influx into brain. + 
38 DPDPE 8.21E-05 3 5 29 Crosses BBB. + 
38 DPDPE 8.21E-05 3 5 136 
Shows in vitro BBB 
permeability. 
+ 
39 [Glu4]Deltorphin 6.33E-05 3 5 29 
Crosses BBB to a lower 
extent than other tested 
compounds. 
+ 
69 
p-[Cl-Phe4’4’] 
biphalin 
1.53E-04 4 7 91, 29 
Significant influx into brain, 
but higher than biphalin. 
- 
72 [p-ClPhe4] DPDPE 1.38E-04 4 7 29 
Crosses BBB to a higher 
extent than DPDPE and 
other tested compounds. 
- 
137 
Dmt1-
Endomorphin 2 
1.49E-05 1 1 101 
Influx of EM-2 and analogs 
into brain is low but 
significantly higher than 
sodium fluorescein. 
+ 
147 
[(1S,2R)-Acpc]²-
Endomorphin 2 
1.48E-05 1 1 101 
Relatively low BBB 
permeability. 
+ 
148 
[(1S,2R)-Achc]²-
Endomorphin 2 
1.51E-05 1 1 101 
Relatively low BBB 
permeability. 
+ 
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ID Peptide Name P (cm/s) 
BBB 
influx 
class 
BBB 
influx 
response 
PubID 
(Brainpeps) 
Comment author Correspond? 
189 
[D-Ala2,Ser4,D-
Val5]deltorphin 
1.95E-05 2 3 132 
Able to cross the in vitro 
BBB. Have lower 
permeability compared to 
parent peptide. 
+ 
190 
[D-Ala2,Ser4,D-
Ala5]deltorphin 
2.35E-05 2 3 132 
Able to cross the in vitro 
BBB. Have lower 
permeability compared to 
parent peptide. 
+ 
191 
[D-Ala2,Gln4,D-
Val5]deltorphin 
1.12E-05 1 1 132 
Able to cross the in vitro 
BBB. Have lower 
permeability compared to 
parent peptide. 
- 
192 
[D-Ala2,Gln4,D-
Ala5]deltorphin 
1.30E-05 1 1 132 
Able to cross the in vitro 
BBB. Have lower 
permeability compared to 
parent peptide. 
- 
193 
[Arg-1,Arg0,D-
Ala2]deltorphin II 
2.69E-05 2 3 132 
Able to cross the in vitro 
BBB. Decreased ability to 
cross the in vitro BBB 
compared to parent 
peptide. 
+ 
194 
[Arg0,D-
Ala2]deltorphin II 
3.18E-05 2 3 132 
Able to cross the in vitro 
BBB.  
+ 
195 
[Lys-1,Lys0,D-
Ala2]deltorphin II 
2.35E-05 2 3 132 
Able to cross the in vitro 
BBB. Decreased ability to 
cross the in vitro BBB 
compared to parent 
peptide. 
+ 
196 
[Lys0,D-
Ala2]deltorphin II 
1.42E-05 1 1 132 
Able to cross the in vitro 
BBB. Decreased ability to 
cross the in vitro BBB 
compared to parent 
peptide. 
- 
197 
[Ala-1,Pro0,D-
Ala2]deltorphin II 
2.90E-05 2 3 132 
Able to cross the in vitro 
BBB. Similar ability to cross 
the in vitro BBB compared 
to parent peptide. 
+ 
198 
[Pro-1,Pro0,D-
Ala2]deltorphin II 
3.70E-05 3 5 132 
Able to cross the in vitro 
BBB. Similar ability to cross 
the in vitro BBB compared 
to parent peptide. 
+ 
199 
[Abu-1,Abu0,D-
Ala2]deltorphin II 
4.88E-05 3 5 132 
Able to cross the in vitro 
BBB. Similar ability to cross 
the in vitro BBB compared 
to parent peptide. 
+ 
201 DPLPE-Phe-NH2 2.78E-05 2 3 134 
Shows passage across 
BBMEC monolayers. 
+ 
202 DPLPE-Phe-OH 1.95E-05 2 3 134 
Shows passage across 
BBMEC monolayers. 
+ 
203 
p-[Cl-Phe4]DPLPE-
Phe 
8.33E-05 4 7 134 
Show enhanced in vitro BBB 
permeability compared to 
the parent peptides, which 
shows passage across 
BBMEC monolayers. 
+ 
204 
p-[Br-Phe4]DPLPE-
Phe 
5.56E-05 3 5 134 
Shows enhanced in vitro 
BBB permeability compared 
to the parent peptides, 
which shows passage 
across BBMEC monolayers. 
+ 
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ID Peptide Name P (cm/s) 
BBB 
influx 
class 
BBB 
influx 
response 
PubID 
(Brainpeps) 
Comment author Correspond? 
205 
p-[F-Phe4]DPLPE-
Phe 
2.08E-05 2 3 134 
No significantly different in 
vitro BBB permeability 
compared to the parent 
peptide which shows 
passage across BBMEC 
monolayers. 
+ 
206 
p-[I-Phe4]DPLPE-
Phe 
1.67E-05 1 1 134 
No significantly different in 
vitro BBB permeability 
compared to the parent 
peptide which shows 
passage across BBMEC 
monolayers. 
- 
207 
Guanidino-
Endomorphin II 
5.42E-05 3 5 135 
Shows similar permeability 
compared to Endomorphin 
II, which traverses the in 
vitro BBB. 
+ 
208 Morphiceptin 3.06E-05 2 3 135 
Morphiceptin showed no 
significant difference in 
permeability compared to 
Endomorphin II, which 
traverses the in vitro BBB. 
+ 
209 
Guanidino-
Morphiceptin 
6.70E-05 3 5 135 
Shows increased 
permeability compared to 
Morphiceptin, which 
traverses the in vitro BBB. 
+ 
210 Phe0-DPDPE 9.66E-05 4 7 136 
Shows higher BBB 
permeability coefficient 
than the parent peptide 
DPDPE (or DPLCE), which 
shows in vitro BBB 
permeability. 
+ 
211 DPDPE-Phe 8.61E-05 4 7 136 
Shows higher BBB 
permeability coefficient 
than the parent peptide 
DPDPE (or DPLCE), which 
shows in vitro BBB 
permeability. 
+ 
212 DPDPE-Arg-Gly 1.01E-04 4 7 136 
Shows higher BBB 
permeability coefficient 
than the parent peptide 
DPDPE (or DPLCE), which 
shows in vitro BBB 
permeability. 
+ 
213 
DPDPE-Phe-Ala-
NH-(CH2)5-CONH2 
8.33E-05 4 7 136 
Shows higher BBB 
permeability coefficient 
than the parent peptide 
DPDPE (or DPLCE), which 
shows in vitro BBB 
permeability. 
+ 
214 DPLCE 9.39E-05 4 7 136 
Shows higher BBB 
permeability coefficient 
than the parent peptide 
DPDPE (or DPLCE), which 
shows in vitro BBB 
permeability. 
+ 
215 DPLCE-Arg-Pro-Ala 9.14E-05 4 7 136 
Shows higher BBB 
permeability coefficient 
than the parent peptide 
DPDPE (or DPLCE), which 
shows in vitro BBB 
permeability. 
+ 
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ID Peptide Name P (cm/s) 
BBB 
influx 
class 
BBB 
influx 
response 
PubID 
(Brainpeps) 
Comment author Correspond? 
218 SNX-194 1.08E-05 1 1 138 
Structural analogs of 
Ziconotide show 
permeation. 
- 
219 SNX-231 1.32E-05 1 1 138 
Structural analogs of 
Ziconotide show 
permeation. 
- 
220 SNX-185 1.45E-05 1 1 138 
Structural analogs of 
Ziconotide show 
permeation. 
- 
 
CHAPTER III – CLASSIFICATION OF PEPTIDES ACCORDING TO THEIR BLOOD-BRAIN BARRIER INFLUX 
  
 
98 
Table S4: Classification Pin vivo data. 
 
Lower  
Limit (cm/s) 
Upper limit 
(cm/s)  
BBBin 
response     
Class 1 0.00E+00 4.75E-08 included 1 
     
Class 2 4.75E-08 9.50E-08 included 3 
     
Class 3 9.50E-08 4.34E-07 included 5 
     
Class 4 4.34E-07 5.65E-07 included 7 
     
Class 5 5.65E-07  
 
9 
     
ID Peptide name 
Pin vivo  
(cm/s) 
BBB 
influx 
class 
BBBin 
response 
PubID 
(Brainpeps) 
Comment author Correspond? 
37 Biphalin 3.90E-07 3 5 91 Significant influx into brain. + 
69 
p-[Cl-Phe4’4’] 
biphalin 
5.65E-07 4 7 91 
Significant influx into brain, 
but higher than biphalin. 
- 
90 DADLE 5.00E-08 2 3 107, 108 
Papp across BBB was very 
low. 
+ 
142 AOA-DADLE 1.20E-07 3 5 107, 108 Poor permeation. + 
143 CA-DADLE 4.00E-08 1 1 107, 108 Poor permeation. + 
144 OMCA-DADLE 7.00E-08 2 3 107, 108 Poor permeation. + 
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Table S5: Calculation median BBBin response. 
 
ID 
 
Name 
BBB influx response 
Kin (MTR) Kin (Perfusion) Pin vitro Pin vivo 
Median BBBin 
response1 
6 Vapreotide; RC-160 1 - - - 1 
7 CRH 3 - - - 3 
8 PACAP 27 9 - - - 9 
9 PACAP 38 9 9 - - 9 
10 VIP 5 3 - - 4 
11 Neuropeptide Y 3 - - - 3 
14 Orexin A 3 - - - 3 
16 Exendin-4 5 9 - - 7 
17 F13, Y19-MCH 1 1 - - 1 
18 Deltorphin I - - 5 - 5 
19 Deltorphin II - - 5 - 5 
21 Adrenomedullin 5 1 - - 3 
22 Urocortin-I 1 1 - - 1 
23 Insulin 5 - - - 5 
25 Ghrelin 3 - - - 3 
27 Amylin 6 - - - 6 
28 [Tyr10] Secretin-27 7 5 - - 6 
29 [Met5] Enkephalin - - 4 - 4 
31 Endomorphin-1 7 - - - 7 
32 Endomorphin-2 7 - 3 - 5 
37 Biphalin - 3 7 5 5 
38 DPDPE - 3 5 - 4 
39 [Glu4]Deltorphin - - 5 - 5 
40 SAM 995 - 3 - - 3 
41 SAM 1095 - 3 - - 3 
47 Pancreatic Polypeptide 7 - - - 7 
55 Epidermal Growth Factor 7 - - - 7 
57 [Met(O)67]CART-(55-102) 5 - - - 5 
58 Mahogany (1377-1428) 5 - - - 5 
59 Urocortin II 5 9 - - 7 
61 LHRH - 7 - - 7 
64 Des-Octanoyl Ghrelin - 1 - - 1 
66 Peptide YY (3-36) 5 3 - - 4 
69 p-[Cl-Phe4’4’] biphalin - 5 7 7 7 
72 [p-ClPhe4] DPDPE - - 7 - 7 
74 CTAP 1 3 - - 2 
83 cHP 1 - - - 1 
90 DADLE - - - 3 3 
93 DAMGO 5 - - - 5 
100 TAPA 3 - - - 3 
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ID Name 
BBB influx response 
Kin (MTR) Kin (Perfusion) Pin vitro Pin vivo 
Median BBBin 
response1 
104 TAPS 1 - - - 1 
105 TAPP 7 - - - 7 
106 CTOP 3 - - - 3 
110 Dermorphin 3 - - - 3 
113 Obestatin (mouse) 7 - - - 7 
114 P41 3 - - - 3 
115 P42 3 - - - 3 
116 P43 1 - - - 1 
117 Sb-Aba 5 - - - 5 
121 Api88 3 - - - 3 
122 Apidaecin Api137 5 - - - 5 
130 
Agouti-Related Protein  
(83-132) 
1 - - - 1 
131 RC-121 1 - - - 1 
132 RC-161 3 - - - 3 
134 
(3-methyl-His²)Thyrotropin-
releasing Hormone 
7 - - - 7 
135 SKB P5 1 - - - 1 
136 AN110 3 - - - 3 
137 Dmt1-Endomorphin 2 - - 1 - 1 
139 ADAB 1 - - - 1 
140 ADAMB 1 - - - 1 
141 cationic AVP4-9 3 - - - 3 
142 AOA-DADLE - - - 5 5 
143 CA-DADLE - - - 1 1 
144 OMCA-DADLE - - - 3 3 
147 
[(1S,2R)-Acpc]²-
Endomorphin 2 
- - 1 - 1 
148 
[(1S,2R)-Achc]²-
Endomorphin 2 
- - 1 - 1 
154 Oncocin 5 - - - 5 
155 Drosocin 5 - - - 5 
156 Drosocin Pro5Hyp 3 - - - 3 
157 LinS 5 - - - 5 
158 LinNMe 1 - - - 1 
159 CycS 1 - - - 1 
160 CycNMe 3 - - - 3 
168 SynB3 5 - - - 5 
169 Tat 47-57 7 - - - 7 
170 pVEC 9 - - - 9 
171 Transportan 10 1 - - - 1 
172 TP10-2 3 - - - 3 
173 D-[Ala1]-peptide T-amide 9 - - - 9 
174 Neurotensin8-13 analog 5 - - - 5 
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ID 
 
Name 
BBB influx response 
Kin (MTR) Kin (Perfusion) Pin vitro Pin vivo 
Median BBBin 
response1 
177 Arginine Vasopressin - 5 - - 5 
185 N-Tyr-MIF-1 - 7 - - 7 
186 MIF-1 9 - - - 9 
187 β-Amyloid1-28 5 - - - 5 
189 
[D-Ala2,Ser4,D-
Val5]deltorphin 
- - 3 - 3 
190 
[D-Ala2,Ser4,D-
Ala5]deltorphin 
- - 3 - 3 
191 
[D-Ala2,Gln4,D-
Val5]deltorphin 
- - 1 - 1 
192 
[D-Ala2,Gln4,D-
Ala5]deltorphin 
- - 1 - 1 
193 
[Arg-1,Arg0,D-Ala2]deltorphin 
II 
- - 3 - 3 
194 [Arg0,D-Ala2]deltorphin II - - 3 - 3 
195 
[Lys-1,Lys0,D-Ala2]deltorphin 
II 
- - 3 - 3 
196 [Lys0,D-Ala2]deltorphin II - - 1 - 1 
197 
[Ala-1,Pro0,D-Ala2]deltorphin 
II 
- - 3 - 3 
198 
[Pro-1,Pro0,D-Ala2]deltorphin 
II 
- - 5 - 5 
199 
[Abu-1,Abu0,D-
Ala2]deltorphin II 
- - 5 - 5 
201 DPLPE-Phe-NH2 - - 3 - 3 
202 DPLPE-Phe-OH - - 3 - 3 
203 p-[Cl-Phe4]DPLPE-Phe - - 7 - 7 
204 p-[Br-Phe4]DPLPE-Phe - - 5 - 5 
205 p-[F-Phe4]DPLPE-Phe - - 3 - 3 
206 p-[I-Phe4]DPLPE-Phe - - 1 - 1 
207 Guanidino-Endomorphin II - - 5 - 5 
208 Morphiceptin - - 3 - 3 
209 Guanidino-Morphiceptin - - 5 - 5 
210 Phe0-DPDPE - - 7 - 7 
211 DPDPE-Phe - - 7 - 7 
212 DPDPE-Arg-Gly - - 7 - 7 
213 
DPDPE-Phe-Ala-NH-(CH2)5-
CONH2 
- - 7 - 7 
214 DPLCE - - 7 - 7 
215 DPLCE-Arg-Pro-Ala - - 7 - 7 
216 Insulin detemir 1 1 
 
- 1 
217 Ziconotide - 5 
 
- 5 
218 SNX-194 - - 1 - 1 
219 SNX-231 - - 1 - 1 
220 SNX-185 - - 1 - 1 
1 Example of calculation of median BBBin response, see below. 
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Example calculation median BBBin response of Urocortin I (ID 22): 
 Kin (MTR): more than one value available: Kin = 1.6810-4 ml/(g × min) and Kin = 0 ml/(g × min). 
Both results correspond with class 1, thus a BBBin-response of 1. The median BBBin-response 
of Urocortin I for the Kin (MTR) response type equals 1. 
 Kin (Perfusion): one result available: Kin = 8.6010-4 ml/(g × min), which corresponds with a 
BBBin-response of 1. 
 No data available for Urocortin I for Pin vitro and Pin vivo responses. 
 The median BBBin-response of Urocortin equals the median of the BBBin-response of the Kin (MTR) 
response (calculated to be 1) and of the Kin (Perfusion) response (calculated to be 1) and is 1. 
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“Quality is never an accident,  
it is always the result of intelligent effort.” 
 
John Ruskin 
(°1819 - †1900, English writer and critic of art and architecture) 
 
 
 
 
 
 
 
Parts of this chapter were published: 
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control of cationic cell-penetrating peptides. J. Pharmaceut. Biomed. 2016; 117: 289-297. 
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ABSTRACT 
During fundamental research, it is recommended to evaluate the test compound identity and 
purity in order to obtain reliable study outcomes. For peptides, quality control (QC) analyses are 
routinely performed using reversed-phase liquid chromatography coupled to an ultraviolet (UV) 
detector system. These traditional QC methods, using a C18 column and a linear gradient with 
formic acid (FA) as acidic modifier in the mobile phase, might not result in optimal 
chromatographic performance for basic peptides due to their cationic nature and hence may lead 
to erroneous results. Therefore, the influence of the used chromatographic system on the final QC 
results of basic peptides was evaluated using five cationic cell-penetrating peptides and five C18-
chromatographic systems, differing in the column particle size (high performance liquid 
chromatography (HPLC) versus ultra-high performance liquid chromatography (UHPLC)), the acidic 
modifier (FA versus trifluoroacetic acid (TFA)), and the column temperature (30°C versus 60°C). 
Our results indicated that a UHPLC system with the C18 column thermostated at 30°C and a mobile 
phase containing TFA, was the most suitable routine QC analysis method for cationic peptides, 
outperforming the other systems in sensitivity and resolution. We also demonstrated the 
applicability of a single quad mass spectrometry (MS) detector system during QC analysis of 
(cationic) peptides, allowing identification of the peptide and its impurities, as well as the 
evaluation of the peak purity.  
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CHAPTER IV 
QUALITY CONTROL OF  
CATIONIC CELL-PENETRATING PEPTIDES 
Main focus in this chapter: 
 To find a suitable reversed-phase C18 chromatographic analysis method for identification and 
purity profiling of cationic cell-penetrating peptides that are used for the evaluation of their 
BBB transport characteristics. 
 To illustrate that the used chromatographic system determines the quality control conclusions. 
 To demonstrate the use of a single quad mass spectrometry detector during routine quality 
control of (cationic) peptides. 
 
1. RELEVANCE OF QUALITY CONTROL OF PEPTIDES DURING 
BIOCHEMICAL RESEARCH 
During fundamental research, pharmaceutical regulatory guidelines do not (yet) apply. However, in 
order to obtain reliable research outcomes, quality assurance practices should already be employed 
during the early research phase [1,2]. In a later stage, when following Good Laboratory Practices 
(GLP), proper characterization of the test compound is mandatory prior to perform studies [3]. 
During quality control (QC) of peptides, the identity is verified and the presence of impurities is 
evaluated in order to quantify and qualify the peptide purity. For ligand binding assays, in vitro 
bioassays and in vivo studies, the total amount of peptide impurities is recommended to be lower 
than 5% [4]. Synthetic peptides can be chemically synthesized using Solid-Phase Peptide Synthesis 
(SPPS), in which amino acids are linked during individual, consecutive coupling steps, ultimately 
resulting in the desired peptide sequence [5]. During the synthesis process, the C-terminus of the 
peptide is covalently linked to a solid support matrix. The N-terminus of the attached amino acid 
reacts with incoming amino acids, which are N-α-protected, to form a covalent peptide bond. The N-
α-protection group, of which the 9-fluorenylmethoxycarbonyl group (Fmoc) is the most widely used, 
avoids undesired reactions during peptide synthesis [5]. Structurally related synthesis impurities 
encompass amino acid deletion or insertion, incomplete removal of protection groups, oxidation or 
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reduction of amino acid residues, diastereoisomerization, dimers and oligomers, as well as side and 
end chain impurities [5]. In literature, several examples are available in which the presence of related 
peptide impurities complicate the interpretation of study results or cause erroneous study 
conclusions [6-9]. Moreover, the major peak found during QC analysis of peptide batches was not 
always the ordered peptide as already demonstrated for the quorum sensing peptide CVFSLFKKCN 
and obestatin, emphasizing the importance of thorough identification and purity evaluation of the 
test compound prior to performing biomedical experiments [4,10].  
In this study, the quality aspects of a set of five cell-penetrating peptides (CPPs) will be evaluated. 
Cell-penetrating peptides are a particular group of peptides, being able to cross cellular barriers 
without causing significant membrane damage [11]. In Chapter II, it was already demonstrated that 
these peptides are a chemically diverse group of peptides, but are mostly characterized by a cationic 
nature, like for the selected peptides of this study, i.e. SynB3, Tat 47-57, pVEC, TP10 and TP10-2 
(Table 1) [12]. The evaluation of the purity of CPPs used during cellular uptake studies is often 
ignored throughout literature, which can be an explanation for the discrepancy in study results. 
Analytical systems for quantification of CPPs described in literature comprise high performance liquid 
chromatographic (HPLC) analysis of fluorescently labeled or chemically modified CPPs [13,14] or the 
matrix-assisted laser desorption-time of flight mass spectrometry (MALDI-TOF MS) for which no 
chromatographic separation is required [15]. Thus, analytical separation systems for analysis of 
unmodified CPPs are hardly described up till now. 
Table 1: Peptide information. 
Peptide Sequence MW (Da) pI1 
SynB3 RRLSYSRRRF-NH2 1395.7 11.5 
Tat 47-57 YGRKKRRQRRR-NH2 1558.9 11.7 
pVEC LLIILRRRIRKQAHAHSK-NH2 2208.8 11.6 
TP10 AGYLLGKINLKALAALAKKIL-NH2 2181.8 10.4 
TP10-2 AGYLLGKINLKPLAALAKKIL-NH2 2207.8 10.4 
R9 RRRRRRRRR-NH2 1422.7 12.0 
1Iso-electric point as calculated using MarvinSketch 5.10.3 (ChemAxon, Budapest, Hungary). 
 
Standard in-house QC evaluation of the peptides traditionally includes a chromatographic system 
using a C18 column on which a linear gradient is run using a mobile phase containing 0.1% (m/V) 
formic acid (FA) in water and acetonitrile. Formic acid is preferred as acidic modifier as it is more 
directly compatible with MS detection systems. However, for cationic peptides, it is known that 
detrimental interactions with the surface silanols of reversed-phase columns occur, resulting in peak 
tailing and poor efficiency. The positive peptide charge, present in the acidified mobile phase, causes 
a low retention and poor resolution as well. Therefore, trifluoroacetic acid (TFA), a highly acidic 
strong ion-pairing agent, is preferred to adjust the retention and efficiency of cationic peptide 
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analysis [16-18]. During QC analysis of peptides, differences between the peptide purity reported by 
the supplier on the certificate of analysis and the results obtained by the biomedical laboratory are 
often observed, which are attributed to different analytical methods for example the use of HPLC 
versus UHPLC columns [4,19]. The latter are packed with sub 2 µm particles and outperform HPLC 
columns in separation efficiency and sensitivity due to sharper and higher peaks, which might explain 
the deviating purity results [19]. To evaluate the influence of the used chromatographic system on 
the conclusions made during routine peptide QC analysis, five different chromatographic systems 
were compared with regards to their QC result conclusions (Figure 1).  
 
Figure 1: Overview of the five chromatographic systems for QC analysis of CPPs. 
 
The chromatographic systems, all coupled to BEH C18 columns, differed in the particle size (HPLC 
versus UHPLC), the used acidic modifier (FA versus TFA), as well as in the column temperature (30°C 
versus 60°C). The results indicate that the used chromatographic system influences the (cationic) 
peptide purity results and affects the apparent impurity profile. The applicability of a GLP/GMP (good 
manufacturing practices)-compliant single quad MS detection system for routine QC analysis of 
(cationic) peptides is also demonstrated.    
 
2. CHROMATOGRAPHIC SYSTEMS USED FOR QUALITY CONTROL OF 
CELL-PENETRATING PEPTIDES 
Chemicals and reagents 
The “traditional” CPPs were obtained from different suppliers: SynB3, Tat 47-57, pVEC and nona-
arginine (R9) were ordered at LifeTein LLC (Somerset, USA) and TP10 and TP10-2 at Caslo ApS 
(Lyngby, Denmark) with a minimal requested purity of 95%. The sequences of the peptides are given 
in Table 1. The short, proline-rich antimicrobial peptides (PrAMPs, Prof. Ralf Hoffmann), i.e. apidaecin 
Api137, oncocin, drosocin and drosocin Pro5Hyp, and disulfide-rich (cyclic) peptides (Prof. David 
Craik), i.e. MCoTI-II, cVc1.1 and chlorotoxin, were provided by a collaborating research group. 
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Peptides were synthesized using a standard Fmoc-SPPS method. For chromatographic analysis, 
ultrapure water (18.2 MΩ × cm and TOC < 5 ppb) was produced using an Arium Pro VF TOC water 
purification system (Sartorius, Vilvoorde, Belgium). The UHPLC-MS grade reagents, i.e. acetonitrile, 2-
propanol, TFA and FA, were purchased at Biosolve (Valkenswaard, The Netherlands), HPLC gradient 
grade acetonitrile at Fisher Chemical (Erembodegem, Belgium), and FA (LC-MS grade), TFA (LC-MS 
grade) and propionic acid at Sigma-Aldrich (Diegem, Belgium). HPLC/UHPLC glass vials and inserts 
were bought at Waters (Zellik, Belgium). 
 
QC purity profiling of “traditional” cell-penetrating peptides 
The HPLC chromatographic system consisted of a Waters Alliance 2695 separations module and 
Waters 2996 photodiode array (PDA) detector equipped with Empower 2 software for data 
acquisition. The UHPLC analyses were conducted on a Waters Acquity H-class UPLC® apparatus 
consisting of a quaternary solvent manager, an automatic sample injection system, combined with a 
flow through needle, a column heater and a UPLC®-PDA detector, with Empower 3 FR 2 software for 
data acquisition. A BEH C18 130 Å column (XBridge (HPLC, 4.6 × 250 mm, 5 µm) or Acquity (UHPLC, 2.1 
mm × 100 mm, 1.7 µm) both from Waters) was selected and the ratio of the column length and 
particle diameter (L/dp) was the same for the HPLC and UHPLC column. A linear gradient separation 
was performed using a mobile phase consisting of 0.1% (m/V) of FA or 0.1% (V/V) TFA in water (A) 
and acetonitrile (B) running from 5% B to 60% B in 15 column volumes. Acetonitrile is used as organic 
modifier, being the generally preferred “solvent B” for peptides showing a lower viscosity and higher 
elution strength than methanol [20,21]. The gradient was preceded by an isocratic hold of three 
times the dwell volume of the chromatographic system. After running the gradient, the column was 
allowed to re-equilibrate during 10 column volumes. The sample compartment was thermostated at 
5°C and the column temperature was maintained at 30°C or 60°C. For HPLC, the injection volume was 
20 µl and the flow rate was 1.0 ml/min, while for UHPLC, the injection volume was 2 µl and the flow 
rate 0.6 ml/min, as determined following Guillarme et al. in order to obtain similar retention factors 
and resolution for both chromatographic systems [22]. UV detection was performed from 190-400 
nm, with quantification at 215 nm. Lyophilized peptides were dissolved in an acidified (0.1% FA 
(m/V)) mixture of water and acetonitrile (95:5, V/V) to obtain a 1 mg/ml solution. The used solvent 
was analyzed as blank as well. During each sample set, one CPP was analyzed in duplicate, i.e. as first 
and last sample, to evaluate the performance of the chromatographic system. Impurities were 
quantified using the normalization procedure: the percentage ratio of the peak area of the impurity 
and the area of the highest peak was calculated. For calculation of the peptide purity, the ratio of the 
peak area of the peptide and the total area of observed peaks, corrected for solvent and system 
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peaks present in the blank chromatogram as well as impurities below the reporting threshold of 0.1% 
according to the European Pharmacopoeia (Ph. Eur.) [23], was calculated and multiplied by 100. In 
total, five chromatographic systems were evaluated as shown in Figure 1. 
 
Evaluation of the chromatographic performance 
To compare quantitatively the performance of the chromatographic systems, the limit of detection 
(LOD), equivalent to a signal-to-noise ratio of three, and the peak capacity were calculated. The peak 
capacity is a measure for the performance of a gradient separation, representing the number of 
peaks that can be resolved per unit of time [24]. The used formulas are given in Table 2.  
Table 2: Response factors used to quantitatively evaluate the chromatographic performance of the (U)HPLC-UV 
systems. 
Response factor Formula1 
Limit of detection (LOD) (ng) 
S/N
volume injectionionconcentrat 3 
 
Peak capacity (np) 


n
1 h
g
w1/n
t
1  
Number of impurity peaks above reporting 
threshold 
number > RT (0.1%) 
1S/N = signal-to-noise ratio = 2H/h according to Ph. Eur. [25], with H = height of the peptide peak, measured from the peak maximum to the 
extrapolated baseline and h = height of the noise in a chromatogram obtained after injection of a blank sample, i.e. without peptide; tg = 
gradient run time; n = number of peaks selected for calculation (i.e. 3: one at the beginning and the end of the gradient and the native 
peptide peak); wh = peak width at half peak height and RT = reporting threshold of 0.1% (Ph. Eur.). 
 
Both the peptide concentration, 1 mg/ml, as well as the injection volume, i.e. 2 µl for the UHPLC 
system and 20 µl for the HPLC system, were taken into account to calculate the LOD (Table 2). Beside 
these chromatographic response factors, the number of impurity peaks above the reporting 
threshold of 0.1% (Ph. Eur.) were counted as well to evaluate the chromatographic performance.  
 
Identification of the main peak and impurities of cell-penetrating peptides 
Mass spectrometric identification of the observed main peak and the impurities was performed using 
a HPLC-UV/MS system consisting of a Spectra System SN4000 interface, a Spectra System SCM1000 
degasser, a Spectra System P1000XR pump, a Spectra System AS3000 autosampler, a Finnigan LCQ 
Classic ion trap mass spectrometer in positive ion mode (all Thermo, San José, CA, USA) and Waters 
2487 dual wavelength UV detector, equipped with XCalibur 2.0 software (Thermo). Electrospray 
ionization (ESI) was conducted using a needle voltage of 4.5 kV. Nitrogen was used as the sheath and 
auxiliary gas with the heated capillary temperature set at 250°C. Peptide identification was 
performed based on m/z values with an abundance higher than 30% in the MS1 spectra (m/z 100-
2000) using the data dependent MS2 spectra, i.e. from high abundant m/z in MS1. The 
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ProteinProspector software (University of California, San Francisco, USA) was used to calculate the 
theoretical MS2 fragmentation pattern according to Roepstorff and Fohlman [26], which is used to 
confirm peptide and/or impurity identification. The same HPLC method was used as described 
earlier, with FA as acidic modifier in the mobile phase. As Tat 47-57 did not show retention using this 
chromatographic system, a Prevail Organic Acid (Grace (Lokeren, Belgium), 4.6 × 250 mm, 5 µm) 
column was used instead, allowing to start the linear gradient at 100% A, which was also lowered to 
40% using a linear gradient in 15 column volumes. All other parameters remained the same.  
The UHPLC system using TFA as acidic modifier in the mobile phase, was coupled to a single quad MS 
detection system, consisting of a Waters Acquity isocratic solvent manager and a Waters Acquity 
QDa detector equipped with an ESI interface. The eluting mobile phase was split towards both the 
PDA and QDa detection system (ratio 10/1). The portion going to the QDa was diluted with 40:10:50 
water:propionic acid:propanol (V/V/V) at a flow rate of 0.35 ml/min to obtain sufficient flow to the 
detector and allowing a post-column TFA displacement from the peptide resolving the TFA ion 
suppression effect, also referred to as TFA-fix method [27,28]. The QDa detector was operated in 
positive ion mode with the ESI capillary voltage set at +0.8 kV and the cone voltage at 15 V. The 
probe temperature was 600°C. A full mass spectrum between m/z 100 and 1250 was acquired at a 
sampling rate of 2.0 points/s. 
 
3. QUALITY OF CELL-PENETRATING PEPTIDES 
Purity of the “traditional” cell-penetrating peptides 
The purity of the five CPPs was calculated based on the chromatograms obtained using the five 
chromatographic systems differing in the BEH C18 column particle size (HPLC versus UHPLC), the used 
acidic modifier in the mobile phase (FA versus TFA) and column temperature (30°C versus 60°C) 
(Table 3). Standard deviations of duplicated injections ranged between 0.12% and 0.42%. 
Table 3: QC purity results of the CPPs obtained using five different chromatographic systems  
(UV detection at 215 nm).  
Chromatographic 
system 
Peptide purity 
SynB3 Tat 47-57 pVEC TP10 TP10-2 
CoA1 95.2% 95.9% 98.7% 96.7% 98.8% 
UHPLC, TFA, 30°C 95.6% 99.9% 94.9% 94.6% 99.2% 
UHPLC, TFA, 60°C 95.4% 99.8% 95.2% 89.0% 99.5% 
UHPLC, FA, 30°C 95.4% -2 97.1% 94.1% 99.5% 
HPLC, TFA, 30°C 94.4% 99.2% 96.3% 90.9% 98.5% 
HPLC, FA, 30°C 94.3% -2 -3 96.7% 99.7% 
1Purity provided by the supplier on the certificate of analysis (CoA). 
2No retention observed in the concerned chromatographic system. 
3Poor chromatography was obtained, not allowing to draw a substantiated conclusion on the purity of the peptide. If the automatic forced 
drop integration mode was used to integrate the obtained peptide peak, an erroneous purity result of 60.8% would have been calculated. 
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The results presented in Table 3 indicate that the same conclusions could be drawn regarding the 
peptide purity for TP10-2 independent of the used system. For SynB3, the calculated purity obtained 
using the five different chromatographic systems ranged between 94 and 95%. Based on the purity 
results of the HPLC chromatographic systems, the purity of the SynB3 peptide was below 95%. When 
pVEC was analyzed using the HPLC-FA (30°C) system, poor chromatographic performance was 
obtained, which did not allow to quantify its purity. Based on the other chromatographic systems, 
the purity of pVEC ranged between 95% and 97%, hence fulfilling its purity requirements. For TP10, 
two chromatographic systems resulted in a purity of approximately 90%, while the other three 
results gave a purity of approximately 95%. Overall, for some of the cationic CPPs, different QC 
conclusions could be drawn depending on the used chromatographic system. Therefore, the general 
adagium that (peptide) purity results should always be specified by the used chromatographic 
method, clearly also strongly applies to cationic CPPs.  
The peptides were positively identified using the MS1 and MS2 spectra using ESI-ion trap MS, based 
on their molecular mass and the presence of typical b- and y-fragments. The annotated MS spectra of 
the investigated CPPs can be retrieved in the Supporting Information (Figure S1).   
 
Purity of the short, proline-rich antimicrobial and disulfide-rich (cyclic) 
peptides 
The PrAMPs, i.e. apidaecin Api137, oncocin, drosocin and drosocin Pro5Hyp and the disulfide-rich 
(cyclic) peptides, i.e. MCoTI-II, cVc1.1 and chlorotoxin, were investigated as part of collaboration 
project with external research groups. The QC of these peptides, which also possess cell-penetrating 
properties, was performed by the collaborating lab. Raw chromatographic data and the used 
methods were provided and critically reviewed at arrival. For all peptides, the main peaks present in 
the HPLC chromatograms were identified as the intended peptide and the purity was above the 
required 95%. These peptides are hence not further analyzed. 
 
Impurity profile of the cell-penetrating peptides 
The experimentally obtained impurity profiles of the “traditional” CPPs remarkably differed between 
the different chromatographic systems. As an example, the obtained chromatograms of SynB3 are 
shown in Figure 2; the chromatograms of the other investigated CPPs can be found in the Supporting 
Information (Figure S2). Based on these chromatograms, TFA seems to be preferred over FA as acidic 
modifier, resulting in better peak resolution between the peptide and its impurities. In order to 
evaluate the chromatographic performance more objectively and quantitatively, the LOD, the peak 
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capacity, as well as the number of peaks above the reporting threshold of 0.1% were calculated 
(Table 4). 
 
Figure 2: Impurity profile of SynB3 obtained by analyzing the peptide using five different chromatographic 
systems (all UV detection at 215 nm). Only the part of the chromatogram containing the peptide and impurity 
peaks is shown. 
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Table 4: Chromatographic performance of the five different chromatographic systems for the analysis of SynB3 
quantitatively expressed using the limit of detection (LOD), the peak capacity and the number of peaks above 
the reporting threshold of 0.1% (Ph. Eur.). 
Chromatographic system LOD (ng) Peak capacity (np) 
Number of peaks  
> RT1 
UHPLC, TFA, 30°C 1.1 430 6 
UHPLC, TFA, 60°C 0.6 376 9 
UHPLC, FA, 30°C 22.9 104 9 
HPLC, TFA, 30°C 42.9 351 11 
HPLC, FA, 30°C 498.7 278 11 
1RT = reporting threshold (0.1% (Ph. Eur.)). 
 
Generally, use of TFA as acidic modifier resulted in sharper peaks, with UHPLC being superior to HPLC 
and consequently an improved LOD. A similar conclusion can be drawn from the peak capacity or the 
number of peaks that can be resolved under the experimental chromatographic conditions [24]. 
Except for SynB3, use of TFA as acidic modifier resulted in a higher number of peaks above the 
reporting threshold of 0.1% compared to FA, without a significant difference between HPLC and 
UHPLC systems (data shown in the Supplementary Information Table S1). However, for SynB3, the 
number of peaks above the reporting threshold of 0.1% was significantly higher for the HPLC system 
compared to the UHPLC systems despite a worse LOD associated with HPLC (Table 4). A plausible 
explanation is the higher separation capacity of UHPLC, leading to the separation of small peaks, 
which individually are below the reporting threshold. When these peaks are not separated in the 
traditional HPLC system, they sum up, resulting in a peak above the reporting threshold, taken into 
account for the number of observed peaks. 
UHPLC systems and TFA as acidic modifier resulted in chromatograms characterized by a better peak 
separation and consequently, more impurities can be distinguished. Moreover, Tat 47-57 is even not 
retained when FA is used in the mobile phase. Increasing the column temperature to 60°C did not 
result in a significant increase of the peak capacity and the LOD slightly improved. The effect of the 
column temperature on the retention varies among the different peptides, but can be used to 
optimize the selectivity of the chromatographic method [29]: increasing the column temperature 
results in a decrease in peptide retention due to an increased solubility in the mobile phase, a 
decrease in the viscosity of the mobile phase, increasing the peptide’s diffusion coefficient, as well as 
an increase in the mass transfer between the mobile phase and the stationary phase [30,31]. For α-
helical peptides heating the mobile phase also disrupts the amphipathicity of the peptides and 
consequently the affinity for the C18 stationary phase, resulting in shorter retention times [30]. 
Increasing the column temperature ultimately improves the kinetic efficiency and thus the 
separation of peptides [29,31]. However, for peptides, especially for the highly charged ones, the 
effect of increasing the temperature on the retention is difficult to predict as also the pKa changes 
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with temperature, hence influencing charge interactions and inherently the selectivity [29,31]. 
Moreover, TFA shows poorer adsorption to the C18 stationary phase at elevated temperatures 
leading to less efficient ion-pairing with cationic peptides and a decrease in their retention [18]. 
Therefore, standard QC analysis of peptides can be operated at 30°C, but column temperature can be 
increased to enhance selectivity on a case-by-case evaluation. The investigated cationic CPPs did not 
benefit from a temperature increase. 
Overall, the evaluation of the chromatographic performance of the five C18 chromatographic systems 
indicated that the UHPLC-TFA (30°C) system was the most suitable chromatographic system to 
perform the QC analysis of the selected cationic CPPs.  
 
Identification of related impurities of the cell-penetrating peptides 
Formic acid is routinely preferred over TFA to perform QC analysis as it is directly compatible with MS 
detection systems. However, we demonstrated that TFA is superior to FA during impurity profiling of 
the cationic CPPs being characterized by a better chromatographic performance. Recently developed 
GLP/GMP-compliant single quad MS detection systems are equipped to perform a post-column 
addition, with isopropanol and propionic acid are used to displace the ion suppressing TFA during the 
TFA-fix method [28]. Therefore, SynB3, having the second lowest peptide purity and a high number 
of impurities above the reporting threshold compared to the other CPPs, was analyzed using the 
UHPLC system (30°C) with TFA as acidic modifier, with the eluting mobile phase split to both the PDA 
detection system and the MS detection system. In Figure 3A, peak 1 corresponds with the SynB3 
peptide based on obtained MS1 spectrum. Peak 2 and 3 are the impurity peaks above the 
identification threshold of 0.5% (Ph. Eur.). Based on the MS1 spectrum, peak 2 corresponds to an 
impurity with a mass difference of -87.22 Da compared to SynB3, indicating a deletion of one serine 
residue, while the mass difference of -156.26 Da of the impurity of peak 3 indicates a deletion of an 
arginine residue. These findings were corroborated by the MS1 and MS2 spectra obtained using the 
HPLC-UV/MS system: peak 2 corresponds to the Ser4-deleted SynB3 peptide, while both the deletion 
of an arginine residue at the N- and C-terminus of SynB3 was identified. In Figure 3B, the typical b- 
and y-fragments of this arginine-deleted impurity are indicated. 
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Figure 3: Application of a single quad MS detection system during routine QC analysis. (A) Obtained UV-
chromatogram (215 nm) and MS1 spectra of the peaks above the identification threshold (0.5%) after analyzing 
SynB3 using an UHPLC-UV/MS system. (B) MS1 and MS2 annotated mass spectra of the impurity of SynB3 
corresponding to the arginine-deleted peptide obtained using an HPLC-UV/MS system. 
 
Validation of the proposed QC method 
In biomedical research, the highly cationic oligo-arginines are widely used CPPs. Therefore, as a 
validation of our proposed method for QC analysis of cationic CPPs, nona-arginine (R9) was analyzed 
using the UHPLC-UV/MS system with TFA as acidic modifier and the column thermostated at 30°C 
(Figure 4). Figure 4A demonstrates that the proposed QC method for cationic CPPs is able to separate 
the deletion analog(s) of R9: peak 1, the major impurity peak observed in the UV-chromatogram, was 
identified by this analytical system as octa-arginine (R8). The purity of the R9 sample, based on the 
UV (215 nm) peak areas and assuming relative response factors of 1 [32], could be quantified and 
estimated 92.7%. 
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Figure 4: Quality control of R9 using an UHPLC-UV/MS system with TFA as acidic modifier in the mobile phase 
(30°C). (A) Chromatogram obtained using UV-detection at 215 nm. Peak 1 represents the major impurity peak; 
peak 2 corresponds with R9. (B) MS1 spectra of peak 1 and 2 obtained using a single quad MS detection system. 
Peak 1 was identified as R8 and peak 2 as R9. The clusters of MS-observed ions represent ions in the same 
charge state (same z). Each cluster consists of ions with the same charge but differing in the number of 
attached protons and number of trifluoroacetate (TFA-) anions forming ion pairs. 
 
The MS1 spectra of both R8 and R9 show an interesting pattern. Further investigation of these MS 
spectra revealed that each distribution of m/z peaks represented different charge states of ions, as 
indicated in the MS1 spectrum of R9 (Figure 4B). For each charge state, multiple m/z peaks were 
present which represented the peptide in different charge states, i.e. [M+nH]n+, forming ion pairs 
with trifluoroacetate ions (TFA-) of the mobile phase resulting in charged ion pairs of the form 
[[M+nH]n+ + mTFA-](n-m)+, with n-m representing the charge of the MS-observed ions (z). So, for each 
cluster of MS-observed ions with the same charge state, the difference between n (the number of 
protons linked to the peptide) and m (the number of TFA- forming the ion pair) remains constant, e.g. 
for z = +2, n-m is +2. In the z = +2 cluster of de MS1 spectrum of R9 (Figure 4B), the ion with m/z equal 
to 883.26 corresponds to the ion [[M+5H] + 3TFA-]2+, which is one proton and one TFA- less than the 
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next ion, i.e. m/z equal to 940.24 representing the ion [[M+6H] + 4TFA-]2+. Likewise, the ions with m/z 
997.26, 1054.26 and 1111.21 represent the ions [[M+7H] + 5TFA-]2+, [[M+8H] + 6TFA-]2+ and [[M+9H] 
+ 7TFA-]2+, respectively. A similar observation was reported for proteins in the presence of non-
volatile salts (e.g. NaCl) [33,34]. 
When evaluating the MS1 spectra of SynB3 and Tat 47-57, the same pattern of distributions of ions 
for the different charge states was observed (see Supporting Information Figure S3). However, for 
these CPPs, being less cationic than R9, the non-TFA- adducts were also present, which was absent 
for the R8 and R9 peptides. Thus, for the cationic CPPs, the MS spectra consist of different levels of 
MS-based ion distributions: apart from the isotopic envelopes, there are the mass clusters with 
identical charge states and finally, the different overall charge states can be observed. For the 
cationic CPPs, the concentration of propionic acid combined with isopropanol used during this 
method was not high enough to displace all TFA- anions of the ion pair with differences observed 
between the different cationic CPPs. 
 
4. DISCUSSION OF THE OBTAINED QUALITY CONTROL RESULTS 
The comparison of the five C18-chromatographic systems used to analyze five selected cationic CPPs, 
indicated that the UHPLC-TFA (30°C) system was the most suitable method for performing the QC 
analysis of cationic CPPs. This was validated by analyzing the highly cationic R9 peptide using the 
proposed QC method, which was able to separate R9 from its deletion analog R8. UHPLC 
chromatographic systems with TFA as acidic modifier resulted in the analytical method with the 
highest peak capacity and lowest LOD, which is the lowest compound concentration that can be 
reliably distinguished from the analytical noise and represents the sensitivity of the chromatographic 
method [35]. The International Conference on Harmonization (ICH) guideline on impurities in new 
drug products states that during impurity profiling, the used analytical method should 
commensurate with the level at which the impurities should be controlled [36]. For routine QC 
analysis of peptides, this means that the LOD is required to be lower than the reporting threshold of 
0.1% when applying the Ph. Eur. Moreover, if there is only a small difference between the LOD and 
the reporting threshold, this can result in false negative responses as analytical data show some 
variability. This phenomenon also explains the observed differences in impurity profile between the 
evaluated chromatographic systems in this study: depending on the LOD of the method, an impurity 
is detected or not. These findings illustrate the need for general guidelines on developing methods 
for analytical characterization of peptide (drug) products as these compounds are currently excluded 
from most ICH guidelines because of their complex nature [37,38]. In these guidelines, the use of MS 
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detection systems, like single quad MS detectors, should also be encouraged. We demonstrated for 
SynB3 that the obtained MS1 spectra can provide information on the identity of the observed peaks, 
but can also be used to evaluate the purity of the peaks, which might be a problem when analyzing 
cationic peptides due to poor separation [37]. For SynB3, it was suggested that impurity peaks 
coincide when analyzed using a HPLC system: non-separated impurity peaks sum up forming a peak 
above the reporting threshold of 0.1%. This has dual consequences: first, concurring peaks imply loss 
of information on the impurity profile of the peptide and secondly, in a pharmaceutical context, this 
can determine the decision on batch release or rejection. We thus demonstrated the use of single 
quad MS detection systems during routine QC analysis of (cationic) peptides, which are more 
accessible and affordable than the advanced MS detectors [39]. A major advantage is that these 
systems are compatible with TFA, which we demonstrated to be superior over FA-containing mobile 
phases for QC analysis of cationic CPPs. We demonstrated that the MS1 spectra of cationic CPPs, 
obtained using this single quad MS detection system combined with a post-column TFA 
displacement, should be carefully interpreted, as TFA- adducts can be present, especially in case of 
highly cationic peptides. We believe these GLP/GMP-compliant single quad MS detectors deserve to 
be a standard detection system in addition to UV detectors during QC analysis of peptides before 
being used in biomedical research as well as in pharmacopoeias and ICH guidelines [40].   
 
5. CONCLUSIONS 
From the comparison of five chromatographic systems, it can be concluded that for routine QC 
analysis of cationic CPPs, the use of an UHPLC system, equipped with BEH C18 column thermostated 
at 30°C, and TFA as acidic modifier is preferred. This chromatographic system is characterized by 
higher sensitivity and resolution, allowing an accurate evaluation of the purity and impurity profile of 
these peptides, which is essential for obtaining reliable study results in biomedical research. We 
demonstrated the use of a single quad MS detection system, which is compatible with a TFA-
containing mobile phase, providing information on the peptide and impurity identity, as well as on 
the purity of the different observed peaks. Therefore, the routine use of these MS detectors during 
QC analysis of peptides should be encouraged by pharmacopoeias and international guidelines. 
The purity of the five investigated CPPs, as well as of the four PrAMPs and three disulfide-rich (cyclic) 
peptides, provided and evaluated by a collaborating research group, was estimated to be above 95% 
as required to perform the in vivo BBB transport studies. The main peaks of the resulting 
chromatograms were identified as the intended peptides.   
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SUPPLEMENTARY INFORMATION 
Figure S1: MS1 and MS2 spectra of the cationic CPPs obtained by analyzing the peptides using an HPLC-UV/MS 
system. In the MS1 spectrum, the framed ion represents the ion of which the MS2 spectrum was obtained. 
SynB3: 
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Tat 47-57: 
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pVEC: 
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TP10: 
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TP10-2: 
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Figure S2: Chromatograms of pVEC, Tat 47-57, TP10 and TP10-2 obtained after analyzing the peptides using the 
five different chromatographic systems. Only the part of the chromatogram containing the peptide and 
impurity peaks are shown. 
pVEC: 
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Tat 47-57: 
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 TP10: 
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TP10-2: 
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Figure 2: MS1 spectra of SynB3 and Tat 47-57 obtained using the UHPLC-UV/MS chromatographic system with 
TFA as acidic modifier in the mobile phase (30°C). The clusters of MS-observed ions represent ions in the same 
charge state (same z). Each cluster consists of ions with the same charge but differing in the number of 
attached protons and number of trifluoroacetate (TFA-) anions forming ion pairs. 
 
CHAPTER IV – QUALITY CONTROL OF CATIONIC CELL-PENETRATING PEPTIDES 
  
 
132 
Table S1: Number of peaks above the reporting threshold of 0.1% (Ph. Eur.) for the five C18-chromatographic 
systems used for the analysis of pVEC, Tat 47-57, TP10 and TP10-2. 
Chromatographic system 
Number of peaks > reporting threshold (0.1%) 
pVEC Tat 47-57 TP10 TP10-2 
UHPLC, TFA, 30°C 4 1 9 3 
UHPLC, TFA, 60°C 3 1 18 2 
UHPLC, FA, 30°C 2 -1 8 2 
HPLC, TFA, 30°C 3 2 14 5 
HPLC, FA, 30°C 2 -1 1 1 
1No retention observed in the concerned chromatographic system. 
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CELL-PENETRATING 
PEPTIDES  
SELECTIVELY CROSS THE 
BLOOD-BRAIN BARRIER 
IN VIVO 
  
 
 
 
“Courage and perseverance have a magical talisman, 
    which difficulties disappear and obstacles vanish into the air” 
 
John Quincy Adams 
(°1767- †1848, Former president of the USA) 
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ABSTRACT 
Cell-penetrating peptides (CPPs) are a group of peptides, which have the ability to cross cell 
membrane bilayers. Moreover, cell-penetrating properties have also been attributed to other 
biofunctional peptides, like antimicrobial peptides (AMPs) and disulfide-rich (cyclic) peptides. 
Fragmentary studies demonstrate the ability of CPPs to enhance transport of different cargoes 
across the blood-brain barrier (BBB). However, comparative, quantitative data on the BBB 
permeability of different CPPs are currently lacking. Therefore, the in vivo BBB transport 
characteristics were determined of five “traditional” CPPs, i.e. pVEC, SynB3, Tat 47-57, TP10 and 
TP10-2, selected based on the different subgroups observed in the chemical space of the CPPs, 
extended with the study of the BBB transport of “new” CPPs being four short, proline-rich AMPs 
(PrAMPs), i.e. apidaecin Api137, oncocin, drosocin and drosocin Pro5Hyp, and three disulfide-rich 
(cyclic) peptides, i.e. MCoTI-II, cVc1.1 and chlorotoxin. The results indicated that the investigated 
peptides showed divergent BBB transport characteristics, ranging from very high to no brain influx 
as determined using multiple time regression analysis and from high parenchymal distribution to 
entrapment in capillary endothelial cells, which was demonstrated using the capillary depletion 
method. Some peptides showed efflux out of the brain. Co-injection of pVEC with radioiodinated 
bovine serum albumin (BSA) did not enhance the brain influx of BSA, indicating that pVEC itself did 
not significantly alter the BBB properties. A saturable mechanism could not be demonstrated by 
co-injecting an excess dose of non-radiolabeled CPP. No significant regional differences in brain 
influx of the CPPs were observed, with the exception of pVEC, for which the regional variations 
were only marginal. The observed BBB influx transport properties cannot be correlated with their 
cell-penetrating ability, and therefore, good CPP properties do not imply efficient brain influx. 
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CHAPTER V 
CELL-PENETRATING PEPTIDES SELECTIVELY 
CROSS THE BLOOD-BRAIN BARRIER IN VIVO 
Main focus in this chapter: 
 To characterize the blood-brain barrier transport of “traditional” cell-penetrating peptides as 
well as “new” cell-penetrating peptides, being biofunctional peptides with cell-penetrating 
properties. 
 To determine whether cell-penetrating properties and blood-brain barrier transport are 
related for peptides. 
 
1. WHY STUDY BLOOD-BRAIN BARRIER TRANSPORT OF CELL-
PENETRATING PEPTIDES? 
Cell-penetrating peptides are a particular group of peptides that have the ability to cross cell 
membranes without causing a significant lethal membrane damage [1]. The exact mechanism of 
cellular entry remains controversial, but a consensus exists that endocytosis and a direct penetration 
mechanism are involved [2,3]. Drawing conclusions on the cellular uptake mechanism of CPPs is 
impeded by different factors as already outlined in Chapter I and II of this thesis. Firstly, a variety of 
techniques and experimental protocols are used to investigate these peptides. Furthermore, multiple 
mechanisms can simultaneously be active and the employed mechanisms depend not only on the 
peptide studied but also on the cell type used, the peptide concentration and the attached cargo or 
label [2,3].   
Since their discovery 20 years ago, hundreds of CPPs have already been described and can roughly be 
classified into three chemical groups: the cationic, amphipathic and hydrophobic CPPs [4]. The 
cationic CPPs contain a stretch of positive charges derived from arginine and lysine residues in their 
sequence, while the amphipathic peptides are characterized by a hydrophilic and hydrophobic part, 
mostly by adopting a helix structure. The hydrophobic CPPs are rich in apolar amino acids and have a 
low net charge. However, a clear overlap exists between these chemical groups, emphasizing that 
CPPs represent a chemically diverse group of peptides [Chapter II]. Moreover, cell-penetrating 
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properties have also been attributed to other classes of peptides, which are not investigated as CPPs 
per se, like AMPs, e.g. short, proline-rich AMPs (PrAMPs) and disulfide-rich (cyclic) peptides 
characterized by multiple disulfide bonds in the peptide structure of which the backbone can be 
cyclized [5-9]. With their amphipathic and cationic nature, due to the high proportion of arginines in 
their sequence, these AMPs are structurally related with the CPPs and are also able to translocate 
cells [10]. 
The majority of the CPPs are derived from naturally occurring proteins and peptides like heparin-
binding proteins, DNA and/or RNA-binding proteins, homeoproteins, signal peptides, AMPs and viral 
proteins [4,11]. For some CPPs, their cell-penetrating properties are linked to the function of the 
parent peptide or protein, but for other peptides, the function of the CPP sequence in the full-length 
parent protein is still unclear [4]. Traditionally, CPPs are considered to be inert molecules, but 
actually these peptides can exert a biological activity themselves [12,13]. Moreover, for some CPPs, 
the biological function of the parent peptide or protein is conserved in the cell-penetrating sequence, 
a feature that can be therapeutically exploited [14-23]. However, up till now, only a limited number 
of studies have described the biological activity of CPPs although this information is indicative for 
potential side effects and relevant for future clinical applications [12,13]. The knowledge on the 
bioactivity of CPPs is particularly interesting for peptides having an endogenous [e.g. 14-18,20-22,24-
28] and viral or bacterial origin [e.g. 19,29-37].  
As CPPs are able to cross cellular membranes, the question arises whether this means that they can 
also pass the BBB, which protects the brain. The barrier function of the BBB is established by 
physical, transport as well as metabolic means, explaining its selective permeability for ions, solutes 
and (macro)molecules [38]. Only some fragmentary studies are describing the ability of CPPs to reach 
the brain parenchyma both in vivo and in vitro [39]. However, almost all studies investigate the brain 
delivery of a CPP attached to a cargo, which is known to influence the cell-penetrating, as well as the 
BBB transport properties. Moreover, different techniques are hereby used: measuring the 
pharmacological effect of the attached cargo or following the fluorescently labeled construct using in 
vivo imaging or fluorescence microscopy techniques. A detailed overview of the currently available 
brain influx studies of CPPs can be found in Table S1 of the Supplementary Information. Comparable, 
quantitative data on the BBB transport of CPPs are still lacking. Moreover, there is only limited 
knowledge on the BBB transport mechanism of CPPs. Only for the SynB vectors, which are cationic 
CPPs, an adsorptive-mediated translocation mechanism was proposed [40,41]. 
To evaluate whether different CPPs cross the BBB to the same extent, the BBB transport of five 
chemically diverse “traditional” CPPs with different cell-penetrating ability was quantitatively 
investigated. TP10, TP10-2, pVEC, SynB3 and Tat 47-57 were selected based on the different 
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subgroups of CPPs determined during the exploration of the chemical space, as indicated in Figure 1. 
The chemical diversity of the investigated peptides was extended with “new” peptides with cell-
penetrating properties: four PrAMPs, i.e. apidaecin Api137, oncocin, drosocin and drosocin Pro5Hyp, 
and three disulfide-rich (cyclic) peptides, i.e. MCoTI-II, cVc1.1 and chlorotoxin. In Figure 1 is 
demonstrated how these peptides fit in the chemical space of the CPPs and in Table 1, an overview 
of the selected peptides is provided. In this study, their BBB influx transport rate, the 
parenchyma/capillary, as well as the efflux properties were investigated using an in vivo mouse 
model. Moreover, the influence of pVEC itself on the BBB permeability was also verified. Finally, the 
intra-brain regional distribution after brain uptake and the saturability of the brain influx mechanism 
of pVEC, TP10 and SynB3 was evaluated. Our results prove that CPPs selectively pass the BBB as not 
all CPPs cross the BBB to the same extent.  
 
Figure 1: Chemical diversity of the peptides with cell-penetrating properties investigated for their BBB 
transport characteristics.  
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Table 1: Overview of the characteristics of the peptides investigated for their BBB transport properties  
(blue = “traditional” CPPs, orange = PrAMPs, purple = disulfide-rich (cyclic) peptides). 
Peptide Sequence 
Molecular 
weight (Da)1 
CP-response² Log P3 pI4 
% basic 
residues5 
pVEC LLIILRRRIRKQAHAHSK-NH2 2208.8 1.318 -7.2 11.6 44% 
TP10 AGYLLGKINLKALAALAKKIL-NH2 2181.8 1.641 -3.7 10.4 19% 
TP10-2 AGYLLGKINLKPLAALAKKIL-NH2 2207.8 0.749 -3.5 10.4 19% 
SynB3 RRLSYSRRRF-NH2 1395.7 0.126 -4.7 11.5 50% 
Tat 47-57 YGRKKRRQRRR-NH2 1558.9 0.309 -9.2 11.7 73% 
Apidaecin 
Api137 
Gu-ONNRPVYIPRPRPPHPRL-OH6 2294.1 -9 -8.0 11.3 28% 
Oncocin VDKPPYLPRPRPPRRIYNR-NH2 2390.2 -
9 -7.9 11.2 32% 
Drosocin7 GKPRPYSPRPTSHPRPIRV-OH 2198.9 -
9 -10.0 11.4 32% 
Drosocin 
Pro5Hyp 
GKPR-4t-Hyp-YSPRPTSHPRPIRV-OH8 2214.9 -
9 -10.9 11.3 32% 
MCoTI-II 
GGVCPKILKKCRRDSDCPGACICRGNGYCGSGSD  
(Cyclic backbone; disulfide briges: Cys4-Cys21; 
Cys11-Cys23; Cys17-Cys29) 
3452.9 0.10310 -23.0 10.3 18% 
cVc1.1 
GCCSDPRCNYDHPEICGGAAGG  
(Cyclic backbone; disulfide bridges: Cys2-Cys8; Cys3-
Cys16) 
2160.3 -9 -16.0 4.2 9% 
Chlorotoxin 
MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR 
(Disulfide bridges: Cys2-Cys19; Cys5-Cys28; Cys16-
Cys33; Cys20-Cys35) 
3996.7 -9 -24.6 9.9 20% 
1Obtained from the certificate of analysis provided by the supplier; ²As described in Chapter II; 3Log P calculated using Hyperchem 8.0 (Hypercube, Gainesville, FL, USA); 4Iso-electric point as calculated using 
MarvinSketch 5.10.3 (ChemAxon, Budapest, Hungary); 5Calculated as the ratio of the number of basic amino acids (arginine, lysine or histidine) and the total number of amino acid residues multiplied by 100; 6Gu = 
N,N,N’,N’-tetramethylguanidino and O = L-ornithine; 7The unglycosylated drosocin analog was investigated; 8Pro5Hyp = 4-trans hydroxyl L-proline (=4t-Hyp); 9CP-response could not be calculated as currently, no 
quantitative data for cellular uptake were already published; 10CP-response calculated based on quantitative data for cellular uptake described in [42].
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2. MATERIALS AND METHODS 
Peptides 
TP10 and TP10-2 were purchased at Caslo ApS (Lyngby, Danmark); pVEC, SynB3 and Tat 47-57 at 
LifeTein LLC (Somerset, USA) and the positive control dermorphin at Bachem (Bubendorf, 
Switzerland) and Hanhong group (Shanghai, China). The PrAMPs, i.e. apidaecin Api137, oncocin, 
drosocin and drosocin Pro5Hyp, and the disulfide-rich (cyclic) peptides, i.e. MCoTI-II, cVc1.1 and 
chlorotoxin, were investigated as part of a collaborating project and were provided by prof. Ralf 
Hoffmann and prof. David Craik, respectively. 
The QC of the peptides is described in Chapter IV: the main peak present in the chromatograms was 
identified as the intended peptide and the chromatographic purity of the peptides was above 95%. 
 
Radioiodination and purification of peptides and BSA 
A carrier-added (CA) protocol was used for radioiodination of the peptides. SynB3, Tat 47-57, the 
four PrAMPs, chlorotoxin, dermorphin and BSA (Merck KGaA, Darmstadt, Germany) were 
radiolabeled using the Iodo-Gen method [43]. After rinsing the Iodo-Gen tube using 1 ml of 130 mM 
phosphate buffer (pH 7.4), 50 µl of a 1 µmol/ml sodium iodide carrier dissolved in 0.1% (m/V) 
aqueous FA (2 µmol/ml for PrAMPs and BSA) was mixed with a volume containing 1 mCi of Na125I 
(Perkin Elmer, Zaventem, Belgium) and allowed to react for 6 min at room temperature. The peptides 
were iodinated by transfer of the iodonium solution to 50 µl of a 1 µmol/ml peptide solution 
dissolved in phosphate buffer (SynB3, Tat 47-57, PrAMPs, dermorphin, BSA) or 0.1% (m/V) FA in 95:5 
(V/V) water:acetonitrile (chlorotoxin). The reaction was allowed to proceed during 6 min at room 
temperature while regularly mixing. TP10, TP10-2, pVEC, MCoTI-II and cVc1.1 were radiolabeled 
using the chloramine-T method [43]. Briefly, to 50 µl of a 1 µmol/ml peptide solution (TP10, TP10-2, 
MCoTI-II and cVc1.1) or 110 µl of a 1 mg/ml pVEC solution, dissolved in 0.1% FA in 95:5 
water:acetonitrile, 20 µl of a 3.75 µmol/ml sodium iodide in aqueous 0.1% (m/V) FA (TP10, TP10-2, 
MCoTI-II and cVc1.1) solution or 20 µl of a 2.5 µmol/ml sodium iodide in 25 mM phosphate buffer 
(pH 8.5 (pVEC)) was added. Then, a volume containing 1 mCi of Na125I was transferred to this 
solution, followed by 30 µl of a 0.5 mg/ml (or 1 mg/ml for MCoTI-II) chloramine-T solution in 25 mM 
phosphate buffer (pH 7.4 (TP10, TP10-2, MCoTI-II and cVc1.1) or pH 8.5 (pVEC)). The iodination 
reaction proceeded during 40 s, followed by the addition of 30 µl of a 1 mg/ml (or 2 mg/ml for 
MCoTI-II) sodium metabisulfite in 25 mM phosphate buffer (pH 7.4 (TP10, TP10-2, MCoTI-II and 
cVc1.1) or pH 8.5 (pVEC)) to stop the iodination reaction. For evaluation of the influx mechanism, 
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pVEC, SynB3 and TP10 were radiolabeled using a no-carrier-added (NCA) protocol, in which the non-
radioactive sodium iodide solution was replaced by its solvent.  
After radiolabeling, the iodinated peptides were fractionated using an HPLC-UV apparatus (LaChrom 
Elite, Hitachi, Tokyo, Japan) equipped with a radioactivity detector (Berthold Technologies GmbH & 
Co. KG, Bad Wildbad, Germany) and fraction collector (Gilson International BV, Den Haag, The 
Netherlands), in line with the HPLC waste. For separation, a Vydac Everest C18 column (250 × 4.6 mm, 
5 µm particle size; Grace, Lokeren, Belgium) was coupled to the HPLC system. Mixtures of water and 
acetonitrile acidified with 0.1% (m/V) FA or 0.1% (m/V) TFA (SynB3 and Tat 47-57) were used to 
create appropriate gradients for separation of peptides and their iodinated forms. After 
fractionation, the fractions containing the radiolabeled peptides were selected and evaporated using 
a N2 flow. After radioiodination of BSA and the PrAMPs, 500 µl of phosphate buffer (130 mM, pH 7.4) 
was added to the reaction mixture and the solution was filtered over a silver filter (Sterlitech, Kent, 
USA), instead of being fractionated. Before each experiment, a QC of the iodinated peptide stock was 
performed using the same radio-HPLC-UV system as desribed above. The presence of the 
radiolabeled peptides was verified by comparing the retention time of the peaks of the iodinated 
peptides, both obtained using UV- and radiodetection, with the retention times observed during 
fractionation after radiolabeling. For all peptides, the QC results indicated the presence and identity 
of the radiolabeled peptides. 
 
In vivo experiments in mice 
Female, ICR-CD-1 mice (Harlan Laboratories, Venray, The Netherlands), aged 7 to 10 weeks and 
weighing 28-36 g, were used during the in vivo BBB transport experiments. For the PrAMPs, being 
part of a separate research project, male mice were used. It is known that sex steroid hormones 
influence the BBB function; however, differences in permeability have only been demonstrated in 
aged and diseased animal models [44,45]. All animal experiments were performed in accordance 
with the Ethical Committee principles of laboratory animal welfare as approved by our institute 
(Ghent University, Faculty of Veterinary Medicine, no. 2009-052 and 2014-128). Prior to experiments, 
mice were anesthetized by intraperitoneal injection of a 40% urethane solution (3 g/kg) (Sigma-
Aldrich, Diegem, Belgium).  
 
Evaluation of blood-brain barrier influx 
For evaluation of the blood-to-brain BBB transport of peptides, the multiple time regression (MTR) 
analysis technique was used. In brief, after anesthetization of the ICR CD-1 mice, the right jugular 
externalis vein and left carotid artery were isolated. Then, 200 µl of a 30000 cpm/µl peptide solution 
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(MTR stock solution), obtained by diluting the radiolabeled peptide stock using lactated Ringer’s 
buffer containing 1% (m/V) BSA (LR/BSA), was injected into right jugular externalis vein of the mouse. 
At 1, 3, 5, 10, 12.5 and 15 min post intravenous (IV) injection, with first and last time points 
performed in duplicate, mice were decapitated, brains were collected, weighed and measured for 
radioactivity (Am(T)) using a gamma counter (Wallac Wizard 1470, Perkin Elmer). Shortly before 
decapitation, blood was collected from the isolated left carotid artery, which was then centrifuged 
(10000 g, 15 min at 21°C) in order to measure the radioactivity of blood and serum (Cp(T)). 
Dermorphin and radioiodinated BSA were used as positive and negative control, respectively. The 
blood-to-brain entry during the experimental period of 15 min was evaluated by plotting the ratio of 
total brain radioactivity (Am(T)) and arterial serum radioactivity (Cp(T)), corrected for the brain weight 
and serum volume, respectively, versus the exposure time (Θ), expressing the theoretical steady 
state serum level of the iodinated peptide at a given serum concentration [46,47]. The exposure time 
is calculated as the integral of the arterial serum radioactivity over time divided by the radioactivity 
at time t. The integral is calculated through the trapezoidal rule of the log-transformed data [47]. In 
the linear part of the curve, assuming a two-compartmental BBB model, data can be fitted using a 
linear model from which the unidirectional brain influx rate (Kin), also referred to as unidirectional 
blood-to-brain clearance K1 [48], and the initial (vascular) brain distribution volume (Vi) can be 
determined using the following equation according to Gjedde and Patlak [46, 49-51]:  
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with K1 is the unidirectional clearance, K is the net clearance, Vg the brain tissue distribution volume, 
and V0 the initial vascular brain distribution volume, experimentally determined as the vascular brain 
distribution volume of radioiodinated BSA [48,53]. If K equals to K1, the model is linear. The meaning 
of the constants and parameters of the linear and biphasic model is illustrated in Figure 2. 
To evaluate whether the BBB remains intact after intravenous injection of the CPPs, a MTR 
experiment was performed for radioiodinated BSA with and without an excess dose of 20 µg of pVEC, 
which is the estimated injected dose of pVEC if the peptide was radiolabeled using the CA protocol. A 
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MTR experiment with and without co-injection of an excess dose of 10 µg of unlabeled peptide was 
used to investigate whether the CPPs use a saturable or non-saturable transport mechanism to cross 
the BBB. During this experiment, peptides were radiolabeled using a NCA method.  
 
 
Figure 2: Meaning of constants and parameters of the linear and biphasic model. 
 
Tissue distribution after IV injection 
At the 15 min time points of the MTR experiment, six tissues, i.e. spleen, kidneys, lungs, heart and 
liver, were collected immediately after decapitation, weighed and measured in a gamma counter. 
The percentage of the injected dose for each isolated tissue was calculated as follows: 
 
mouseinjected IV
tissuetissue
wA
wA
  dose  injected %         (3) 
with Atissue and AIV injected the measured radioactivity of the isolated tissue and the radioactivity of 
200 µl of MTR stock solution, respectively, and wtissue and wmouse the weight of the considered tissue 
and injected mouse, respectively. 
 
Regional variation in brain influx between different brain regions 
For the CPPs, the regional variation in brain influx was evaluated. Therefore, after weighing and 
measuring the whole brain radioactivity, the brains collected during the MTR experiment of pVEC, 
SynB3 and TP10, as well as of the controls dermorphin and radiodiodinated BSA, were dissected into 
eight brain regions: (1) cerebellum, (2) medulla oblongata, (3) frontal cortex, (4) striatum, (5) 
hippocampus, (6) thalamus + hypothalamus, (7) midbrain and (8) occipital + parietal cortex, including 
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“rest of brain”. Different dissected brain regions were weighed and measured in the gamma counter. 
The unidirectional influx rate and initial (vascular) brain distribution volume of the iodinated peptides 
for the different brain regions are determined using equation (1). 
 
Peptide distribution to brain parenchyma and capillaries 
The capillary depletion (CD) method was used to evaluate the distribution of the peptide between 
the brain parenchyma and capillaries [54,55]. In summary, the jugular internalis vein of two 
anesthetized ICR CD-1 mice were isolated. Then, 200 µl of a 10000 cpm/µl radiolabeled peptide 
solution (CD stock solution), obtained by diluting the radiolabeled peptide stock solution using 
LR/BSA buffer, was IV injected. Ten minutes after IV injection, mice were decapitated and brains 
were collected, weighed and measured for radioactivity. Prior to decapitation, blood was collected 
from the abdominal aorta followed by intracardial perfusion of the brain using 20 ml of LR buffer 
after clamping the aorta and severing the jugular veins. Then, brain was homogenized with 0.7 ml of 
ice-cold capillary buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM MgSO4, 1mM 
NaH2PO4 and 10 mM D-glucose adjusted to pH 7.4) and 1.7 ml of 26% ice-cold dextran solution in 
capillary buffer. The resulting homogenate was weighed and centrifuged in a swinging bucket rotor 
at 5400 g for 30 min at 4°C, resulting in a pellet, i.e. capillaries, and supernatant, i.e. parenchyma and 
fat tissue, which were weighed and measured in the gamma counter. The radioactivity of blood and 
serum, obtained by centrifuging blood at 10000 g, 15 min at 21°C, were measured as well. 
Compartmental distribution was calculated as follows: 
100
A
A
A
A
A
A
(%)Fraction
serum
parenchyma
serum
scapillarie
serum
parenchyma or scapillarie
parenchyma or scapillarie 

        (4) 
 
Brain-to-blood transport 
For evaluation of the efflux of the peptides out of the brain, ICR CD-1 mice were intraperitoneally 
anesthetized and the skin of the skull was removed. A puncture was made into the lateral ventricle 
using a 22 G needle marked with tape at 2 mm at the following coordinates: 1 mm lateral and 0.34 
mm posterior with respect to the bregma. Then, 1 µl of a 25000 cpm/µl radiolabeled peptide solution 
(efflux stock solution), obtained by diluting the radiolabeled peptide stock solution using LR/BSA 
buffer, was injected in the lateral ventricle at a speed of 360 µl/h for 10 s using a syringe pump 
(KDS100, KR analytical, Cheshire, UK). At 1, 3, 5, 10, 12.5 and 15 min post injection, mice were 
decapitated and the brains were isolated, weighed and measured in the gamma counter. Prior to 
decapitation, blood was collected from the abdominal aorta, which was subsequently centrifuged 
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(10000 g, 15 min at 21°C) to obtain serum of which the radioactivity was measured. The brain half-
time disappearance, t1/2,brain, was calculated from the linear regression of the natural logarithm of the 
residual radioactivity in brain versus the experimental time as follows: 
out
brain1/2,
k
ln(2)
t             (5) 
with kout defined as the efflux rate constant calculated as the absolute value of the slope of the linear 
regression, applying first order kinetics [56].  
 
In vitro metabolic stability 
The in vitro metabolic stability of CPPs and PrAMPs was determined in mouse serum, or plasma in 
case of the PrAMPs, and mouse brain homogenate according to pre-established protocols [57,58]. 
For the CPPs, the in vitro metabolic stability was also evaluated in liver and kidney homogenates. 
Prior to use, the protein content of each homogenate was determined using the Pierce Modified 
Lowry Protein Assay method (Thermo Scientific) to generate a stock solution with a protein 
concentration of 0.6 mg/ml by dilution with Krebs-Henseleit buffer (pH 7.4, Sigma-Aldrich). In brief, 
100 µl of a 1 mg/ml peptide solution, dissolved in Krebs-Henseleit buffer (pH 7.4) was added to 900 
μl of tissue extract or serum/plasma (500 µl of tissue homogenate or serum/plasma + 400 µl of 
Krebs-Henseleit buffer (pH 7.4) = 300 µg of protein in total) and incubated at 37°C while shaking at 
750 rpm. Aliquots of 100 µl were sampled after 0, 15, 30, 60, 90 and 120 min of incubation into tubes 
containing an equal volume of aqueous TFA (1% V/V). For the serum samples of SynB3 and Tat 47-57, 
aliquots were taken as well at 2, 4, 6, 8, 10 and 12 min (in a separate experiment) and for TP10 and 
TP10-2 at 2, 5 and 10 min. Time points for sampling during the in vitro metabolic stability of the 
PrAMPs were 0, 5, 10, 20, 40 and 60 min. 
After sampling, enzymatic activity was terminated by additional heat inactivation at 95°C for 5 min, 
followed by cooling the samples in an ice bath for 30 min. Centrifugation at 20000 g for 5 min at 5°C 
yielded a clear supernatant ready for HPLC-UV analysis. For the analysis of the serum samples of 
TP10 and TP10-2, a more extensive sample preparation was required to remove interfering 
compounds. Therefore, a solid-phase extraction (SPE) protocol using an Oasis® WCX µelution plate 
(Waters, Zellik, Belgium) was used prior to HPLC-UV analysis: at the specified time points, 100 µl 
aliquots were transferred to tubes containing 100 µl of a 4% (V/V) phosphoric acid solution and were 
consequently heated at 95°C during 5 min. After cooling the samples on an ice batch, interfering 
compounds were removed by SPE using a positive pressure-96 processor (Waters). Before 
application of the acidified sample on the Oasis® WCX µelution plate, which was conditioned with 
200 µl of methanol and equilibrated with 200 µl of ultrapure water, the internal standard was added 
(TP10 for TP10-2 and vice versa). After loading the samples, the Oasis® WCX µelution plate was 
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washed using successively 200 µl of a 5% ammoniumhydroxide and 200 µl of a 70% acetonitrile 
solution. The peptides were eluted using four times 25 µL of a 1% TFA (V/V) in 10:90 
water:acetonitrile. The resulting eluate was analyzed by HPLC-UV. Blank control solutions (placebo 
samples) were prepared as described above, but without adding the peptide. To confirm chemical 
stability and mass balance, control reference solutions without tissue homogenate or with a prior 
heat inactivation were analyzed as well.  The HPLC-UV system consisted of a Waters Alliance 2695 
separation module and a Waters 2996 PDA detector (detection from 190-400 nm, quantification at 
215 nm), fitted with Empower 2 software for data handling (Waters). For each sample, 20 µl was 
injected and separated on an Vydac Everest C18 column (SynB3, Tat 47-57 and PrAMPs) or Prevail 
Organic Acid (pVEC, TP10 and TP10-2) column (250 × 4.6 mm, 5 µm particle size) both from Grace at 
1 ml/min in an oven set at 30°C. Appropriate gradients for separation of the peptides and their 
metabolites were created by mixtures of 0.1% TFA (V/V) in water and 0.1% TFA (V/V) in acetonitrile. 
For analysis of the PrAMP in vitro metabolic stability samples, FA was used as acidic modifier in the 
mobile phase. The half-life was determined as: 
slope
ln(2)
t1/2         (6) 
with the slope derived from the curve of the natural logarithm of the percentage of the amount at 
the start of the incubation, i.e. t = 0 min, versus time.  
For identification of the formed metabolites during incubation of pVEC in mouse serum, serum 
samples obtained at 0 min and 15 min post injection were injected into an Acquity H-class UPLC® 
apparatus consisting of a quaternary solvent manager, an automatic sample injection system, 
combined with a flow through needle, a column heater and an UPLC® PDA detector, with Empower 3 
FR 2 software for data acquisition (all from Waters). An Acquity BEH C18 300 Å column (2.1 mm × 100 
mm, 1.7 µm, Waters), thermostated at 30°C, was selected for separation using the same mobile 
phase as above. The eluting mobile phase was split towards both the PDA and a QDa detection 
system (ratio 10/1), consisting of an Acquity isocratic solvent manager and an Acquity QDa detector 
(both from Waters), equipped with an ESI interface. The fraction going to the QDa was diluted with 
40:10:50 (V/V/V) water:propionic acid:2-propanol at a flow rate of 0.35 ml/min. The QDa detector 
was operated in positive ion mode with the ESI capillary voltage set at +0.8 kV and the cone voltage 
at 15 V. The probe temperature was 600°C. A full mass spectrum between m/z 100 and 1250 was 
acquired at a sampling rate of 2.0 points/s.  
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Statistics 
Regression lines were computed using the least squares method. For fitting the MTR data using the 
biphasic model, Prism 6 software (GraphPad, La Jolla, USA) was used. The slopes of the regression 
lines of the ratio of the brain-to-serum radioactivity versus the exposure time were compared using 
the Prism 6 software. If the calculated P-value was greater than 0.05, the slopes were not statistically 
significantly different. 
 
3. CHARACTERIZATION OF BLOOD-BRAIN BARRIER TRANSPORT OF 
CELL-PENETRATING PEPTIDES 
The result section is subdivided into three subsections: in the first section, the BBB transport results 
of the five “traditional” CPPs, i.e. pVEC, TP10, TP10-2, SynB3 and Tat 47-57, will be presented, 
followed by the BBB transport data of the “new” CPPs: four PrAMPs, i.e. apidaecin Api137, oncocin, 
drosocin and drosocin Pro5Hyp, and three disulfide-rich (cyclic) peptides, i.e. MCoTI-II, cVc1.1 and 
chlorotoxin. In the third subsection, the results of the tissue distribution of the investigated peptides 
and the in vitro metabolic stability are given.  
 
3.1. BLOOD-BRAIN BARRIER TRANSPORT OF “TRADITIONAL” CELL-
PENETRATING PEPTIDES 
Blood-to-brain transport kinetics 
The results of the MTR analysis indicated that the five investigated CPPs crossed the BBB to a 
different extent. In Figure 3, the ratio of the brain and serum radioactivity is plotted versus the 
exposure time and the linear part of the curve was fitted using the Gjedde-Patlak model [46,49-51]. 
The unidirectional brain influx rates (Kin) and initial (vascular) brain distribution volumes (Vi) are 
summarized in Table 2. For pVEC, SynB3 and TP10, the MTR experiments were performed twice and 
their Kin and Vi were calculated by fitting all obtained data points. pVEC showed the highest brain 
influx rate of 6.02 µl/(g × min), followed by SynB3 and Tat 47-57 having a Kin of 5.63 µl/(g × min) and 
4.73 µl/(g × min), respectively. In contrast, the transportan analogs showed a limited brain influx, 
especially TP10 having a Kin close to zero (0.05 µl/(g × min)); the Kin of TP10-2 was 0.36 µl/(g × min). 
The calculated unidirectional blood-to-brain influx rate of dermorphin (Kin = 0.63 µl/(g × min)) 
corresponds to the brain influx results previously obtained data for this positive control at our lab 
[48]. The radioiodinated vascular marker BSA shows a significant influx into the brain (Kin = 0.16 µl/(g 
× min)). Bovine serum albumin has been demonstrated to show non-specific binding to cerebral 
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capillaries of which the extent was much greater for radioiodinated than tritiated BSA, explaining its 
significant Kin-value [59]. 
 
 
Figure 3: Results of the MTR analysis experiment of the five CPP using the linear model. 
The ratio of the brain-to-serum radioactivity is plotted versus the exposure time and fitted using the linear 
Gjedde-Patlak model. For SynB3, Tat 47-57 and dermorphin, only the linear part of the curve is fitted using the 
linear model. 
 
Table 2: Overview of the quantitative influx characteristics (± 65% confidence limits) of the five investigated 
CPPs based on linear and biphasic modeling of the MTR analysis data. 
Influx parameter pVEC TP10 TP10-2 SynB3 Tat 47-57 Dermorphin BSA 
Linear Gjedde-Patlak model 
Kin (µl/(g× min)) 6.02 ± 0.29 0.05 ± 0.04 0.36 ± 0.06 5.63 ± 1.83 4.73 ± 1.23 0.63 ± 0.10 0.16 ± 0.07 
Vi (µl/g) 23.13 ± 4.33 9.88 ± 0.66 10.07 ± 1.00 27.62 ± 5.58 17.43 ± 4.04 13.98 ± 0.79 15.42 ± 1.11 
Biphasic model 
V0 (vascular) (µl/g) - - - 10.27 10.27 10.27 - 
Vg (tissue) (µl/g) - - - 44.47 ± 7.75 34.38 ± 9.32 13.72 ± 2.17 - 
K1 (µl/(g × min)) - - - 29.84 ± 8.42 13.50 ± 3.88 2.54 ± 0.50 - 
K (µl/(g × min)) - - - ≈ 1.92·10-16 0.27 ± 0.46 0.03 ± 0.06 - 
Kin = Unidirectional brain influx rate. 
Vi = Initial (vacular) brain distribution volume. 
V0 = Vascular brain distribution volume, experimentally determined as the brain distribution volume of radioiodinated BSA (10.27 µl/g). 
Vg = Tissue brain distribution volume. 
K1 = Unidirectional clearance or slope of the initial phase of the brain influx curve. 
K = Net clearance or slope of the plateau phase of the brain influx curve. 
 
The curves of the ratio of the brain and serum radioactivity versus the exposure time of SynB3 and 
Tat 47-57 reached a plateau-phase after about 5 min. In Figure 4, the MTR data of these peptides 
were fitted using a biphasic model and is summarized in Table 2 [52]. K1 represents the unidirectional 
influx of the initial phase of curve and for SynB3 the K1 (29.84 µl/(g × min)) is more than twice as high 
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as that of Tat 47-57 (13.50 µl/(g × min)). After reaching the plateau-phase, which can be explained by 
efflux of the peptide out of the brain and/or distribution and elimination of the peptide, the ratio of 
the brain and serum radioactivity did no longer increase for these peptides: K is about 0 µl/(g × min) 
for SynB3 and is 0.27 ± 0.46 µl/(g × min) for Tat 47-57, which is not statistically significantly different 
from zero. Thus, after the initial phase characterized by high brain influx rates, the BBB transport of 
SynB3 and Tat 47-57 reached a plateau of no net brain clearance.  
 
Figure 4: Result of the MTR analysis experiment of SynB3, Tat 47-57 and dermorphin using the biphasic model. 
The ratio of the brain-to-serum radioactivity is plotted versus the exposure time and fitted using the biphasic 
model. 
 
The MTR curve of pVEC did not show a plateau-phase in the 15 min time range of the performed 
MTR experiments. Moreover, the amount of pVEC reaching the brain, represented by the ratio of the 
brain-to-serum radioactivity, greatly transcends that of the other investigated CPPs. For this CPP, the 
initial (vascular) brain distribution volume, representing the effective vascular space of the peptide, 
was higher than that of the vascular marker radioiodinated BSA which was about 15 µl/g. This was 
also observed for SynB3 for which the Vi was 27.62 µl/g. For the other CPPs, the Vi was of the same 
magnitude as of radioiodinated BSA (Tat 47-57) or was significantly smaller (transportan analogs). 
The capillary depletion method was used to evaluate the brain parenchymal and capillary distribution 
of the radiolabeled peptides after perfusion of the brain in order to remove capillary bound peptides. 
The parenchymal fraction was 80% for pVEC, 77% for SynB3, 79% for Tat 47-57, 85% for TP10 and 
84% for TP10-2. Thus, the measured radioactivity of the brain during the MTR experiment mainly 
originated from peptides present in the brain parenchyma. Only about 15 to 25% of the CPPs 
remained trapped by the endothelial cells.  
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Brain-to-blood transport kinetics 
The efflux properties of the CPPs out of the brain were investigated by measuring the residual  brain 
radioactivity after intracerebroventricular injection of the radiolabeled peptides. The efflux transfer 
constant kout was derived from the absolute value of the slope of the natural logarithm of the brain 
radioactivity versus the experimental time curve (Figure 5). The kout of pVEC (0.10 ± 0.11 min-1) was 
not statistically significantly different from zero. The efflux data of pVEC showed a larger variability 
compared to the other investigated CPPs. However, the analysis of the radioactivity of the control 
samples of efflux stock solution, used to evaluate of the performance of the experimental set-up of 
the efflux study, did not provide any reason to reject the data. All other investigated CPPs showed a 
statistically significant efflux out of the brain. The kout calculated for SynB3 was 0.05 ± 0.01 min-1, for 
TP10 kout was 0.09 ± 0.02 min-1, and for TP10-2 kout was 0.06 ± 0.01 min-1. These efflux rate constants 
equal a half-time disappearance (t1/2,brain) of 15 min, 8 min and 11 min, respectively. The highest 
efflux rate was observed for Tat 47-57, having a kout of 0.21 ± 0.08 min-1 or t1/2,brain of 3 min. These 
brain half-time disappearances of less than 15 min suggest the existence of an active efflux transport 
system for the investigated peptides [60]. The observed efflux of SynB3 and Tat 47-57 is also 
consistent with the observed plateau-phase during the MTR experiment. 
 
Figure 5: Brain-to-blood kinetics of the CPPs. The natural logarithm of the residual brain radioactivity is plotted 
versus the experimental time. The slope of the curve represents the efflux rate constant, kout. 
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Evaluation of the influx mechanism  
As pVEC showed an extraordinary high brain influx, the BBB transport of this peptide was further 
explored. We hypothesized that pVEC itself (transiently) could increase the BBB permeability. To 
evaluate this hypothesis, a MTR experiment was performed with the radioiodinated vascular marker 
BSA, with and without co-injection of 20 µg of pVEC. The slopes of the curves of radioiodinated BSA 
and radioiodinated BSA with an excess dose of pVEC were not statistically different (P > 0.05, Figure 
6A). Thus, under the experimental conditions of this study, the BBB did not show an increased 
permeability for radioiodinated BSA after IV injection of pVEC, indicating the BBB integrity was not 
significantly influenced by pVEC. 
 
Figure 6: Evaluation of the BBB permeability after injection of pVEC and used brain influx mechanism of pVEC, 
TP10 and SynB3. Data were fitted using the linear Gjedde-Patlak model, except for the data of SynB3, which 
were fitted using the biphasic model. (A) Evaluation of the BBB permeability after IV injection of pVEC: ratio of 
brain-to-serum radioactivity versus exposure time of radioiodinated BSA with (purple squares) and without 
(black dots) an excess dose of pVEC (20 µg). (B-D) Evaluation of the saturability of influx of pVEC, TP10 and 
SynB3, respectively across the BBB: ratio of brain-to-serum radioactivity versus exposure time with (purple 
squares) and without (black dots) an excess dose of the CPP (10 µg).  
 
Next, the saturability of the brain influx mechanism of pVEC, SynB3 and TP10, being representatives 
of the three different groups of CPPs observed during the BBB transport studies, was evaluated. 
Therefore, a MTR experiment was performed for these peptides, radiolabeled using a NCA method, 
with and without an excess dose of 10 µg of the unlabeled peptide. The results are shown in Figure 
6B-D: there was no statistically significant difference in unidirectional brain influx rate between the 
experiment of the peptides alone or when co-injected with an excess dose (P > 0.05). For SynB3, the 
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the slopes of the initial, linear part of the curves fitted using the linear Gjedde-Patlak model, were 
not statistically significantly different (P > 0.05). Thus, during the performed experiments, the brain 
influx mechanism of pVEC, SynB3 and TP10 was not saturable. Although the Kin was unaffected, the 
excess dose of unlabeled pVEC caused a significant decrease of Vi from 24 µl/g to 1 µl/g, suggesting 
saturable binding sites on the brain endothelium, a phenomenon which was similarly observed for 
glucagon [61]. 
 
Regional intra-brain distribution 
For pVEC, SynB3 and TP10, the regional differences in brain influx were investigated. Therefore, 
during the MTR experiments of these peptides, brains were dissected into eight different brain 
regions and their regional unidirectional influx rate Kin was determined using the Gjedde-Patlak 
model. For SynB3, TP10, as well as the controls radioiodinated BSA and dermorphin, no statistically 
significant difference in brain influx rates were observed between the different dissected brain 
regions (P > 0.05, Figure 7). The slopes, i.e. Kin, of the initial, linear part of the curves fitted using the 
linear Gjedde-Patlak model were compared for SynB3 and dermorphin. 
 
Figure 7: Regional variations in BBB influx of pVEC, TP10, SynB3, dermorphin and radioiodinated BSA. The data 
of pVEC, TP10 and radioiodinated BSA are fitted using the linear Gjedde-Patlak model; the data of SynB3 and 
dermorphin were fitted using the biphasic model. Grey = whole brain, yellow = frontal cortex, purple = occipital 
+ parietal cortex, light blue = cerebellum, dark blue = striatum, brown = thalamus + hypothalamus, orange = 
pons medulla, green = hippocampus and red = midbrain. 
 
For pVEC, the slopes of the curves of the ratio of the brain-to-serum radioactivity versus the 
exposure time differed significantly (P < 0.05). In Table 3, the individual Kin and Vi values of the whole 
brain and brain regions after IV injection of pVEC are summarized. Nevertheless, the difference in 
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unidirectional brain influx rates is not pronounced: the influx of pVEC was only slightly higher in the 
cerebellum, cortex and midbrain compared to the pons medulla, hippocampus, thalamus and 
hypothalamus and striatum. 
Table 3: Kin and Vi values of the whole brain and eight brain regions of pVEC  
(between brackets the 65% confidence interval is indicated). 
Brain region Kin (µl/(g × min)) Vi (µl/g) 
Whole brain 6.04 [5.78, 6.30] 24.37 [21.23, 27.51] 
Cerebellum 5.61 [5.12, 6.10] 21.02 [15.09, 26.95] 
Pons medulla 4.51 [3.87, 5.15] 36.06 [28.34, 43.78] 
Frontal cortex 4.84 [4.66, 5.02] 12.93 [10.77, 15.09] 
Striatum 4.07 [3.77, 4.37] 11.47 [7.81, 15.13] 
Hippocampus 3.94 [3.51, 4.37] 9.33 [4.13, 14.54] 
Occipital and parietal cortex 5.03 [4.73, 5.32] 16.61 [13.02, 20.19] 
Thalamus and hypothalamus 4.12 [3.86, 4.38] 17.72 [11.58, 17.86] 
Midbrain 5.32 [5.17, 5.46] 13.88 [12.15, 15.62] 
 
3.2. BLOOD-BRAIN BARRIER TRANSPORT OF “NEW” CELL-PENETRATING 
PEPTIDES 
Blood-to-brain transport kinetics 
In Figure 8, the results of the MTR analysis of the four investigated PrAMPs and three disulfide-rich 
(cyclic) peptides are shown. Clearly, the two classes of peptides differed in the extent of BBB influx. 
 
Figure 8: Results of the multiple time regression analysis experiment of four PrAMPs (left) and three disulfide-
rich (cyclic) peptides, fitted using the linear Gjedde-Patlak model. For drosocin and dermorphin, only the linear 
part of the curve was fitted by the linear model. 
 
The unidirectional brain influx rates and initial (vascular) brain distribution volumes are summarized 
in Table 4 and 5. The PrAMPs showed a significant brain influx: drosocin showed the highest Kin of 
2.18 µl/(g × min), followed by apidaecin Api137, with an estimated Kin of 0.77 µl/(g × min). Similar 
unidirectional brain influx rates were observed for oncocin and drosocin Pro5Hyp having a Kin of 0.44 
µl/(g × min) and 0.37 µl/(g × min), respectively. On the other hand, the disulfide-rich (cyclic) peptides 
did not show a significant brain influx: only a very low Kin was observed for cVc1.1 and chlorotoxin 
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and a non-significant value for MCoTI-II (Table 5). The Kin of these peptides was not significantly 
different from radioiodinated vascular marker BSA (P > 0.05).  
 
Table 4: Overview of the quantitative influx characteristics (± 65% confidence limits) of the four investigated 
PrAMPs peptides based on linear and biphasic modeling of the MTR analysis data. 
Influx parameter Apidaecin Api137 Oncocin Drosocin Drosocin Pro5Hyp 
Linear Gjedde-Patlak model 
Kin (µl/(g× min)) 0.73 ± 0.13 0.44 ± 0.17 2.18 ± 0.53 0.37 ± 0.14 
Vi (µl/g) 23.43 ± 1.70 25.84 ± 2.32 12.59 ± 3.87 19.57 ± 1.79 
Biphasic model 
V0 (vascular) (µl/g) - - 10.271 - 
Vg (tissue) (µl/g) - - 29.1 ± 37.41 - 
K1 (µl/(g × min)) - - 4.29 ± 1.93 - 
K (µl/(g × min)) - - ≈ 1.77 ·10-16 - 
1No data available for dermorphin and radioiodinated BSA for the BBB transport study of the PrAMPs. V0 of radioiodinated BSA, obtained 
during BBB transport of CPPs was used (Table 2). 
Kin = Unidirectional (brain) influx rate. 
Vi = Initial (vascular) brain distribution volume. 
V0 = Vascular brain distribution volume, experimentally determined as the brain distribution volume of radioiodinated BSA. 
Vg = Tissue brain distribution volume. 
K1 = Unidirectional clearance or slope of the initial phase of the brain influx curve. 
K = Net clearance or slope of the plateau phase of the brain influx curve. 
 
Table 5: Overview of the quantitative influx characteristics (± 65% confidence limits) of the three disulfide-rich 
(cyclic) peptides as well as dermorphin and radioiodinated BSA based on linear and biphasic modeling of the 
MTR analysis data. 
Influx parameter MCoTI-II cVc1.1 Chlorotoxin Dermorphin BSA 
Linear Gjedde-Patlak model 
Kin (µl/(g× min)) 9.37·10-5 ± 0.03 0.06 ± 0.04 0.16 ± 0.10 2.65 ± 0.86 0.10 ± 0.08 
Vi (µl/g) 10.39 ± 0.50 9.76 ± 0.65 7.10 ± 2.26 12.60 ± 3.44 12.15 ± 1.62 
Biphasic model 
V0 (vascular) (µl/g) - - - 9.15 - 
Vg (tissue) (µl/g) - - - 16.23 ± 3.56 - 
K1 (µl/(g × min)) - - - 8.76 ± 3.32 - 
K (µl/(g × min)) - - - 0.08 ± 0.15 - 
Kin = Unidirectional (brain) influx rate. 
Vi = Initial (vascular) brain distribution volume. 
V0 = Vascular brain distribution volume, experimentally determined as the brain distribution volume of radioiodinated BSA. 
Vg = Tissue brain distribution volume. 
K1 = Unidirectional clearance or slope of the initial phase of the brain influx curve. 
K = Net clearance or slope of the plateau phase of the brain influx curve. 
 
Only for drosocin, a biphasic BBB influx behavior was observed, thus for this peptide the MTR results 
were also fitted using the biphasic model (Table 4). After an initial increase in the ratio of the brain 
and serum radioactivity (K1 was 4.29 µl/(g × min)), a plateau is reached characterized by no net brain 
clearance (K not significantly different from zero).  
For PrAMPs, showing a significant brain influx, the parenchymal and capillary distribution was 
investigated using the capillary depletion method. The observed parenchymal fractions ranged 
between 67% for drosocin and drosocin Pro5Hyp, and 77% for apidaecin Api137. The brain 
radioactivity of these PrAMPs are mainly derived from peptides distributed to the brain parenchyma. 
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In contrast, the parenchymal fraction of oncocin was only 18%, indicating the 82% of peptide remains 
trapped in the brain capillary endothelial cell.  
  
Brain-to-blood transport kinetics 
During the brain efflux study of the four PrAMPs, a clear efflux out of the brain was demonstrated for 
drosocin, the only peptide showing a biphasic brain influx behavior. The calculated kout was 
0.22 ± 0.10 min-1, which corresponds with a brain half-time disappearance of 3 min. This low value of 
t1/2,brain suggests the use of an active efflux system [60]. The other three PrAMPs did not show a 
significant brain-to-blood transport. After intracerebroventricular injection of the disulfide-rich 
(cyclic) peptides, only MCoTI-II could reach the peripheral blood circulation with a kout of 0.07 ± 0.04 
min-1 (t1/2,brain = 9 min) also indicating the existence of an active efflux system for this peptide.  
 
3.3. TISSUE DISTRIBUTION AND IN VITRO METABOLIC STABILITY 
Tissue distribution after IV injection 
The tissue distribution of the investigated peptides was evaluated at the 15 min time point of the 
MTR experiments. In Figure 9, the results of the CPPs, as well as the controls dermorphin and 
radioiodinated BSA are shown. pVEC and Tat 47-57 showed a high liver distribution compared to the 
other tissues. The transportan analogs did also show this high liver concentration, but an even higher 
serum distribution was observed. SynB3 was mainly distributed to the spleen and serum and to a 
lesser extent to the liver. This CPP also showed a significant heart distribution. The results of the 
controls dermorphin and radioiodinated BSA were similar as reported in previous studies, with high 
liver distributions for both controls and also high serum concentrations for radioiodinated BSA 
[48,62,63].  
The tissue distribution pattern of the PrAMPs was analogous: the highest radioactivity was found in 
serum (Figure 10). Apidaecin Api137, drosocin and drosocin Pro5Hyp also distributed significantly to 
the kidneys, but to a lesser extent than serum. For oncocin, a significant distribution to the lungs is 
noted as well. For the disulfide-rich (cyclic) peptides, the tissue distribution was also similar within 
this group of peptides (Figure 10). MCoTI-II, cVc1.1 and chlorotoxin were extensively distributed to 
the kidneys and to a lesser extent to the serum compartment. Thus, the distribution to the different 
tissues varied among the different investigated peptides, which is also observed for other already 
investigated peptides [48,62,63]. 
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Figure 9: Relative tissue distribution of the radiolabeled CPPs and the controls dermorphin and radioiodinated 
BSA 15 min post IV injection expressed as the percentage of the injected dose, representing the ratio of the 
weight corrected radioactivity of the tissue and the injected radioactivity (± SEM, n = 2). From the left to the 
right: brain (light blue), spleen (dark blue), kidneys (purple), lungs (red), heart (orange), liver (yellow) and 
serum (light green). 
 
Figure 10: Relative tissue distribution of the radiolabeled PrAMPs and disulfide-rich (cyclic) peptides 15 min 
post IV injection expressed as the percentage of the injected dose, representing the ratio of the weight 
corrected radioactivity of the tissue and the injected radioactivity (± SEM, n = 2). From the left to the right: 
brain (light blue), spleen (dark blue), kidneys (purple), lungs (red), heart (orange), liver (yellow) and serum (light 
green). 
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In vitro peptide stability in mouse serum and brain, kidney and liver 
homogenates 
Data on the metabolic stability of CPPs are scarce [42,64-66]. Therefore, the stability of the 
investigated CPPs was determined in mouse serum, as well as in mouse brain, liver and kidney 
homogenates. Also for the PrAMPs, the in vitro metabolic stability was evaluated in mouse plasma 
and brain tissue homogenate. The results are summarized in Table 5. The in vitro serum stability of 
MCoTI-II, cVc1.1 and chlorotoxin was investigated by prof. D. Craik and personally communicated to 
us.   
Table 5: Overview of the in vitro metabolic stability results of the investigated peptides. 
 Peptide  t1/2 serum (min) t1/2 brain (min) t1/2 kidneys (min) t1/2 liver (min) 
pVEC < 3 68 7 43 
TP10 1316 176 34 139 
TP10-2 229 102 11 118 
SynB3 6 21 5 37 
Tat 47-57 3 54 18 60 
MCoTI-II1  > 13 000 - - - 
cVc1.11 > 13 000 - - - 
Chlorotoxin1 > 13 000 - - - 
Peptide t1/2 plasma (min) t1/2 brain (min) t1/2 kidneys (min) t1/2 liver (min) 
Apidaecin Api137 220 637 - - 
Oncocin 47 142 - - 
Drosocin 81 363 - - 
Drosocin Pro5Hyp 157 409 - - 
1Data personally communicated by prof. D. Craik (e-mailed by Aaron Poth on 10 December 2014). 
  
In the brain and liver homogenate, the stability varied among the CPPs: in mouse brain, the half-lives 
ranged between 21 min (SynB3) and 176 min (TP10) and in the liver homogenate between 37 min 
(SynB3) and 139 min (TP10). The transportan analogs showed high serum stability, with a half-life of 
22 h for TP10 and 4 h for TP10-2. In contrast, Tat 47-57, SynB3 and pVEC were not so stable in serum, 
having a half-life of less than 5 min. Kidney enzymes also extensively metabolized the investigated 
CPPs: the half-lives ranged between 5.5 min (SynB3) and 34 min (TP10). For pVEC, showing an 
extraordinary brain influx, the formed metabolites during serum incubation were further 
investigated. One metabolite was determined and identified as the pVEC peptide with the first six  
hydrophobic N-terminal amino acids deleted, formed by cleavage of the first N-terminal arginine-
arginine bond (pVEC7-18), which is known to be unstable in serum (Figure 11) [64].  
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Figure 11: Identification of metabolite of pVEC formed during in vitro incubation in mouse serum. 
The PrAMPs also showed a high in vitro brain stability with the lowest t1/2 of 142 min observed for 
oncocin. The plasma half-lives ranged between 47 min and 81 min for oncocin and drosocin, 
respectively, and 157 min and 220 min for drosocin Pro5Hyp and apidaecin Api137, respectively.  
These results are in line with already published results, although established in serum using a 
different protocol [67-69]. MCoTI-II, cVc1.1 and chlorotoxin showed an extremely high serum 
stability, which is a particular feature of these peptides attributed to the cyclic backbone and/or the 
presence of multiple disulfide bonds in their structure [70,71]. 
 
4. EVALUATION OF BLOOD-BRAIN BARRIER TRANSPORT DATA OF 
CELL-PENETRATING PEPTIDES 
Despite the ability of CPPs to enter mammalian cells, only a few studies have fragmentarily 
investigated their transcellular transport characteristics. Lindgren et al. demonstrated for TP10 its 
ability to cross a Caco-2 cell layer, while penetratin passed the cell layer to a lower extent due to 
rapid degradation [72]. For the Tat peptide, in vitro transcellular delivery studies could not 
demonstrate the capacity of the peptide to cross the cell layers [73-75]. In vivo evaluation of CPP-
mediated delivery of cargoes resulted in divergent outcomes. Tat-mediated delivery of 
neuroprotective therapeutics across the BBB in ischemia and seizure models gave promising results, 
CHAPTER V – CELL-PENETRATING PEPTIDES SELECTIVELY CROSS THE BLOOD-BRAIN BARRIER IN VIVO 
  
 
158 
but in these models the BBB is compromised [75]. For a limited set of CPPs, studies are available 
demonstrating their ability to mediate CNS delivery of different cargoes in vivo (Table S1 of the 
Supplementary Information) [39]. Currently, CPPs are investigated as possible carriers for BBB-
impermeable cargoes. However, quantitative knowledge on the BBB transport characteristics of CPPs 
without a cargo is also needed as these peptides can be produced endogenously through 
metabolization of proteins and might exert biological activity. As this information is currently lacking, 
the in vivo BBB transport of five “traditional” CPPs was investigated to evaluate whether cell-
penetrating properties of peptides inherently imply the ability to cross the BBB. The selected 
peptides constitute different clusters in the exploration of the chemical space of the CPPs and thus 
structurally disseminate (Figure 1). TP10-2 only differs one amino acid from TP10, but differentiates 
in α-helicity and extent of cellular uptake [76]. Beside this structural variability, the model peptides 
also differ in cell-penetrating ability, expressed as the CP-response, which was introduced in Chapter 
II: TP10 and pVEC have the highest cellular influx with a CP-response of 1.641 and 1.318, respectively, 
while SynB3 and Tat 47-57 show the lowest cellular penetration, having a CP-response of 0.126 and 
0.309, respectively (Table 1). The chemical space of the investigated peptides was further extended 
with four PrAMPs and three disulfide-rich (cyclic) peptides. Cell-penetrating properties have already 
been attributed to these peptides, which are not specifically investigated as CPPs. Moreover, their 
chemical structures are positioned in the chemical space of the CPPs (Figure 1), justifying their 
inclusion in our study aiming to evaluate the correlation between cell-penetrating properties and the 
extent of BBB penetration. 
In this study, the selected peptides showed quite different BBB transport properties. The CPPs Tat 
47-57, pVEC and SynB3 showed relatively high unidirectional brain influx rates (Kin), of 4.73 µl/(g × 
min), 6.02 µl/(g × min) and 5.63 µl/(g × min), respectively, as obtained by fitting the MTR data using 
the linear Gjedde-Patlak model. On the other hand, the transportan analogs showed a very low to 
negligible brain influx. This was also observed for the disulfide-rich (cyclic) peptides, which was 
expected for chlorotoxin [77]. All PrAMPs significantly crossed the BBB with the unidirectional brain 
influx rates ranging between 0.37 µl/(g × min) for drosocin Pro5Hyp and 2.18 µl/(g × min) for 
drosocin. The brain influx kinetics of the controls dermorphin and radioiodinated BSA obtained 
during the different BBB transport studies were consistent as well as in line with previously 
performed experiments. The blood-to-brain transport of pVEC was extraordinary high: the amount of 
peptide reaching the brain was much higher compared to SynB3, Tat 47-57 and the PrAMPs, with a 
maximal ratio of brain-to-serum radioactivity of about 180 µl/g for pVEC versus about 70 µl/g for 
SynB3. This high brain influx was not caused by an apparent increase in BBB permeability, as co-
injection of radioiodinated BSA with pVEC did not result in an increased brain entry of the vascular 
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marker. Using the capillary depletion method, it was demonstrated that the peptides effectively 
crossed the BBB with a parenchymal fraction of about 80% for all CPPs and 67% (drosocin and its 
analog) to 77% (apidaecin Api137) for the PrAMPs. The capillary depletion experiment indicated that 
oncocin remained trapped in the capillary endothelial cells as its parenchymal fraction was only 18%. 
In contrast to pVEC, both SynB3 and Tat 47-57 showed a biphasic BBB influx behavior, which was also 
observed for drosocin: after an initial sharp increase, the MTR-curve reached a plateau-phase, 
resulting in a non-significant net brain clearance of these peptides. This plateau-phase can at least 
partly be explained by the significant efflux out of the brain for these peptides with kout of 0.05 min-1 
for SynB3, of 0.21 min-1 for Tat 47-57 and of 0.22 min-1 for drosocin. Also TP10  (kout = 0.09 min-1), 
TP10-2 (kout = 0.06 min- 1) and MCoTI-II (0.07 min-1) showed a significant efflux out of the brain. The 
brain half-time disappearances suggest the existence of an active efflux transport system for these 
peptides [60]. For SynB3, TP10 and the controls dermorphin and radioiodinated BSA, no differences 
in influx between the eight dissected brain regions were observed. For pVEC, the Kin values of the 
dissected brain regions statistically differed, but the observed regional difference was not 
pronounced compared to other peptides such as amylin and insulin showing clear regional variations 
in brain influx [78]. It is unlikely that alterations in cerebral blood flow due to the changing local 
metabolic demand explain the observed differences in regional brain uptake, as this only affects the 
uptake of compounds showing a very rapid brain influx, i.e. those of which the brain influx can be 
determined using the brain uptake index (BUI) method [78-80]. The BBB influx (Kin) of pVEC, TP10 and 
SynB3 was not saturated when peptides were co-injected with an excess dose of 10 µg of unlabeled 
peptide. For pVEC, the Vi significantly decreased suggesting the presence of saturable binding sites, 
similarly as observed for glucagon. These saturable binding sites may include receptors or enzymes 
located at the brain capillary endothelium [61]. 
All investigated CPPs were mainly distributed to the liver and serum, which was also previously 
demonstrated for pVEC and TP10 [64]. For pVEC and Tat 47-57, a very high liver concentration was 
observed compared to the other tissues, which can indicate metabolization, but also uptake of the 
peptides and their metabolites in hepatocytes. The disulfide-rich (cyclic) peptides were extensively 
distributed to the kidneys, also pointing to metabolization and/or uptake in nephrocytes, as well as 
to renal excretion of these peptides. The transportan analogs, SynB3 and the four PrAMPs, showed a 
high serum distribution, that can be explained either by protein binding or high serum stability and 
the latter was confirmed during the in vitro metabolic stability study of the transportan analogs and 
PrAMPs where a serum half-life of 22 h was calculated for TP10 and of 4 h for TP10-2, while the 
plasma half-lives of the PrAMPs were higher than or equal to 47 min. SynB3, pVEC and Tat 47-57 
were not stable in serum, having half-lives of less than 6 min. Thereby, it cannot be excluded that 
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radiolabeled metabolites of these CPPs contribute to the observed brain radioactivity during the 
evaluation of the blood-to-brain transport. During in vivo metabolic stability studies, metabolites 
present in serum, as well as in brain tissue can be identified, providing the full picture of which 
peptides do actually cross the BBB. This information is valuable during structure-property 
relationship studies for BBB transport of CPPs, or peptides in general. The low serum stability 
originates from the presence of arginine-arginine bonds, which are absent in the sequence of the 
transportan analogues [64]. The low stability was already reported for Tat 47-57 [65], as well as for 
pVEC, for which a rapid C-terminal lysine (Lys18) cleavage was demonstrated when incubated in 
human serum [66]. In contrast, Sarko et al. demonstrated a (human) serum half-life of a few hours by 
evaluating the activity of the 68Ga-DOTA labeled pVEC [64]. During this in vitro study, we could not 
demonstrate the formation of this Lys18-cleaved pVEC metabolite when incubated in mouse serum. 
Instead, we identified a metabolite being pVEC from which the first six hydrophobic N-terminal 
amino acid residues were cleaved off (pVEC7-18). A structure-activity relationship study revealed that 
these cleaved-off N-terminal hydrophobic residues are crucial for the cellular uptake properties, 
suggesting that the found metabolite pVEC7-18 is not cell-penetrating [81]. Thus, both pVEC and 
pVEC7-18, having similar cationic nature, could contribute to the measured brain radioactivity during 
the MTR experiment of pVEC as both contain a radiolabeled tyrosine residue. Once the brain tissue 
was reached, the mouse brain half-life indicates the peptides remain sufficiently stable to allow 
further distribution in the brain parenchyma. 
The investigated “traditional” CPPs differ in the used cellular influx mechanism and adopted 
secondary structure at the membrane interface. For SynB3, an endocytosis-dependent mechanism is 
described, which is initiated after an electrostatic interaction [82]. The uptake of Tat 47-57 is 
endocytosis-driven as well, but starting from a certain threshold concentration, the peptide directly 
penetrates into the cell [2,82-84]. The use of endocytosis-dependent and -independent mechanisms 
has been demonstrated for pVEC [2,81,85,86]. This peptide is derived from the murine vascular 
endothelial cadherin, located in the adherens junctions between the vascular endothelial cells, and 
constitutes the 13 cytosolic amino acids closest to the membrane and five amino acids from the C-
terminus of the transmembrane region (615-632) [24]. As already mentioned, these five hydrophobic 
residues, located at the N-terminus of the pVEC sequence, appear to be crucial for cellular uptake 
and directly interact with the plasma membrane [81]. The cellular interaction of pVEC, SynB3 or Tat 
47-57 does not cause any membrane disturbances [81,82]. This corroborates with our results where 
we could not demonstrate that pVEC increased the BBB permeability, as the influx of radioiodinated 
BSA did not augment after co-injection with pVEC. For TP10, the used cell-penetrating mechanism 
remains controversial: Padari et al. described an endocytosis-driven mechanism, while more recent 
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studies ascribe a pore-forming mechanism [87-89]. The investigated peptides also have a different 
secondary structure at the membrane interface: when in solution, all peptides have a random coil 
structure, but at the membrane interface, pVEC adopts a β-sheet structure and TP10 becomes α-
helical, while SynB3 and Tat 47-57 remain random coiled [76,90]. Overall, the investigated CPPs differ 
essentially in the presence or absence of arginine residues, thus their cationic nature (chemical 
properties), in their secondary structure at the membrane interface (physicochemical properties) and 
inherently, in the cellular uptake mechanism (biological properties). 
 
Based on the BBB transport results, three groups of CPPs can be distinguished. The cationic-
amphipathic peptide pVEC constitutes the first group, which shows a rapid brain influx, resulting 
finally in a relatively high ratio of brain-to-serum radioactivity. SynB3 and Tat 47-57, both short 
cationic CPPs, form the second group and have relatively high initial brain influx rates, but their brain 
influx shows a biphasic behavior. The third group consists of the transportan analogs, TP10 and TP10-
2, which show no to slow brain influx, respectively. The first two groups are composed of arginine-
rich peptides, while the transportans only contain lysine-residues in their sequences and have a 
much lower charge density of 19% versus 44%, 50% and 73% of pVEC, SynB3 and Tat 47-57, 
respectively (Table 1). Thus, arginine-rich CPPs seem to more effectively and rapidly influx the BBB in 
the investigated experimental time period. These findings are affirmed by the BBB transport results 
of the PrAMPs, which are also arginine-rich but have a lower charge-density compared to pVEC, 
SynB3 and Tat 47-57. The disulfide-rich (cyclic) peptides are characterized by a very low charge-
density (Table 1). The BBB influx properties of pVEC, SynB3 and Tat 47-57 are also superior to other 
peptides already investigated for their BBB transport characteristics: using the proposed 
classification method described in Chapter III of this thesis, these peptides show a very high brain 
influx (class 5), while TP10 and TP10-2 have a very low (class 1) and low (class 2) brain influx, 
respectively. These findings were not expected based on the cell-penetrating properties of these 
CPPs, quantitatively expressed as the CP-response. TP10 had the highest CP-response (1.641), but 
the poorest BBB influx characteristics. In contrast, medium cell-penetrating properties were 
attributed to SynB3 and Tat 47-57, but high BBB influx was concluded. Moreover, cell-penetrating 
properties were attributed to the disulfide-rich (cyclic) peptides with a CP-response of 0.103 for 
MCoTI-II indicating a rather low cellular influx, but no significant BBB influx was observed. Our data 
indicate that CPPs selectively cross the BBB and that their brain influx behavior cannot be directly 
positively correlated with their cell-penetrating properties (Figure 12).  
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Figure 12: Schematic overview of the relationship between cell-penetrating (upper part of the figure) and BBB-
penetrating properties of the five investigated CPPs (lower part of the figure). The thickness of the arrows 
indicates the extent of influx and/or efflux. The non-significant efflux of pVEC is indicated by a dashed line. 
 
As described in Chapter I of this thesis, crossing the BBB comprises multiple steps, which can explain 
why the cell-penetrating properties of peptides are not related to the BBB influx properties of CPPs. 
The first step includes the passage of the luminal membrane at the blood-brain interface of which 
the extent can be related to the cell-penetrating properties of the peptides, unless a specific 
interaction with a transporter or receptor is involved. Next the peptide enters the cytosol of the 
capillary endothelial cell, where the CPP can be metabolized or can remain in tact and finally reach 
the abluminal membrane. If exocytosed out of the capillary endothelial cell, the peptide has crossed 
the BBB. It is expected that the CPPs, their formed radiolabeled metabolites in case of cytosolic 
metabolization, or both can cross the abluminal membrane as the capillary fraction obtained during 
capillary depletion experiment was only about 20%, except for oncocin. Because of the cationic 
nature of the CPPs, it was expected that the CPPs would cross the BBB using the adsorptive-mediated 
transcytosis mechanism, which was already demonstrated to be the influx mechanism of SynB3 [41]. 
However under the applied experimental conditions, the BBB influx of the CPPs was not saturable. 
Only for pVEC, a decrease of Vi was observed when the peptide was co-injected with an excess dose, 
suggesting the saturable binding sites for this peptides, including receptor(s), enzymes or a charge 
interaction. Taken our data together, it is assumed that the BBB transport of CPPs involves an initial 
charge interaction with the negatively charged glycocalyx and phospholipid head groups as a high 
charge density derived from arginine residues seems to favor BBB influx. This charge interaction 
triggers the uptake into the capillary endothelial cell, presumably by passive diffusion as the BBB 
influx mechanism is not saturable. Clearly, the mechanism of transport of the CPPs, or peptides in 
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general, is unresolved. Also knowledge on the intracellular fate of these peptides in the capillary 
endothelial cell is helpful for understanding the transport acrosss the BBB. Nevertheless, the results 
of this study provide several pieces of the puzzle of this complex, but highly relevant research topic. 
 
5. CELL-PENETRATING PEPTIDES SELECTIVELY CROSS THE BLOOD-
BRAIN BARRIER IN VIVO 
The BBB transport properties of five structurally different model CPPs, showing a variable extent of 
cellular penetration, were investigated. SynB3, Tat 47-57 and pVEC showed relatively high (initial) 
brain influx rates, while the influx of TP10 and TP10-2 was low. The CPPs use a non-saturable influx 
mechanism and do not cause a (transient) increase in BBB permeability, as demonstrated for pVEC. 
Except for pVEC, all peptides showed a significant efflux out of the brain, which partly explains the 
biphasic behavior of SynB3 and Tat 47-57. Our BBB transport results indicate that CPPs selectively 
cross the BBB and thus cell-penetrating properties of peptides do not imply BBB-penetrating ability. 
These findings were corroborated by the BBB transport data of the PrAMPs and disulfide-rich (cyclic) 
peptides.  
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 SUPPLEMENTARY INFORMATION  
Table S1: Overview literature studies describing brain delivery by CPPs. 
CPP Cargo Technique 
In vivo/ 
in vitro 
(Quantitative) result1 Reference 
SynB1 Benzylpenicillin 
In situ brain perfusion in rats 
(single time) + capillary 
depletion 
In vivo 
Q: Without SynB1: Kin = 0.15 µl/s/g    
coupled to SynB1: Kin = 1.14 µl/s/g. 
80% synB1 coupled benzylpenicillin in 
parenchyma. 
[1] 
SynB1 Dalargin 
In situ brain perfusion (single 
time) in rats + 
antinociceptive test 
In vivo 
Q: Without CPP: Vd = 16.7 µl/g     
coupled to SynB1: Vd = 309 µl/g. 
Enhancement of analgesic activity. 
[2] 
SynB1 Doxorubicin 
In situ brain perfusion in rats 
(single time) + capillary 
depletion 
In vivo 
Q: Without CPP: Kin = 0.25 µl/s/g    
coupled to SynB1: Kin = 1.50 µl/s/g. 
70% SynB1 coupled benzylpenicillin in 
parenchyma. 
[3] 
SynB1 Doxorubicin 
In situ brain perfusion in 
mice (single time) + capillary 
depletion 
In vivo 
Q: Without CPP: Vd = < 100 µl/g     
coupled to SynB1: Vd = 776.4 µl/g. 
60% SynB1 coupled doxorubicin in 
parenchyma. 
[4] 
SynB1 
PEG-gelatin-
siloxane 
nanoparticles 
Determination transcellular 
transport across co-culture 
BBB model and 
determination of PG-GS-
SynB particles in brain after 
IV injection of mice using in 
vivo imaging. 
In vitro/ 
In vivo 
D: Vectorizing the nanoparticles with the 
SynB peptide enhances the transport 
across the BBB in vitro as well as in vivo. 
[18] 
SynB3 Dalargin 
In situ brain perfusion (single 
time) in rats + 
antinociceptive test 
In vivo 
Q: Without CPP: Vd = 16.7 µl/g     
coupled to SynB3: Vd = 240 µl/g. 
Enhancement of analgesic activity. 
[2] 
(L- en D-) 
SynB3 
Doxorubicin 
In situ brain perfusion in 
mice (single time) + capillary 
depletion 
In vivo 
Q: Without CPP: Vd = < 100 µl/g     
coupled to (L-en D-)SynB3: Vd = 961.8 (L) 
en 788.4 (D) µl/g. 
50% SynB1 coupled doxorubicin in 
parenchyma. 
[4] 
SynB3 Paclitaxel 
In situ brain perfusion in 
mice 
In vivo 
D: Vectorized paclitaxel bypasses P-gp at 
luminal side of BBB. 
[5] 
SynB3 
Morphine-6-
glucuronide 
In situ brain perfusion in 
mice + antinociceptive tests 
In vivo 
Q: Without CPP: Kin = 0.024 µl/s/g    
coupled to SynB3: Kin = 1.27 µl/s/g. 
Improvement of pharmacological activity. 
[6] 
SynB3 
Endomorphin-1 
(linked by 
disulfide linkage) 
Tail flick antinociceptive test In vivo 
Q: Five-fold increase in antinociception 
compared to EM-1 alone. 
[39] 
D-Penetratin Doxorubicin 
In situ brain perfusion in rats 
(single time) + capillary 
depletion. 
In vivo 
Q: Without CPP: Kin = 0.25 µl/s/g    
coupled to D-Penetratin: Kin = 2.14 µl/s/g. 
70% SynB1 coupled benzylpenicillin in 
parenchyma. 
[3] 
Penetratin - 
IV injection  stained with 
fluorescent tag. 
In vivo D: no staining  no brain influx. [7] 
Penetratin scFvs 
Mice were IV injected with 
scFv-CPP construct. Then the 
presence of scFv-CPP in brain 
cryosections was evaluated 
after fluorescent labeling 
using a fluorescence 
microscope. 
In vivo D: scFv-CPP construct clearly appeared in 
brain cells after IV injection. 
[26] 
Penetratin 
Doxorubicin 
loaded transferrin 
liposomes 
The amount of doxorubicin 
in brain homogenate was 
evaluated using HPLC at 
different time points after IV 
injection in rats. 
In vivo 
Q: Tf-Penetratin liposomes showed 
maximal brain penetration after 24h 
(about 3.67% ID/g).  
[27] 
Penetratin 
PEG-PLA 
nanoparticles 
loaded with 
coumarin-6 
In vivo imaging and 
pharmacokinetic and 
biodistribution studies using 
LC-MS/MS analysis of 
coumarin-6 in brain 
homogenate. 
In vivo 
D: Fluorescence in rat brain was higher for 
penetratin-NP treated rats than for NP-
treated ones. Brain uptake was enhanced 
when NP was coupled to penetratin. 
[28] 
Tat 47-57 NEP1-40 
Focal ischemia model in  rats 
 evaluate outcome after 
ischemia + detect presence 
of vectorized NEP1-40. 
In vivo 
B: Improvement of neurologic outcomes. 
D: Tat-NEP1-40 detected in brain using 
Western blot and immunofluorescence. 
[8] 
Tat 47-57 NR2B9c  
Measuring effect of 
vectorized NR2B9c in a rat 
stroke model. 
In vivo 
Q: Treatment with Tat-NR2B9c reduced 
the volume of cerebral infarction with 
67% and 87% in cortical infarction volume. 
[10] 
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CPP Cargo Technique 
In vivo/ 
in vitro 
(Quantitative) result1 Reference 
Tat 47-57 β-galactosidase 
Fluorescence confocal 
microscopy: tissues were 
dissected from mice 20 min 
after i.p. injection 
In vivo 
D: - Tat-FITC: strong signals in all areas of  
brain (not with control FITC). 
- Tat-β-Gal: brain sections from mice 
analyzed: 2h post injection, strong activity 
around capillaries, not in parenchyma, 
starting from 4h after injection all brain 
regions showed strong β-Gal activity.  
- BBB remained intact (Evan’s blue 
albumin complexes not in brain sections). 
[11] 
Tat 47-57 
Green fluorescent 
protein (GFP) 
Evaluation of transcellular 
transport of Tat-GFP across 
bEnd-3-astrocyte coculture 
layer. 
In vitro 
D: Tat-GFP was able to translocate bEnd-3 
cell layer but not astrocyte layer. No 
influence on barrier integrity observed. 
[12] 
Tat 47-57 
PEG-b-Chol 
nanoparticles 
(loaded with 
ciprofloxacine, 
quantum dots or 
FITC) 
Confocal microscopy of rat 
brain sections 4h after IV 
injection in the tail vein. 
In vivo 
D: Tat-conjugated nanoparticles loaded 
with FITC or quantum dots crossed the 
BBB, while FITC and quantum dots alone 
did not and were localized around blood 
vessels in the brain. 
[13] 
Tat 47-57 
PEG decorated 
gelatin-siloxane 
nanoparticles 
In vivo imaging (mice) and 
TEM. 
In vivo 
Q: Tat-modification of the nanoparticles 
resulted in a quantitatively higher 
fluorescent signal in the brain than no-Tat 
nanoparticles (total signal counts of 
708.69 ± 4.8 counts/ (sc × s) versus 670.47 
± 8.96 counts/ (sc × s)). TEM analysis 
revealed that the BBB remained intact. 
[14] 
Tat 47-57 
δ-V1-1 (isozyme 
specific inhibitor 
of  δ-PKC) 
Two in vivo models of 
vascular stress: transient 
focal ischemia in 
normotensive rats and 
chronic hypertension. 
In vivo 
B: δ-V1-1-Tat increased the number of 
patent microvessels by 92% compared to 
control (Tat) treated animals and 
increased cerebral blood flow by 26% 
following acute focal ischemia (not with 
Tat peptide alone). In chronic 
hypertension model, the cerebral blood 
flow increased by 12%. 
[15] 
Tat 47-57 PACAP-38 
Six hours after i.p. injection 
of FITC-labeled peptides, the 
fluorescence intensity of 
isolated brains was 
determined.  
In vivo 
B: PACAP-Tat showed a 2.5 fold higher 
efficiency to traverse the BBB than PACAP. 
[16] 
Tat 47-57 GDNF 
Evaluation of cryosections of 
mouse brain 4h post i.p. 
injection using fluorescence 
microscopy. 
In vivo 
D: The fusion proteins crossed the BBB 
and transduced the brain parenchyma. 
[17] 
Tat 47-57 
PEG-cholesterol 
(PEG-b-Col) 
nanoparticles 
Evaluation of presence of 
FITC loaded PEG-b-Col-Tat 
nanoparticles in brain 
cryosections using confocal 
microscope 4h after IV 
injection of rats. 
In vivo 
D: PEG-b-Col-Tat particles crossed the 
BBB. 
[19] 
Tat 47-57 Bcl-XL 
Evaluation of infarct volume 
and neurological deficit in 
ischemic insult mice model. 
In vivo 
D: Tat- Bcl-XL reduces the infarct volume 
and neurological deficits when 
administered before and after ischemic 
insult.  
[22] 
Tat 47-57 GDNF 
Evaluation whether IV 
administration of Tat-GDNF 
prevent brain injury after 
transient focal ischemia. 
In vivo 
D: After IV administration, the Tat-GDNF 
protein reaches the ischemic zone and 
reduced the brain injury and infarction 
zone. 
[23] 
Tat 47-57 
Ritonavir loaded 
nanoparticles 
Measuring radioactivity of  
ritonavir in brain tissue 
digest after decapitation of 
mice at different time points.  
In vivo 
Q: The brain drug level was 800-fold 
higher than that with drug in solution at 
two weeks (0.1 µg/g (solution) versus 80.3 
µg/g (Tat-nanoparticles)). 
[25] 
Tat 
Doxorubicine 
loaded transferrin 
ligated liposomes 
The amount of doxorubicine 
in brain homogenate was 
evaluated using HPLC at 
different time points after IV 
injection in rats. 
In vivo 
Q: Tf-Penetratin liposomes showed max 
brain penetration after 24h (about 2.89% 
ID/g).  
[27] 
Tat Quantum dots 
Rats were infused intra-
arterially and after 
euthanizing the rat, the brain 
was isolated and quantum 
dot fluorescence was 
evaluated. 
In vivo 
D: If quantum dots are conjugated to Tat, 
the brain tissue was labeled. Histological 
data confirm the passage across the 
endothelial cell line of the blood-brain 
barrier. 
[31] 
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CPP Cargo Technique 
In vivo/ 
in vitro 
(Quantitative) result1 Reference 
D-Tat 
99mTc-Tricarbonyl 
and fluorescein-5-
maleimide 
Biodistribution was 
evaluated in mice. At several 
time points after IV injection, 
tissues were evaluated by 
fluorescence microscopy and 
radiometric analysis. 
In vivo 
D: Little brain permeation was 
determined. 
[32] 
Tat 
G3R6-cholesterol 
(conjugated to Tat 
and forms 
nanoparticles)  
4h after i.v. injection of the 
nanoparticles, rabbit brain 
sections were evaluated for 
FITC-loaded nanoparticles 
using a confocal microscope. 
In vivo 
D: FITC was detected in the brain sections 
when coupled to CG3R6TAT nanoparticles 
(not if not coupled to nanoparticles), 
indicating the nanoparticles cross the BBB. 
[34] 
Tat 47-57 
Cholesterol 
liposomes loaded 
with coumarin-6 
After i.v. injection of the 
coumarin-6 loaded TAT-
liposomes in mice, the 
coumarin-6 concentration 
was determined in brain 
tissue. 
In vivo 
D: The AUC (0-t) for TAT-liposomes was 
1.79 to 2.54 times higher than non-
conjugated liposomes.  
[35] 
(D-)Tat 47-57 Liposomes 
In vivo biodistribution study 
in mice of (D-)Tat-coupled 
liposomes loaded with 
coumarin-6. At different 
time points after IV injection, 
the concentration of 
coumarin-6 was determined 
i.a. in brain tissue. Capillary 
depletion study was used to 
demonstrate distribution to 
brain parenchyma. 
In vivo 
Q: The concentration of coumarin-6 
delivered using (D-)Tat-coupled liposomes 
was 2 to 2.5 times higher than liposomes 
coupled to a Tat analogue with basic 
residues replaced by glycine and glutamic 
acid residues.  
[36] 
Tat 48-57 
FITC doped silica 
nanoparticles 
(FSNPs) 
The Tat-FSNPs were intra-
arterially injected into rats. 
After completing the 
procedure, the rats were 
decapitated and the brain 
was sliced into 4 pieces and 
imaged using a fluorescence 
microscope.  
In vivo 
D: The images confirm labeling of 
branches of the right middle cerebral 
artery. Thus, not the nanoparticles 
crossed the blood-brain barrier.  
[37] 
Tat 46-57 
Doxorubicin 
loaded 
nanoparticles 
(and co-modified 
with T7 ligand) 
In vivo imaging and 
evaluation of survival time of 
tumor bearing mice. 
In vivo 
D/B: Compared to control liposomes, the 
TAT-T7 co-modified doxorubicin-loaded 
liposomes markedly accumulated in the 
glioma brain tumor. Also the survival time 
of these mice significantly increased. 
[40] 
Tat 47-57 VIP 
Efficiency assay of traversing 
the BBB by fluorimetry; food 
intake assay and evaluation 
of effect on scopolamine 
induced amnesia. 
In vivo 
Q: After i.p. injection, the brain uptake 
efficiency of VIP-TAT (1.81) was twice as 
high as that of VIP (0.78). 
B: VIP-TAT had a significantly stronger 
anorexigenic effect than VIP. 
Q/B: Administration of VIP-TAT 
significantly inhibited stronger than VIP 
alone the reduction of the latent time 
induced by scopolamine. 
[41] 
Tat 47-57 
BRBP1 (and linked 
to the 
proapoptotic 
peptide KLA as 
well) 
IV injection of fluorescently 
labeled BRBP1-TAT-KLA in 
mice with breast cancer 
brain metastasis. 
In vivo 
D: Compared to TAT-KLA, BRBP1-TAT-KLA 
showed higher fluorescence intensity in 
the brain metastasis lesions. 
[44] 
R7-
myristoylated 
- 
NIR fluorescence imaging 
after IV injection + 
immunohistochemical 
staining. 
In vivo 
D: Presence of fluorescently labeled 
vector demonstrated. 
[9] 
rR9 
RVG29-cargo 
(plasmid DNA) 
Evaluation of luciferase 
activity of in several tissues 
after injection of rR9-RVG29-
pGL3 (gene) construct in the 
tail vein of mice.  
In vivo 
B: At 72h, the luciferase expression was 3-
fold higher than for the control group.  
[21] 
R8 RGD 
Translocation across an in 
vitro BBB model AND in vivo 
imaging in C6 glioma bearing 
mouse model. 
In vitro/ 
In vivo 
D: R8-RGD reached the brain and 
accumulated in the glioma foci. Also in 
vitro, R8-RGD crossed the BBB. 
[24] 
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CPP Cargo Technique 
In vivo/ 
in vitro 
(Quantitative) result1 Reference 
R8 
Liposomes 
 
 
In vivo biodistribution study 
of R8-coupled liposomes 
loaded with coumarin-6. At 
different time points after IV 
injection, the concentration 
of coumarin-6 was 
determined i.a. in brain 
tissue. Capillary depletion 
study was used to 
demonstrate distribution to 
brain parenchyma. 
In vivo 
Q: The concentration of coumarin-6 
delivered using R8-coupled liposomes was 
3.5 times higher than liposomes coupled 
to a Tat analogue with basic residues 
replaced by glycine and glutamic acid 
residues.  
[36] 
R2-R5 EM-1 analogs Antinociceptive test  In vivo 
D: Unless the decreased affinity for the 
opioid receptor, the vectorized analogs 
showed potent antinociceptive effect, 
partly caused by the improved 
bioavailability. 
[29] 
Oligoarginine 
Transferrin ligated 
liposomes 
Rat were IV injected with 
vectorized liposomes and at 
different time points, brain 
was isolated and evaluated 
using NIR imaging. 
In vivo 
D: The brain penetration of Tf-PR-
liposomes was 8-fold greater than plain 
liposomes. 
[30] 
R11 
No cargo, but FITC 
labeled. 
Evaluation of 
immunoreactivity (using goat 
anti-FITC antibodies) in 
mouse brain sections after 
systemic administration of 
11R-FITC. 
In vivo 
D: Strong immunoreactivity was observed 
in vessels and surrounding cells of cortex, 
striatum and thalamus, which was not 
seen when systemically injecting 11E-FITC. 
[43] 
pVEC 
pVEC covalently 
attached to gHo 
(glioma homing 
sequence) = 
gHoPe2 
Evaluation of presence of 
FAM-labeled gHoPe2, IV 
injected in mice, in 
cryosections of the brain. 
In vivo 
D: In intracranial brain tumor model, the 
gHoPe2-FAM peptides were present in the 
intracranial tumors, not in healthy brain 
tissue. Thus the construct crossed the 
BBB. 
[20] 
Mastoparan 
Doxorubicin 
loaded transferrin 
liposomes 
The amount of doxorubicin in 
brain homogenate was 
evaluated using HPLC at 
different time points after IV 
injection in rats. 
In vivo 
D: Accumulation of Tf-Mastoparan 
liposomes was lower compared to Tf-Tat 
and Tf-Penetratin liposomes.  
[27] 
(RXRRBR)2XB 
AMO (antisense 
morpholino 
oligonucleotides) 
IV injection to mice (single 
time and multiple time 
injection) and evaluation of 
presence of fluorescence in 
different brain areas using 
fluorescence microscopy. 
In vivo 
D: Fluorescence was widely detected 
throughout the brain and increased when 
multiple injections were given. 
[33] 
PepFect 32 
(PepFect 14-
Angiopep-2 
construct) 
pDNA 
In vitro Transwell experiment. 
Transport across the bEnd.3 
layer was demonstrated by 
measuring plasmid 
transfection in U87 cells. 
In vitro 
Q: PepFect 32 showed the most efficient 
transfection of the luciferase-expressing 
plasmid in U87 cells. 
[38] 
LNP pDNA 
Evaluation of in vitro 
transport of LNP-modified 
pDNA nanoparticles across 
the BMEC layer. 
In vitro 
Q: Papp of LNP-modified pDNA 
nanoparticles was 92.43 × 10-6 cm/s, while 
if not LNP-modified, the Papp was ≤ 65 × 
10-6 cm/s. 
[42] 
1Q: Quantitative result; B: biological effect; D: effect described. 
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“An old man is twice a child”  
 
William Shakespeare 
(°1564 - †1616, English poet, playwright and actor) 
 
 
 
 
 
 
 
 
Parts of this chapter were published: 
 
De Spiegeleer B, Wynendaele E, Bracke E, Veryser L, Taevernier L, Degroote A, Stalmans S. 
Development of geriatric medicines: To GIP or not to GIP? Submitted. 
CHAPTER VI – REGULATORY DEVELOPMENT OF GERIATRIC MEDICINES: TO GIP OR NOT TO GIP? 
  
 
178 
ABSTRACT 
Geriatric patients represent the main users of medicines, but were historically often minimally 
included in clinical trials, resulting in a gap in the knowledge of the benefit/risk balance of 
medicines in this heterogeneous population. As the worldwide population is aging, the need for 
safe and effective medicines for older patients is proportionally increasing. The aim of this review 
is to provide an overview of the current regulatory status of the development of geriatric 
medicines, the encountered challenges and the view of the involved stakeholders, coming to the 
conclusion, by analogy with pediatrics, whether to GIP or not to GIP (Geriatric Investigation Plan). 
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CHAPTER VI 
REGULAGORY DEVELOPMENT OF 
GERIATRIC MEDICINES:  
TO GIP OR NOT TO GIP? 
Main focus in this chapter: 
 Regulatory status of the development of medicines for geriatric patients. 
 Views of the different involved stakeholders. 
 Identification and exploration of challenges in the development of geriatric medicines, with 
special emphasis on the alteration of the blood-brain barrier permeability during the aging 
process. 
 
1. INTRODUCTION 
Worldwide, the population aged 60 and over is the fastest growing group of persons. Due to the 
reduction in fertility, the population is globally aging. In developing countries, the population is still 
young as the percentage of children and young persons is high. In contrast, the number of older 
people has surpassed the number of children younger than age 15 in the more developed countries: 
the population aged 60 years and older is expected to rise from 287 million (23%) in 2013 to 417 
million (32%) in 2050 [1]. As an example, the population pyramid of the European Union (EU) is 
shown in Figure 1: per sex, each bar corresponds to the proportion of the population at that age in 
the total population [2]. The baby boomer bulge is moving up, while the other age groups are 
narrowing by 2080 [2].  
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Figure 1: Population pyramid of European Union in 2014 (bordered) and 2080 (solid).The blue or left part 
represent men and the orange or right part women (Source: Eurostat). 
Aging is commonly accepted to be a multifactorial process, but still, many theories on aging exist. 
Within the different theories on aging, three categories can be differentiated: the first category 
comprises the accumulation of damage to informational molecules, a second category concerns 
regulation of specific genes and the third category are theories claiming depletion of stem cells [3].  
The age-associated changes are the result from a gradual loss in homeostatic mechanisms, which 
already starts in adulthood. When at later age a certain level is reached, this loss of functions will 
become apparent, especially when external stress is applied [3]. Thus, aging implies the gradual 
change of various physiological, biological, physical and social functions in the human being [4]. The 
geriatric syndrome includes all common problems the older population may encounter due to aging, 
like iatrogenesis (adverse drug reactions), immobility, immune deficiency and impairment of vision 
and hearing [3]. Frailty includes the most problematic uttering of aging and is a clinical condition 
characterized by an increased vulnerability to poor resolution of homeostasis after exposure to 
(minimal) stress, expressed as a disproportionate change in health status. The frailty condition is 
characterized by an increased risk of adverse outcomes like falls, delirium and disability, but frail 
geriatric patients also demonstrate non-specific clinical presentations like extreme fatigue, weight 
loss and frequent infections [5]. Thus, geriatric patients can be stratified by numerical age or based 
on the frailty status. 
In Figure 2, age-related physiological and functional changes are summarized [6-10]. The resulting 
alterations in body composition and organ functions cause changes in the pharmacokinetics and 
pharmacodynamics (PK/PD) of drugs [7,8].  
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Figure 2: Selection of relevant age-related physical and functional changes [6-12]. 
Table 1 contains the pharmacokinetic consequences of relevant age-related functional changes.  
Table 1: Pharmacokinetic consequences of age-related physiological and functional changes [6,7]. 
Process Age-related change Pharmacokinetic consequence 
Absorption 
Increased gastric pH Slightly decreased absorption 
Delayed gastric emptying  
Reduced splanchnic blood flow  
Decreased absorption surface  
Decreased gastrointestinal motility  
Decreased hepatic blood flow Reduced fist pass metabolism 
Distribution 
Increased body fat Increased distribution volume and half-life of 
lipophilic drugs 
Decreased total body water Increased plasma concentration of 
hydrophilic drugs 
Decreased serum albumin Increased of free fraction in plasma of highly 
protein-bound acidic drugs 
Increased α1-acid glycoprotein Decreased free fraction of basic drugs 
Increased blood-brain barrier (BBB) 
permeability 
Increased brain distribution 
Metabolism Decreased hepatic mass Phase I metabolism may be impaired. 
Elimination 
Decreased renal blood flow Impaired renal elimination 
Decreased glomerular filtration rate  
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Pharmacodynamics are less researched in the elderly population. Several studies already indicated 
the increased sensitivity to cardiovascular medicines, anticoagulants, drugs acting via the central 
nervous system (CNS) and general anesthetics, which cannot only be ascribed to pharmacokinetic 
changes [8,13]. For example, use of neuroleptic drugs by the geriatric patient is associated with 
increased delirium, extrapyramidal symptoms and postural hypotension and increased body sway 
and exaggerated sedative effects are seen with geriatric use of benzodiazepines. Also drugs with 
anticholinergic actions affect cognition and orientation of the elderly patient [13]. 
The aging process is not a disease, but increases the vulnerability to it [14]. In the geriatric 
population, cardiovascular diseases (i.a. hypertension and heart failure), dementia (including 
Alzheimer’s disease (AD)), Parkinson’s disease, Chronic Obstructive Pulmonary Diseases (COPD), 
depression, diabetes, cancer and musculoskeletal disorders (i.a. rheumatoid arthritis, osteoarthritis 
and osteoporosis) are commonly reported chronic disease conditions [15,16]. Moreover, there exists 
a high rate of co-occurrence of chronic conditions, termed comorbidity [16]. The rate and 
manifestation of the aging process varies among individuals, explaining the more pronounced 
heterogeneity of the geriatric population [4].  
The comorbid elderly population is characterized by polypharmacy, i.e. taking multiple medicines 
simultaneously, which complicates their drug regimen [8]. A Medline survey indicated that the 
average number of prescription drugs in people older than 65 years was two to nine and increases 
with age [4]. Beside increased drug costs, polypharmacy causes the geriatric patient to be at risk for 
adverse drug reactions, drug-drug interactions, non-adherence to drug therapy and functional 
decline [17]. Although older patients use 30 to 50% of all prescription drugs, they are to a large 
extent excluded from clinical trials, even from trials investigating drugs for highly age-associated 
diseases like heart failure and Parkinson’s disease [4,18-20]. A systematic review indicated that in 
38.5% of the randomized clinical trials, people aged above 65 years were excluded and in 81.3% of 
the trials, patients with comorbidities were absent [21]. The main reason for their historical exclusion 
is the heterogeneity of the geriatric population, which may cause dilution of the effect of the drug 
and the inability to demonstrate statistically sound results. The older patients are also at higher risk 
for adverse drug reactions and drug-drug interactions, as well as to become sick or die during the 
trial period, implying dropout. Finally, also personal, practical (e.g. transportation problems) and 
economic reasons are identified [18,19]. This minimal inclusion of elderly in clinical trials causes that 
for the majority of the available drugs, the safety and efficacy is not known for the geriatric patients, 
especially for the very old (> 80 years) and frail elderly, impeding evidence-based drug therapy and 
further augmenting the risk for adverse drug reactions [18]. Moreover, geriatric patients differ from 
the younger adults in their specific medication-related needs, e.g. with regards to the manageability 
of the drug product [4]. Therefore, this heterogeneous population requires an individual patient-
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centered therapeutic approach instead of treatment of a single disease or population, because the 
latter approach may have little efficacy in this comorbid and vulnerable patient group [4,22]. 
There also exists a gap in the knowledge of safety and efficacy of drugs in the pediatric population. 
However, both the USA, since 1997, and the EU, since 2007, have established a pediatric regulation, 
aiming to improve the health of children through improvements of research and to provide a 
regulatory framework for obtaining safe and effective pediatric medicines [23]. Upon compliance to 
the Written Request for the FDA and the Paediatric Investigation Plan (PIP) for the EMA, which 
contain the timings and description of pediatric studies, incentives can be obtained [23]. As there is 
also an urgent need for evidence-based drug therapies in the elderly, the current regulatory status of 
the development of geriatric medicines will be evaluated here, as well as the view of the different 
involved stakeholders. Finally, current challenges will be identified and analyzed, coming to the 
conclusion, whether to GIP or not to GIP (Geriatric Investigation Plan). 
 
2. CURRENT REGULATORY STATUS OF GERIATRIC MEDICINE 
DEVELOPMENT 
 
In this first section, it is evaluated whether the need for the development of safe and effective drugs 
of geriatric medicines is translated in the regulatory guidelines and/or regulations of the three main 
regulatory bodies: European Medicines Agency (EMA) for the European Union (EU), Food and Drug 
Administration for the United States of America (USA) and the Pharmaceutical and Medical Devices 
Agency (PMDA) for Japan. The guidelines of the International Conference on Harmonisation (ICH), 
which are adopted by these regulatory authorities, will be discussed in a separate section. Beside the 
evaluation of the current regulatory status, the availability of a strategy to anticipate on the aging 
population is investigated. A summary is given in Figure 3. 
 
Figure 3: Summary of the current regulatory status of the development of geriatric medicines. 
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ICH guidelines 
In 1993, the ICH published the ICH E7 guideline entitled “Studies in Support of Special Populations: 
Geriatrics E7”. This E7 document was published as a harmonized tripartite guideline, established and 
adopted by the European, American and Japanese regulatory authorities [24]. In the late 1980s, 
these regulatory authorities recognized that the increasing elderly population requires special 
consideration in clinical trials and participants of these trials should represent the population that 
will be treated by the drug in clinical practice [24]. In 2006, on request of the EMA, the ICH E7 
guideline was revised, resulting in a concept paper which was then translated into an addendum E7 
Questions & Answers (Q&A) document in 2010 [25,26].  
The E7 guideline defines the geriatric population arbitrarily as patients aged above 65 years [24]. 
However, in the Q&A document is encouraged to incorporate various age groups in the clinical 
database like for example 65-74, 75-84 and ≥ 85, with special emphasis on the very old (≥75 years) 
representing the fastest growing population group, as well as those with concomitant therapies and 
comorbidities and the frail elderly [25]. It is preferred that geriatric patients are represented in Phase 
3 clinical trials in a sufficient number allowing to demonstrate the benefit-risk balance in this 
population and covering the entire age spectrum representative for the target population. These 
trials allow to determine age-related differences in drug response like adverse event rates, 
effectiveness and dose-response. During the clinical trials including older patients, it is also 
recommended to address specific adverse events occurring in the elderly and to include age-specific 
endpoints [24,25].  
Age-related differences are often due to differences in the pharmacokinetics of the drug, related to 
the abnormal renal and hepatic function in the elderly and should be evaluated during 
pharmacokinetic studies. The guideline does not require routine dose-response or other 
pharmacodynamic studies in geriatric patients, except for drugs with CNS effects like hypnotic and 
sedative drugs, and if clinical trials indicate a potentially medically significant age-associated 
difference in the drug’s effectiveness or adverse event profile, which cannot be explained by 
pharmacokinetic differences. Drug-drug interaction studies should only be performed if the 
therapeutic range of the drug or likely concomitant drugs is narrow [24,25].  
Surprisingly, although the importance of adapted formulations and dosages was discussed in the 
concept paper of 2006 revising the E7 guideline, this aspect was not further elaborated in the Q&A 
document of the E7 guideline [25,26]. Other ICH documents that incorporate age-related aspects in a 
general way are the E4 and E5(R1) guidelines, in which it is stated that the influence of age on the 
dose and dose-response should be evaluated during drug development [27,28]. 
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European Medicines Agency (EU) 
In 2011, the EMA published the Geriatric Medicines Strategy, containing the efforts the Agency 
wants to undertake to ensure that the needs of older people are taken into account in the 
development and evaluation of new medicines. Their strategy is based on two principles: (1) ensuring 
that medicines used by geriatric patients are of high quality and appropriately researched in this 
population, both before and after authorization, and (2) improving availability of information on the 
use of medicines for older people, in order to allow informed prescription [29]. The EMA focusses on 
four key areas. First, gaps are being identified in the regulatory and scientific knowledge and 
appropriate measures are taken to tackle them, i.a. by seeking input from the Committee for 
Medicinal Products for Human Use (CHMP) and the Pharmacovigilance Risk Assessment Committee 
(PRAC, previously Pharmacovigilance Working Party (PhVWP)) and in the provision of scientific advice 
to the industry during drug development. Second, a Geriatric Expert Group (GEG) is established to 
provide the CHMP with advice on specific issues on the elderly [29]. This GEG is currently working on 
a proposal for the characterization of the frailty status of patients enrolled in clinical trials [30]. Third, 
to ensure the development of new medicines for the elderly is following the adopted ICH E7 
guideline, the EMA provides scientific advice, comments on peer review applications and updates the 
assessment report templates to focus assessor’s attention on geriatric data. Finally, the need for 
specific pharmacovigilance activities is under consideration [29]. 
In 2013, the implementation of the Geriatric Medicines Strategy with respect to product information 
of newly approved medicinal products was evaluated. Of the 81 peer reviewed applications, 75% 
received comments with regards to geriatric data and 84% of these applicants finally included these 
comments [31]. This specific review of applications for geriatric aspects was beneficial for the 
inclusion of data with regards to the safety and efficacy in the application and consequently in the 
Product Information Leaflet (PIL) and Summary of the Product Characteristics (SmPC) [31]. 
Simultaneously, scientific guidelines were also reviewed for compliance with the E7 guideline [32]. In 
93% of the cases, the guidelines did not fully comply, especially with regards to the requirements for 
the type and amount of data on the efficacy and safety in the elderly population. It was concluded 
that input of GEG in the drafting phase of the scientific guidelines is recommended [32].  
The EMA is also aware that in order to identify all quality aspects that are unique for the geriatric 
medicines, all stakeholders should be involved. Currently, EMA is working on a reflection paper on 
the quality aspects of medicines for older people, which should assist the industry in the 
development of geriatric medicines and in the regulatory review of these applications [33]. 
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Food and Drug Administration (USA) 
Before the adoption of the ICH E7 guideline in 1994, the FDA published already in 1989 a guideline 
for the study of drugs likely to be used in the elderly [34]. In 1997, the FDA established the Geriatric 
Use subsection of the Precautions section of the labeling for human prescription drugs and biological 
products. This section includes relevant information about the use of the drug product in the elderly. 
Guidance is provided to the industry on submitting geriatric labeling. Importantly, this measure was 
also retrospective, implying that for specified approved drug products, the application holders must 
submit a geriatric labeling supplement [35].  
In 2014, the FDA published the “FDA action plan to enhance the collection and availability of 
demographic subgroup data” [36]. The main aim is to provide safe and effective medical products 
that must be available for a broad range of patients that need them. This action plan is part of 
Section 907 of the FDA Safety and Innovation Act of 2012, in which the FDA had to investigate to 
which extent clinical trial participation and inclusion of safety and effectiveness data of demographic 
subgroups, including age, sex, race and ethnicity, are included in the applications submitted to the 
Agency [36]. Following this study, in which different stakeholders were consulted, an action plan was 
established, which can be divided into three priorities. The first priority, quality, includes the 
improvement of the completeness and quality of demographic subgroup data collection, reporting 
and analysis. Therefore, relevant guidances, like the ICH E7 guideline, were revised and updated and 
FDA reviewers were trained on demographic inclusion, analysis and communication of clinical data 
and better standardization of data collection categories for age. For example, the Good Review 
Practice guidance was prepared to assist FDA staff in the clinical review of Investigational New Drug 
(IND) applications, stating i.a. to avoid the use of unjustified upper age limits [37].  
The second priority, participation, is the identification of the barriers to subgroup enrollment in 
clinical trials and the employment of strategies to encourage greater participation, with special 
emphasis on the patients aged above 75 years. The FDA thus seeks to collaborate with the industry 
to help ensure appropriate use of enrollment criteria in clinical trial protocols in order to avoid the 
disproportional exclusion of the older patients [36]. Making demographic subgroup data more 
available, understandable and transparent covers the third priority, transparency. In the end, the 
FDA aims at improving data quality, encouraging greater participation in clinical trials and making the 
demographic subgroup information data more available and transparent, resulting in easy access of 
all stakeholders to meaningful clinical information and thus allowing informed decisions [36]. A 
survey of the digital Infuzion® database, which was established upon collaboration with the FDA to 
structure electronic clinical trial data, focused on the inclusion of patients with multiple chronic 
conditions in clinical trials during the fiscal year 2010. The survey covered 147 studies with in total 
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115342 study subjects of which only 19% was aged above 65 years [38]. Recently approved 
medicines like ivabradine for the treatment of congestive heart failure, a chronic condition with 
higher prevalence with older people, already show a higher proportion of geriatric patients aged 
above 65 years in their clinical trials (38%), of which 11% was older than 75 years [39]. 
 
Pharmaceutical and Medical Devices Agency (Japan) 
To our knowledge, in contrast to the European and American regulatory authorities, no additional 
strategy with regards to the development of geriatric medicine is established by the Japanese 
regulatory authorities. However, in a recent article, PMDA employees expressed their concern about 
the underrepresentation of geriatric patients in clinical trials. Although the authors do not represent 
the formal view of the PMDA, there is an awareness that more efforts are needed to properly 
characterize the benefits and risks of drugs for older people [40]. 
Thus, in contrast to the pediatric medicines, there are only guidelines available on the development 
of geriatric medicines, which have no legislative power. Moreover, the available E7 guideline 
focusses on clinical trials, not on the full development of geriatric medicines. Within the framework 
of the Geriatric Medicines Strategy and the FDA action plan to enhance the collection and availability 
of demographic subgroup data, the EMA and the FDA have taken additional measures in order to 
more completely answer the medicinal needs of the elderly (Figure 3).  
 
3. VIEWS OF DIFFERENT STAKEHOLDERS  
The different stakeholders involved in the development of geriatric medicines are the 
pharmaceutical industry, developing and manufacturing medicines, the regulatory authorities, 
evaluating and approving medicines, the healthcare professionals, prescribing medicines and the 
patients, using medicines. Each involved party considers the development of geriatric medicines from 
a different perspective. 
 
Pharmaceutical Industry 
EFPIA, the European Federation of Pharmaceutical Industries and Associations, committed to 
collaborate with other stakeholders in order to promote the development of safe and effective 
medicines for the aging population [41]. In a position paper, EFPIA recommended the pharmaceutical 
industry to implement the ICH E7 guideline and its Q&A document. By improvement of patient 
recruitment in clinical trials, older patients with stable and common comorbidities should be 
included in order that drug efficacy, safety and tolerability can be characterized in this population. 
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EFPIA also recommends to address the medical needs of older patients through innovation. New 
innovative medicines should address current gaps in the prevention and treatment of specific 
geriatric conditions, like sarcopenia, and these medicines should be developed using new tools, 
models and study methodologies [41]. Also development of age-appropriate drug formulations will 
be a challenge [42]. Finally, the pre- and post-marketing safety evaluation in older patients should be 
optimized, aiming at the early detection of safety issues [41].  
However, there is a concern that the inclusion of a geriatric group in clinical trials may increase the 
variability of endpoints, resulting in larger and more complex studies and delaying the development 
of new medicines. Therefore, the pharmaceutical industry also emphasizes more involvement of the 
regulatory bodies to provide specific scientific advices, for example on the inclusion of patients above 
75 years with co-morbidities, loss of function or geriatric syndromes [43]. 
 
Regulatory authorities 
Already in the late 1980s, the FDA published a guideline on studying drugs likely to be used in the 
elderly [34]. Later, in 1993, an internationally agreed ICH E7 guideline, Studies in Support of Special 
Populations: Geriatrics, was established by the FDA, EMA and PMDA representing an agreed 
guidance concerning the inclusion of geriatric patients in clinical trials [24]. Both FDA, through the 
FDA Innovation Act of 2012 Section 907, and EMA, through the Geriatric Medicines Strategy, took 
additional measures to ensure the availability of safe and effective drugs for the elderly and to 
address their specific needs [29,36]. Based on initial evaluations of new marketing authorizations, the 
view is that the situation is improving, despite that the geriatric patients aged >75, especially the frail 
and those with comorbidities, are still excluded from clinical trials [42-44]. Yet, the current opinion of 
the FDA, EMA and PMDA is that there is no need for specific regulations. 
In the European Union, the opinion on the importance of addressing the specific needs of the elderly 
differs between the different member states. A first study gauging the views of health-related 
professionals from nine European countries, identified differences especially between the newer and 
older members of the EU [45]. Although this study represents the views of health-related 
professionals, the observed discrepancy in views may be the result of political differences in the 
decision making on clinical trial regulation and practice in older people in the different EU countries 
[45]. Another study indicated that 67% of the national agencies of 21 European countries felt that 
input from geriatric medicine would be useful in evaluating drugs in their country. However, 90% of 
these countries had neither committees, nor policies related to prescribing to older people, while 
58% had such policies for children [46].  
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Healthcare providers 
Both the European and American geriatric societies agree that the persistent exclusion of older 
people from clinical trials impede evidence-based medicine in the geriatric population. Inclusion of 
the elderly in clinical trials is needed in order to better understand benefits and the potential adverse 
effects in this population. This is in accordance with the general principle that the patients that will 
use the drug in clinical practice must be represented by the clinical trial participants [18]. Beers et al. 
evaluated the difference in view of clinical and non-clinical professionals on the information needed 
for rational drug prescription [47]. Clinical professionals (healthcare providers) indicated that they 
need more information on the safety aspects of medicines, such as sedative, cardiovascular, 
locomotor and anticholinergic effects, as well as information about the drug-disease interaction and 
dosing instructions for older patients [47]. These items are not yet included in the ICH E7 guideline 
nor in the Q&A document and therefore, the healthcare providers suggest to optimize the guideline. 
This contrasts the current opinion of the non-clinical professionals (regulators and industry) [46]. The 
same research group also investigated the availability of information necessary for appropriately 
prescribing in older patients in the SmPC of recently approved medicines [48]. It was concluded that 
the SmPCs do not sufficiently provide adequate information about efficacy and safety on the older 
people, especially the very old and frail. However, the European Public Assessment Reports (EPARs) 
presented this information sufficiently well [48]. Similar conclusions were drawn during an American 
study [49]. Thus, optimization of the ICH E7 guideline towards adoption in the SmPC of the clinical 
relevant information on the geriatric population is recommended. Moreover, after concluding a 
persistent exclusion of elderly from clinical trials regarding heart failure despite of existing regulatory 
recommendations, a group of geriatricians believed that analogous to the pediatric medicines, 
regulatory authorities should enforce in inclusion of elderly in (relevant) clinical trials in order to 
improve the current situation [19]. 
 
Patients 
The developmental challenges related to the use of medicines reported by the older people and their 
caregivers could be classified into physical, cognitive and medicine-related difficulties. Physical 
difficulties are related to the age-related physiological and functional changes, for example inability 
to read the leaflet information and to open packaging or difficulties to swallow the drug. Cognitive 
difficulties cover confusion, memory problems, comprehension and stress due to disease symptoms, 
e.g. lack of immediate effect of slow release formulations. Medicine-related difficulties encompass 
the polypharmacy reality: concerns about mixing up tablets and confusion on names of medicines 
and generics [50]. 
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Old patients indicate the need for practical information on the drug like what to do in case a dose 
was forgotten. Importantly, this information should be understandable, as currently the used 
language is often still too technical and medical. Using a quick response (QR) code on the packaging, 
the availability of drug-related information can be enhanced. Elderly also encounter problems with 
the identification of a medicine. Standardized symbols and colors for the packaging and tablets could 
be used to help to distinguish between the different types of drugs. Finally, older patients would like 
to choose from different formulations for one medicine like liquid or solid dosage forms [50].   
 
4. CHALLENGES IN THE DEVELOPMENT OF GERIATRIC MEDICINES 
Several challenges related to the development of geriatric medicines were identified and some 
further explored. A first challenge comprises the altered organ functions, which manifest 
heterogeneously in the geriatric population. The age-related changes of the immune system, skin 
physiology, gut microbiota composition, BBB and stem cells are given as an example, with special 
emphasis on the changes of the BBB permeability. Other selected challenges include the 
requirements of age-appropriate drug products, challenges with regards to clinical trials in the 
elderly population and the related ethical issues, pharmacovigilance activities in the older 
population, the applicability of personalized geriatric medicines and finally the pharmacoeconomic 
aspects of drug therapy for the elderly. 
 
4.1. ALTERED ORGAN FUNCTIONS 
With aging, different organ systems show functional and physical alterations as illustrated in Figure 2 
[6-12]. These changes influence the pharmacokinetics, i.e. absorption, distribution, metabolization 
and elimination, as well as the pharmacodynamics of the drug. The pharmacokinetic alterations are 
mainly due to changes in the gastrointestinal system and body composition, as well as to hepatic 
and/or renal impairment (Table 1) [6-7]. The influence of alterations of these organ systems is 
extensively evaluated during pharmacokinetic studies as stated in the ICH E7 guideline [24]. 
However, other age-related organ changes can significantly affect the drug therapy in the elderly as 
well. 
 
Immunosenescence and inflammaging 
Aging is characterized by progressive changes of the immune system, also referred to as 
immunosenescence, causing higher susceptibility to infections, cancer and autoimmune diseases 
[51]. Immunosenescence affects the constituent cells of both the innate and adaptive immune 
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system and is due to prolonged antigenic stimulation [51,52]. A reduction of the thymus function 
causes a decrease in T-lymphocyte production and consequently a modification in cytokine secretion. 
This results in elevated levels of TNF-α, interleukin-6 and C-reactive protein, which are also produced 
by adipose tissue and due to a decline in the production of sex hormones and exposure to stress, and 
cause a low-grade chronic inflammatory status or so-called inflammaging [51-53]. Thus, many factors 
and molecules originating from different tissues, like adipose tissue and muscles, organs like liver and 
brain, the immune system and gut microbiota, contribute to inflammaging [53]. This state of low-
grade inflammation is responsible for the decline and onset of several diseases like cancer, frailty and 
sarcopenia, osteoporosis, cardiovascular diseases, atherosclerosis, hypertension, obesity, type-2 
diabetes and dementia [51,53]. Therefore, inflammaging is a promising therapeutic target for the 
treatment of several diseases in the elderly and deserves more research in order to unravel the 
underlying complex mechanisms causing this chronic inflammatory status [53]. 
 
Aged skin physiology 
During aging, structural and functional changes occur at the skin, characterized by i.a. dryness of the 
stratum corneum, decrease in skin surface lipids, atrophy of the skin capillary network and altered 
cutaneous metabolism [54-56]. Currently, it is not clear how and if these factors influence the 
percutaneous penetration of drugs [56]. Studies investigating the difference in transdermal 
penetration of drugs between younger adults and elderly resulted in conflicting results. For marketed 
transdermal products, no age-related differences could be demonstrated [57,58]. Thus, because of 
the uncertainty on the effect of aging on the percutaneous absorption of drugs and the age-related 
PK/PD changes, it would be beneficial to determine if adapted doses of transdermal formulated 
drugs must be provided for the elderly population, certainly within the framework of the 
development of age-appropriate drug formulations. Indeed, transdermal drug delivery forms a 
suitable alternative for oral dosage forms, not only because it avoids gastrointestinal absorption and 
hepatic first-pass effect, but rather because it allows to minimize adverse drug reactions and 
inherently, to increase drug adherence [54,55,58]. 
 
Age-related changes in gut microbiota 
Aging is also characterized by changes in the composition of the gut microbiota, the bacterial 
population present in the gastrointestinal tract [59]. Gut microbiota affect several physiological 
functions, like digestion, drug efficacy, being involved in the enterohepatic circulation, carcinogenesis 
and immune function [58-62]. Swallowing dysfunction, dentition problems, the increased gut transit 
time and environmental and nutritional changes associated with aging cause alterations in the 
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microbiotal composition. As already mentioned, these changes can contribute to the state of 
inflammaging [53,62-64]. The study of the age-associated changes of the gut microbiota is in an early 
phase and thus there are still some unresolved questions. For example, can these changes in 
microbiota affect the enterohepatic circulation of drugs and thus contribute to altered PK/PD of 
medicines in geriatric patients [60]? As frail patients appear to have specific changes in gut 
microbiota, can these changes be used as biomarkers for frailty or more in general for the health 
status of the elderly [64]? Can probiotics be used to balance the gut microbiota [62]? 
 
Stem cell depletion 
One of the theories on aging is the depletion of stem cells [3]. Indeed, stem cells undergo profound 
changes during the aging process, resulting in diminished responsiveness to tissue injury, 
dysregulation of proliferative activities and deterioration of functional activities [65]. This depletion 
of stem cells is driven by several cell-intrinsic, environmental and systemic factors like accumulation 
of toxic metabolites and DNA damage in stem cells, defects in proteostasis, which comprises the 
cellular processes responsible for synthesis, folding and turnover of proteins. Other factors are 
proliferative exhaustion of stem cells, characterized by a depletion in stem cell pool and disturbed 
cell-cycle activity, extracellular signaling, like inflammatory regulators and alterations in the 
microenvironment where stem cells reside or niches, and finally epigenetic remodeling [65]. The age-
associated changes in stem cell function are especially of interest for Advanced Therapy Medicinal 
Products (ATMPs). Recently, the EMA recommended the approval in the EU of the first stem cell 
therapy for the treatment of moderate to severe limbal stem cell deficiency due to physical and 
chemical burns to the eye in adults for approval [66]. The question was explicitly raised during risk 
assessment whether this therapy is applicable for the elderly, awaiting clinical data will become 
available for application of this ATMP therapy in the geriatric population [67]. 
 
Blood-brain barrier dysfunction 
During the aging process, important changes occur at the BBB, which ultimately result in an 
increased permeability [68-72]. Early research on the effect of aging on the BBB indicated subtle but 
significant histologic and physiologic changes of the BBB, as well as an increased vulnerability to 
external factors like hypertension and cerebrovascular ischemia [73-75]. However, these findings 
were mainly based on aged animal models and showed interspecies variability, undermining to draw 
general conclusions for humans. A systematic review of the literature data on the influence of aging 
on the human BBB function using imaging techniques and assessment of the cerebrospinal 
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fluid/serum ratio of albumin or immunoglobulin G (IgG), effectively indicated that the BBB 
permeability increases with normal aging [68]. 
 
Structural and functional changes in the aging BBB 
Both structural and functional changes are observed at the BBB during the aging process. An 
overview is given in Figure 4.  
 
Figure 4: Overview of the age-related diseases and the structural and functional changes at the BBB [69-71]. 
 
Structural alterations in the neurovascular unit include focal necrosis of the cerebral endothelial cells, 
resulting in decreased cortical and white matter microvascular density, smaller capillary lumen size, 
stiffening of the vessels, accumulation of extracellular matrix components in the vascular basement 
membrane, increased pinocytotic vesicles, decreased mitochondrial density, implying that energy-
dependent processes become impaired at the aging BBB. The cells of the neurovascular unit, i.e. 
astrocytes, microglial cells and neurons, play a key role in maintaining the brain iron homeostasis, 
necessary for normal physiological brain function. During aging, it is observed that iron accumulates 
both in the astrocytes and microglia in the brain regions associated with motor and cognitive 
functions. A suggested mechanism for this accumulation in astrocytes is the reduction of 
ceruloplasmin expression, a ferroxidase necessary for conversion to ferrous iron in order that it can 
be exported out of the cell [68,76]. This accumulated iron causes a dysregulation of the brain iron 
homeostasis and can have neurotoxic effects as this iron excess can generate free radicals [76]. Brain 
aging is also characterized by a loss in pericytes leading to brain vascular damage through reduction 
in the brain microcirculation as well as an increase in the BBB permeability due to a reduction in the 
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expression of tight junction proteins like ZO-1, occludin and claudin-5 [70-72,77]. This increase in BBB 
permeability allows the accumulation of vasculotoxic and neurotoxic macromolecules [77]. Due to 
this BBB dysfunction, aging is also associated with vascular inflammation [71,72]. Heightened 
peripheral inflammation causes increased levels of pro-inflammatory TNF-α in brain endothelial cells 
in geriatric persons, which in turn enhances the expression of pro-inflammatory cytokines at the BBB 
level. These cytokines, more specifically TNF-α, also suppress the expression of tight junction protein 
complexes like occludin-1 and ZO-1, resulting in a loosening of the BBB [57,60]. The vascular 
inflammation is also manifested at the microglia, the immunological part of the neurovascular unit, 
which alter their phenotype with age: they adopt an activated, pro-inflammatory phenotype in 
response to IFN-γ, which is produced by infiltrated immune cells that gained access to the BBB due to 
the age-related increase in permeability [69,72]. The activated microglia, together with the iron 
accumulation in these glial cells, form a source of oxidative damage to cells composing the BBB. 
More studies are needed to understand the relationship between the effects of reactive oxygen 
species (ROS) and the BBB impairment [69,76,79]. A decrease in estrogen levels associated with aging 
is also involved in the age-related malfunction of the BBB. Estrogen is known to have important 
protective effects on the cerebral endothelial cells, decreases the cerebral vascular tone and 
increases cerebral blood flow [69,80,81]. Thus, a combination of age-related changes at the BBB 
interface results in an increase of the BBB permeability, heightening the passage of pro-inflammatory 
compounds and cells as well as toxic agents, that in a vicious circle further enhance the increase in 
BBB disruption.  
Several transporter functions at the BBB alter with aging. The expression of the glucose transporter, 
GLUT-1, is reduced, together with transporters for amino acids, choline and peptides, subverting the 
bioavailability of these essential compounds in the brain [69-71,75]. Also the Pgp function is 
decreased, causing accumulation of (potential) toxic compounds that reach the brain [68-71,82,83]. 
Other reported changes are the decrease of the low-density lipoprotein receptor-related protein 
(LRP)-receptors and the increased expression of the receptors for advanced glycation end products 
(RAGE). LRPs (LRP-1) as well as Pgp mediate the efflux of amyloid β (Aβ) from the brain, while RAGE is 
involved in the influx of Aβ in the brain. Thus, changes of these transporters at the BBB result in an 
increased amyloid burden in the aging brain [69].  
 
Age-related diseases influencing the BBB 
Age-associated diseases like arterial hypertension, diabetes and stroke are risk factors for alterations 
of the BBB permeability or aggravate it (Figure 4). Several studies also demonstrated a link between 
diet consumption and BBB function [84]. One study concluded that mid-life obesity was positively 
related to a decrease in integrity of the BBB at older age in women [85]. Another study suggested 
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that diets rich in saturated fatty acids accelerated the onset of BBB dysfunction with aging [86]. 
Obesity is also found to be associated with the heightened systemic state of inflammation in older 
mice, exacerbating the BBB dysfunction and contributing to the neuroinflammation process and 
oxidative stress in the brain [87]. The BBB breakdown associated with the aging process is found to 
initiate in the hippocampus, the brain region critical for memory and learning [88]. This was 
demonstrated by comparison of the regional BBB permeability between aged patients with no and 
mild cognitive impairment using an advanced dynamic contrast-enhanced MRI protocol [88]. Both 
groups showed BBB breakdown in the hippocampus but not in the other brain regions. The BBB 
dysfunction was more pronounced for the patient with mild cognitive impairment [88]. These results 
indicate that in the early aging stage, BBB disruption is initiated in the hippocampus and is associated 
with cognitive impairment [87-89]. This cognitive impairment is seen in Alzheimer’s disease (AD), a 
type of dementia typically affecting geriatric persons and characterized by accumulation of Aβ and 
hyperphosphorylated tau [69,90]. 
Currently, a lot of research is performed to elucidate the role of BBB dysfunction in the etiology of 
neurodegenerative diseases, like Parkinson’s disease and, especially, AD [91]. For both diseases, it is 
assumed that neuroinflammation and BBB disruption are involved in the pathogenesis of 
neurodegeneration, because of the increased permeability for neurotoxic agents. Most, but not all, 
studies concluded an increased BBB permeability in AD patients or animal models and that structural 
and functional changes occur at the BBB of these patients [91]. As previously indicated, changes in 
the transporter functions with aging result in accumulation of Aβ, forming an important link between 
aging and AD, characterized by senile plaques of Aβ in the brain [90,91]. Amyloid β alters several 
functions of the neurovascular unit, causing further BBB dysfunction and neurodegeneration. First, 
pericyte coverage of capillaries is reduced compared to non-demented persons, which is possibly 
caused by the neurotoxic effect of Aβ, as demonstrated in vitro [90]. Amyloid β also induces changes 
in the astrocyte function in AD brain: astrocytes found in the proximity of Aβ plaques lack the 
expression of scavenger receptors, which are needed for the internalization and degradation of Aβ, 
contributing to its accumulation. The mechanism how Aβ induces this altered function of astrocytes 
is still not clear. Finally, activated microglia surround the Aβ plaques in AD brains. As explained 
earlier, this activated phenotype results in neurotoxicity, but also induces phagocytosis of Aβ 
plaques. Amyloid β is normally phagocytosed by a specialized subset of macrophages, recruited from 
the peripheral circulation. In AD individuals, it was demonstrated that these macrophages 
inefficiently phagocytose Aβ compared to healthy individuals, also contributing to the accumulation 
of Aβ [90]. In contrast, other studies indicate that reduced Aβ metabolism causes its accumulation 
and plaque formation [91]. Moreover, beside the Aβ hypothesis, other Aβ-independent risk factors 
and pathologic conditions like inflammation, oxidative stress, diabetes, cardiovascular disease, are 
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associated with AD. These factors also affect the BBB, demonstrating again the link between BBB 
dysfunction and AD [69,91]. The question remains whether BBB dysfunction is the primary cause or is 
a secondary consequence of AD, but clearly the BBB plays a multifaceted role in the etiology of AD 
[71,90,91].    
 
4.2. AGE-APPROPRIATE DRUG PRODUCTS 
A drug should be formulated in a way that independent and safe management, handling and 
administration can be accomplished by the patient, which is stated in the ICH Q8(R2) guideline on 
pharmaceutical development [92-94]. To achieve this goal, a comprehensive understanding of the 
needs of the target population is required. In Table 2, exemplary specific needs of the elderly 
patients are listed, as well as the possible solutions to address them [4].  
Table 2: Specific needs of geriatric patients and possible solutions to address these needs  
(partly adopted from Stegemann et al.) [4,95]. 
Requirements Specific needs of elderly Possible solution 
Appropriate dose strength 
Dose strengths covering declining 
metabolic capacity and drug-drug 
interactions in polymedication 
conditions 
Lower dose strengths, allowing dose 
titration 
Identification of drug 
product 
Simplify drug product identification 
Colored or specifically shaped dosage 
forms 
Simplified and readable medicines 
information through use of 
pictograms and adapted labeling 
Larger font and simple wording in 
leaflet, product picture on the pill-box 
Potential medication errors in 
polypharmacy 
Easy and clearly identifiable drug 
products 
Manageability of drug 
product 
Suitable age-adequate packaging to 
access the drug product with 
motoric capability limitations and 
diseases 
E.g. low strength screw top, no child-
resistant packaging 
Swallowability of drug 
product  
Easy to swallow oral dosage forms 
options (age-appropriate drug 
formulations) 
Conversion into multiparticulates or 
sprinkle, prefilled oral liquid dosage 
form options 
 Decrease pill burden 
Modified release formulation, dual or 
multiple release formulations or 
combination products 
Complexity of drug therapy Complex medication schedules 
Define implementation strategies and 
contextual cues 
 Supportive device tools 
Medication organizers with 
medication control or alert system 
Safety of excipients 
Excipients with low toxicological 
profile 
Appropriately researched excipients 
for use in the elderly population 
 
First, available dose strengths should cover all patients’ needs, and provide the flexibility to clinicians 
to adapt the drug therapy in the elderly patient in function of the altered pharmacokinetic and 
pharmacodynamic profile, as well as in function of concomitant therapy. In other words, the 
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availability of appropriate doses will allow an individually tailored and optimal drug therapy in the 
elderly [92,95]. Manageability of the drug product is another important pillar, as the geriatric patient 
is often confronted with a decline in motoric functions, whether or not associated with disease. For 
these patients, the packaging and splitting of a drug product can be an important hindrance. 
Especially child-resistant packaging, which is a regulatory requirement, forms a serious hurdle [92]. A 
third requirement for the elderly is the ease of product identification [92,95]. Guidances are already 
available for the readability of the labeling and the package leaflet of medicinal products [96,97], 
however because of the decrease of vision in function of age, use of color or color combinations and 
shapes of solid dosage forms must be encouraged [92,95]. Another major concern is the 
swallowability of the drug product. To overcome swallowing issues of capsules and tablets, 
alternative solid dosage forms, like liquids, orally disintegrating tablets or small solid forms (e.g. 
multiparticulates), should be investigated resulting in age-appropriate drug formulations 
[4,42,55,95]. There is also a great need to find ways to cope with the complex drug schedules to 
which the elderly patients are often confronted. These solutions will also decrease the risk for 
adverse drug reactions due to drug interactions and poor adherence related with polypharmacy. 
Fixed-dose combination products and sustained release products form possible solutions to reduce 
the pill burden and frequency of dosing [4,42,92]. Finally, when developing age-appropriate drug 
formulations, attention should be paid to the safety of excipients in the geriatric population [95]. 
Especially excipients for liquid formulations are of toxicological risk, like propylene glycol which can 
pass an impaired BBB and cause neurological damage, like seen with neonates [95].  
It is noted that during pediatric drug development, the pharmaceutical industry is confronted with 
similar problems, like swallowing difficulties. As still much research needs to be performed in both 
fields and as there are many parallels in needs between the geriatrics and pediatrics like the need for 
dose adaptation and age-appropriate drug formulations, the pharmaceutical industry should 
combine their efforts in order to develop optimal age-appropriate drug products, taking into account 
the differences between the two populations [4,21,42,55,92,95]. The needs of the pediatric 
population mainly depend on age, while the needs of the geriatric population are determined by the 
individual health status [95]. Regulatory challenges include the questions how to cope with child-
resistant packaging of geriatric drug products and with combined drug therapies [92].  
 
4.3. CLINICAL TRIALS AND ETHICAL ASPECTS OF GERIATRIC MEDICINES 
Several guidance and opinion documents with regards to clinical trials and ethical aspects of geriatric 
medicines are yet available. The PREDICT (increasing the PaRticipation of the ElDerly In Clinical Trials) 
consortium, funded by the European Union, conducted a study aimed at identifying, addressing and 
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resolving the issues related to the exclusion of older people from clinical trials. Based on the study 
outcomes, a charter was established in order to put an end to the persistent exclusion of geriatric 
patients (Table 3) [98].  
Table 3: Charter for the rights of older people in clinical trials (PREDICT consortium [98]). 
1. Older people have the right to access evidence-based treatments 
2. Promoting the inclusion of older people in clinical trials and preventing discrimination 
3. Clinical trials should be made as practicable as possible for older people 
4. The safety of clinical trials in older people 
5. Outcome measures should be relevant for older people 
6. The values of older people participating in clinical trials should be respected 
 
In 2013, the Geriatric Medicines Working Party of the European Forum for Good Clinical Practice’s 
(EFGCP), a non-profit organization by and for individuals conducting biomedical research, published 
guidelines on the medical research for and with older people [99,100]. The guidelines describe 
recommendations on the ethical aspects of clinical trials in older people within the legal framework 
of regulations and guidelines [99,100]. In the report of the annual meeting of the American Geriatrics 
Society in 2008, the European and American geriatric societies outlined the challenges for the 
inclusion of older adults in clinical trials [18]. Based on these three different documents, four main 
challenges regarding clinical trials of geriatric medicines can be distilled. 
 
Clear justification of inclusion and exclusion criteria for participants of clinical 
trials 
Industry-sponsored trials are aimed at obtaining approval of the investigated drug and 
demonstrating the drug’s effectiveness and safety is of minor importance. Therefore, restrictive 
eligibility criteria exclude the older patient, often characterized by complex illnesses, from these 
trials and include patients that significantly differ from the population that will take the drug in 
clinical practice [18]. In order to overcome this problem of unrealistic clinical trials, every exclusion 
criterion should be clearly justified [18,99,100]. 
 
Recruitment and obtaining informed consent in the older population 
Another challenging difficulty will be the recruitment and obtaining informed consent in the older 
participants, who can be cognitively impaired [18]. Maximizing effective and clear communication, 
with emphasis on readability and easy-to-understand information, involvement of caregivers, use of 
research networks and overcoming potential problems with access and transport, can improve 
recruitment and retention of older participants [99,101,102]. Careful attention should be given to 
screening of cognitive impairment and to the verification if the participant understood the given 
information and implications of participation. In case the participant fails to fully understand the 
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given information, a proxy decision-maker can be involved [18,99,100]. Older patients in a trial also 
should be hosted in a familiar environment appropriate for older care in order to minimize distress 
and fear [100]. 
 
Dealing with comorbidity and polypharmacy 
The geriatric population is characterized by comorbidity and polypharmacy, which make them more 
susceptible to adverse drug reactions, causing selective attrition and missing data and thus 
complicating data evaluation. Although randomized controlled clinical trials are used to minimize the 
differences in comorbidities between the different participant groups, the heterogeneity of the 
elderly population raises the question whether this standard methodology of clinical trials should be 
refined [18]. The EMA’s Modeling and Simulation Working Group was established to help in the 
development of standards for the design, conduct, analysis and reporting of modeling and simulation 
(M&S). PK/PD population M&S can help to evaluate PK/PD in older patients identifying covariates 
important for variability in drug response and quantifying age-related effects on safety and efficacy. 
Thus, PK/PD M&S is a promising tool to optimize clinical trial design and operation in the elderly 
population [43].  
 
Definition of age-relevant outcomes 
As recommended in the ICH E7 guideline, age-relevant outcomes or endpoints should be defined in 
clinical trials involving elderly patients [24,25]. Due to its comorbidity and/or frailty, a therapy can 
cause disease-specific improvements, but can have little impact on the day-to-day function of the 
geriatric patient. Therefore, functional outcomes should be considered during the clinical trials in the 
older population. An example of a functional outcome is gait speed, which has a predictive validity 
for adverse outcomes like mortality and onset of disability. However, more experience is needed to 
refine clinical trial methodology that uses functional outcomes [103]. Moreover, various diseases 
may have different clinical manifestations in the geriatric population, making the evaluation of 
clinical trials more complicated [104]. Quality of life is also an important outcome, especially for the 
very old patients at the end of life [100]. Currently, age-related conditions like frailty and sarcopenia 
are not labeled as diseases, but should be considered as targets for a clinical intervention [103]. As 
frailty is the most problematic expression of aging, affecting a quarter to half of the older population 
(aged above 85), research for a medicinal therapy for prevention and treatment of this condition is 
urgent [5]. 
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Representation of geriatric expertise in the ethics committee reviewing geriatric trials will be crucial 
to assure these challenges will be taking into account. This ethics committee should always ward the 
balance between the levels of risk and the benefits for the geriatric patient [100]. 
 
4.4. PHARMACOVIGILANCE 
According to the WHO, pharmacovigilance includes the science and activities aiming at detecting, 
assessing, understanding and preventing adverse effects or other drug related problems in the post-
authorization phase of medicines [105]. A major cause for adverse drug reactions in the clinical 
practice is the inappropriate use of drugs due to inappropriate dose or duration of the therapy, drug 
interactions, off-label use or use in contraindicated circumstances [106]. These adverse drug 
reactions can be monitored during pharmacovigilance activities, which is especially of importance for 
the elderly population as they are frequently excluded from clinical trials and are at higher risk for 
adverse drug reactions than younger adults [106,107]. In 2012, the new pharmacovigilance 
legislation came into force in the EU, which is translated in practical terms in the Good 
Pharmacovigilance Practices (GVP). In the Geriatric Medicines Strategy of the EMA, the need for 
specific pharmacovigilance activities for the geriatric population was expressed [29]. However, only 
limited guidance concerning the elderly could be retrieved in the different modules (V, VI, VII, VIII 
and IX) of the GVP, like on the incorporation of the implications of drug use in the elderly in the Risk 
Management Plan if this patient group was not included in the clinical trials (module V) and the 
importance to pay special attention to safety information of the elderly (module VI) [108-112]. In 
contrast to the pediatrics, no specific guidance was found for the pharmacovigilance practices in the 
geriatric population [113]. FDA guidelines on pharmacovigilance also contained no or only limited 
guidance with regards to the elderly [114-116]. However, pharmacovigilance in the geriatric 
population is challenging and deserves special guidelines. The occurrence of adverse drug reactions is 
underestimated in this patient group, because they are often considered as age-related problems or 
manifest atypically and thereby not reported. Moreover, polypharmacy and the presence of multiple 
co-morbidities complicate the establishment of adverse drug reactions [117]. In older patients, the 
endpoints of the drug therapy deviate from those in younger adults [116]. This stresses the 
importance of obtaining sufficient data in the pre-authorization phase if medicines are intended to 
be used by geriatric patients, by inclusion of a representative group of elderly in clinical trials, in 
which age-related endpoints are evaluated [117,118]. If the older population was not included in the 
pre-authorization clinical trials and use by this population is probable, the Risk Management Plan 
should reflect this gap of benefit-risk information and post-authorization studies are required [118]. 
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In the EU, these post-authorization safety studies (PASS) are legally binding when requested by the 
EMA both in the marketing authorization phase, as well as in the post-authorization phase [106,111]. 
 
4.5. PERSONALIZED MEDICINE 
The geriatric population is recognized to be heterogeneous. However, because of the lack of 
sufficient knowledge on the efficacy and safety of medicines, the trial and error approach is currently 
used to medically treat the geriatric patients. This may result in patient dissatisfaction, adverse drug 
reactions and consequently poor adherence to the therapy [119]. This is especially of concern for 
therapies with a narrow therapeutic index, like chemotherapeutic agents [120]. A more suitable 
approach would be personalized or individualized medicine, in which the medical therapy is tailored 
to the individual characteristics of the patient [119]. Initially, personalized medicine was based on 
symptoms (e.g. angina) and phenotypical characteristics (e.g. LDL cholesterol), which resemble the 
approach used in daily practice. Since the completion of the human genome project, the 
personalization of medicine was boosted by progress of the pharmacogenomics, mainly applied in 
the oncology field [119,121]. Optimization of the drug therapy in the elderly can be accomplished by 
using biomarkers, which indicate the functional, disease and frailty status of the older patient, as well 
as the biological age [122-124]. Based on these biomarker values, the appropriate dose for the 
geriatric patient can be determined, as obtained during clinical trials in this population. Beside 
appropriate dosages, age-appropriate drug formulations are also required in order to provide 
optimal, individualized drug therapy for the elderly [125].  
 
4.6. PHARMACOECONOMICS 
The past decade, the research and development cost (R&D) has more than doubled from US$800 
million to an estimated cost of US$2.6 billion in 2013. This increase can be attributed to the higher 
failure rates, as well as to the larger and more complex clinical trials [126]. Unless innovative clinical 
trial principles will be rapidly developed, inclusion of geriatric patients will contribute to this increase 
in R&D cost.  
Partly due to the lack of benefit-risk balance data for the geriatric population, inappropriate drug use 
is common in this patient group, forming the main cause of adverse drug reactions [106,127]. In a 
national survey performed in the USA, 11.4-35.3% of the emergency department visits by the elderly 
was because of a drug-related reason. An European study indicated that 20% of the ambulatory 
patients are faced with adverse drug reactions and 10-20% of the geriatric hospital admissions was 
drug-related [106,127]. Adverse drug reactions also cause a prolonged hospital stay [106]. This has 
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economic consequences: in the USA, the annual costs related to the management of adverse drug 
reactions is estimated to be $US 30.1 billion; in the EU, the total economic burden to the social 
security or healthcare system is € 79 billion. Moreover, 32 to 69% of the drug related hospital 
admissions was considered to be (possibly) preventable [127]. These preventable adverse drug 
reactions are mostly more serious and life-threatening than the non-preventable events and are thus 
associated with higher costs [128]. There also exists a mutual causal correlation between adverse 
drug reactions and adherence to drug therapy, which is generally poor in the geriatric population 
faced with a complex drug regimen due to polypharmacy [127]. Thus, age-appropriate drug products 
with demonstrated efficacy and safety in the elderly population, taking into account their specific 
needs, will help to decrease the rate of adverse drug reactions in the geriatric population and thus 
lower the economic impact of geriatric drug therapy on the social security system [106,127]. Several 
drug classes like antibiotics, anticoagulants, medicines with narrow toxic-therapeutic range (e.g. 
digoxin and fenytoin), diuretics, hypoglycemic agents, antineoplastic agents and NSAIDS, are mainly 
responsible for hospitalization due to adverse drug reactions [127]. Based on these data, a priority 
list can be established to determine the medicines that need urgently to be appropriately researched 
in the elderly in the post-authorization phase. 
In health economics, cost-utility (or cost-effectiveness) analyses are used to measure the cost-
effectiveness of a medicinal therapy and is a good indication of the economic impact of a therapy on 
the social security or healthcare system [129,130]. This cost-utility analysis supports policy makers in 
determining the pricing and reimbursement of new medicines [129,130]. The aging population 
impacts and challenges the society and especially the social security systems. To optimally allocate 
health and social care resources within limited budgets, competing health and social services should 
be investigated for their relative value for money [130]. During cost-utility studies, Quality Adjusted 
Life Years (QALYs) are used as health-related utility measures and take into account the quality, i.e. 
health status, and quantity, i.e. mortality, of life generated by a healthcare intervention [130,131]. A 
cost-utility ratio expresses the cost of the therapy per QALY or the cost to gain a year of perfect 
health [130,131]. QALYs are obtained by categorizing the self-reported health status by the patient 
based on previous research which is used to value this health status in terms of quality of life [130].  
For the measurement of the quality adjusted component of QALY, Health Related Quality of Life 
(HRQOL) measures are used, such as the generic quality of life instruments EQ-5D, WHOQoL or SF-6D 
[129,130,132-134]. Several issues are identified when assessing the health state in the elderly using 
these generic instruments. A first issue concerns the (poor) ability of older people to identify their 
health status, which is necessary to obtain QALYs. Another issue is that elderly value quality of life 
differently than younger adults and distinctly define health [130]. Therefore, more relevant quality of 
life scales specific for older people, with or without dementia, should be used when performing cost-
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utility analyses in the elderly population such as CASP-19, PGC Morale scale or ICECAP-O 
[129,130,132-134]. 
The use of QALYs in the setting of geriatric medicines is criticized because of its focus on survival, 
which inevitably results in a lower value for an older person because of the reduced capacity for 
survival duration compared to a younger individual [129]. Moreover, the presence of co-morbidities 
in the elderly, limits the ability to benefit from a successful therapy as these comorbidities impede to 
return to the state of perfect health [130]. For geriatric patients, the aim of a healthcare intervention 
is not to improve the health status per se, but rather the broader wellbeing. Thus, only generic 
HRQOL instruments in this population may undervalue the range of services provided, biasing 
allocation decisions. Instruments covering dimensions “beyond health” can be labeled as wellbeing 
instruments in which two main conceptualizations can be identified: the first one focusses on 
wellbeing as an inherently subjective concept, not containing health dimensions [135]. In contrast, 
the second approach treats wellbeing as representing individuals’ welfare, which is dependent of 
individuals’ functionality and thus encompassing HRQOL dimensions [136]. Moreover, for frail older 
people, small improvements of health tend to be highly valued in the improvement of the quality of 
life. Not health alone determines the quality of life of an elderly person but also the presence of 
emotional support and empathy contributing to the general wellbeing [129,137]. Thus a broader 
approach, incorporating the attributes that highly determine the quality of life, should be used to 
economically evaluate the geriatric medicines and importantly taking into account the comorbidity 
and polypharmacy of the geriatric patients [129,138]. The number of instruments developed 
specifically to address and evaluate outcomes of healthcare services targeted at older people is 
growing. However, guidance is lacking on which instrument as golden standard can or should be used 
for cost-utility analysis for interventions aimed at older peoples and deserves more research. Finally, 
the quality of decisions during cost-utility analyses are as good as the evidence that supports it. This 
evidence is often poor due to the minimal inclusion of elderly in clinical trials and the measurement 
of different outcomes during trials in this population, impeding comparison with treatments 
researched in broader age groups. More research in the elderly population is needed to reduce the 
uncertainty of decisions during cost-utility analyses concerning older people [130]. 
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5. TO GIP OR NOT TO GIP? 
Currently, the ICH E7 and FDA’s Geriatric Labeling guidelines encompass the available regulatory 
framework regarding the development of geriatric medicines. However, these guidelines could not 
achieve the systematic inclusion of the elderly in clinical trials, even when the older population will 
be the main user of the investigated drug [18,139]. Both the EMA and FDA are aware of this mostly 
minimal inclusion of older patients in clinical trials and have taken measures to address the specific 
needs of the elderly. The question is whether guidelines are enough to achieve safe and effective 
drug therapy for the elderly.  
The ICH E7 guideline focusses only on clinical trials, but development of age-appropriate geriatric 
medicines needs to start before the clinical phase. For example, the development of appropriate 
dosage forms and the influence of the age-related physiological changes and disease on the PK/PD of 
the drug must already be studied prior to administration to the elderly. In the framework of the 
Paediatric Regulation published by the EMA, the pharmaceutical industry is obliged to submit a PIP, 
which contains the studies that will be performed in children and the measures that have been taken 
to develop child-appropriate dosage forms, covers the needs of all age groups of children and defines 
the timings of the studies compared to adults [23]. This PIP is reviewed by the Paediatric Committee 
(PDCO), which is composed of experts in the field and once agreed, it is binding and forms the basis 
for the development and authorization of drug products [23]. Currently, regulatory authorities are 
not yet prone to establish similar regulations or Geriatric Investigation Plan (GIP) for the geriatric 
medicines and want to improve the current framework of guidelines, assisted by the GEG of the EMA 
or trained reviewers by the FDA, who will check the applications for their compliance to these 
guidelines. However, the time span in which older people use medicines is longer than the time 
frame of the pediatrics, i.e. 0-18 years, especially now life-expectancy is increasing. This stresses the 
stringency to take measures to provide age-appropriate medicines for the elderly.  
Currently, regulatory progress is limited as guidelines are delayed, like the points to consider to 
characterize the frailty status, which was drafted in 2013 [30]. Also healthcare providers feel the 
need for a more legally binding regulatory framework. Involvement of all stakeholders is needed to 
achieve that all aspects of geriatric medicines are covered, ranging from scientific advice and, 
eventually, incentives for the pharmaceutical industry to the availability of sufficient information 
both for the older patients and healthcare providers and age-appropriate drug formulations, allowing 
optimal therapy in the elderly (Figure 5).  
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Figure 5: Different steps and stakeholders in the development of geriatric medicines. 
 
We acknowledge that within the current regulatory framework on development of medicines, the 
utility of some regulations is questionable. However, we believe that GIP is not, and, even more, will 
have a high value for money being of benefit for all stakeholders. Lessons learned from the 
application of the pediatric legislation are valuable and should be taken into account when 
considering similar geriatric regulations. Importantly, a balance between the economic burden and 
benefit, e.g. in the form of extended market exclusivity or reduced regulatory fees, should be found 
to encourage the industry to apply these regulations.  
Moreover, these proposed strategies concern only the newly developed drug products, but do not 
address already approved medicines. Are pharmacovigilance data enough to update the SmPCs with 
data on the geriatric patients? Should SmPCs be proactively updated using pharmacovigilance or 
clinical trial data, e.g. for priority medicines based on adverse drug reactions rates in the elderly?  
So, whether we should GIP or not will depend on whether the current strategies to ensure safe and 
effective drugs for the elderly achieve their objectives. However, there is no time to waste.   
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SUMMARY & GENERAL CONCLUSIONS 
This research project aims to quantitatively evaluate the blood-brain barrier (BBB) transport of cell-
penetrating peptides (CPPs). As described in Chapter I, CPPs are a structural diverse group of 
peptides that are able to cross cellular membranes. These peptides have a low toxicity profile, but 
might also exert biological activity. Cell-penetrating peptides are mainly investigated as possible 
vectors for cell-impermeable cargoes with already numerous success stories that have been 
reported, also when applied for brain-targeting purposes. The BBB, fundamentally composed of 
capillary endothelial cells sealed by tight junctions, strictly regulates the transport of ions, solutes, 
water, macromolecules and blood cells into the brain in order to maintain the brain homeostasis, 
which is essential for normal CNS function. This barrier is not static and can be regulated and 
modulated as illustrated by several studies demonstrating that peptides can cross the BBB.  With 
aging, the BBB shows an increased permeability due to structural and functional alterations, which is 
further aggravated by age-related diseases.  
In Chapter II, the chemical space of a set of 186 (non-)CPPs was explored using multivariate data 
analysis techniques, allowing to rationally select model peptides for this research. Based upon 
differences in the chemical structure, the selected peptides could be categorized into six groups, in 
which eight smaller subclusters were identified. Quantitative data for cellular influx available for the 
186 selected peptides was used to calculate the CP-response, a unified response expressing the 
extent of cellular uptake. This CP-response was introduced to allow direct comparison of the cell-
penetrating properties of peptides within the constraints of inconsistency in used experimental 
protocols. The CP-response was also used to perform a quantitative structure-property relationship 
(QSPR) study, which provided new insides into the structural features determining the cellular uptake 
of peptides, like the influence of the shape, structure complexity and compactness, but also 
confirmed the importance of cationic charge and amphipathicity. 
A classification system for peptides based on their BBB influx properties was introduced in Chapter 
III. Like for the cellular uptake studies, a plethora of methods and experimental set-ups are used to 
characterize the BBB transport of peptides. During an exploration of the Brainpeps database, four 
different BBB influx response types were selected for which quantitative data were available. Based 
on the distribution of these data, five classes of BBB influx magnitude, i.e. ranging from very low to 
very high influx, were defined. These classes were converted to a BBBin-response, a scaled value 
ranging from zero (very low influx) to ten (very high influx), which is independent of the BBB influx 
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response from which it is derived. The classification system and BBBin-response allow an objective 
evaluation of obtained BBB influx data like evaluation of outliers, but also can be applied during QSPR 
studies.  
The quality control (QC) of the peptides investigated during this research is described in Chapter IV. 
Five cationic CPPs were analyzed using five different C18-chromatographic systems differing in 
column particle size (HPLC versus UHPLC), acidic modifier (FA versus TFA) and column temperature 
(30°C versus 60°C). The performance of the different systems for analysis of these peptides was 
compared. It was demonstrated that the used chromatographic system determined the final QC 
results, with the C18-UHPLC system, operated at 30°C and using TFA as acidic modifier in the mobile 
phase was identified to be the most suitable method. Trifluoroacetic acid-containing mobile phases 
are compatible with single quad MS detector systems for which the use during routine QC of 
peptides was demonstrated, providing information on the identity and purity of the peaks observed 
during chromatographic analysis. It was concluded that the purity of all peptides evaluated for their 
BBB transport was above the requested 95% and their identity was confirmed using HPLC-UV/MS.  
The main research question of this thesis is answered in Chapter V, in which the in vivo BBB transport 
of CPPs is described. The brain influx, parenchymal/capillary distribution and efflux out of the brain 
was quantitatively investigated of five “traditional” CPPs, i.e. pVEC, TP10, TP10-2, SynB3 and Tat 47-
57, as well as of “new” CPPs, being four short, proline-rich AMPs (PrAMPs) i.e. apidaecin Api137, 
oncocin, drosocin and drosocin Pro5Hyp, and three disulfide-rich (cyclic) peptides, i.e. MCoTI-II, 
cVc1.1 and chlorotoxin, which also have cell-penetrating properties and are positioned in the 
chemical space of the CPPs. The results indicate that the investigated peptides showed divergent BBB 
transport properties characterized by the blood-to-brain transport ranging from very low or no influx 
to very high brain influx, by a mainly parenchymal distribution to entrapment in capillary endothelial 
cells and in some cases by efflux out of the brain. The tissue distribution, which varied among the 
investigated peptides, as well as the in vitro metabolic stability of the peptides was also described. 
From these results, it can be concluded that peptides with cell-penetrating properties selectively 
cross the BBB. 
Finally, in line with the DruQuaR tradition, a regulatory aspect of this research is elaborated. The BBB 
is assumed to be intact during the BBB transport studies as a healthy and young mouse model is 
used. With aging, the BBB shows an increased permeability and thus BBB transport might be altered. 
Other organ systems also show functional changes during the aging process, which has consequences 
for the use of medicines in the elderly, a population group that is numerically expanding worldwide. 
Therefore, in Chapter VI, it is investigated how these age-related functional changes are taken into 
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account during the development of medicines for geriatric patients and which regulatory framework 
is currently provided. The views of the different involved stakeholders are analyzed and the 
encountered challenges are identified. It can be concluded that today, a gap exists in the knowledge 
on the benefit-risk ratio of medicines in the geriatric population due to mostly minimal inclusion in 
clinical trials. Non-binding guidelines are available, but regulatory authorities are aware of this 
knowledge gap. All stakeholders, each representing a different aspect of the development of geriatric 
medicines should be involved in the regulatory process, ultimately aiming to provide safe and 
efficacious drugs for this population.  
Based on the obtained results, the main research question of this thesis being “Do CPPs selectively 
cross the BBB?”, could be answered: YES, CPPs cross the BBB to a different extent. The investigated 
model peptides differed chemically and showed a different extent in cellular influx, numerically 
expressed by the CP-response. However, for the investigated CPPs, the CP-response was not 
correlated with the extent of BBB influx, expressed by the BBBin-response. Therefore, it is concluded 
that cell-penetrating properties of peptides do not automatically imply efficient brain influx.  
 
While answering the main question of this Ph.D. project, new research opportunities were identified, 
which deserve further investigation. Another burning question is whether a similar mechanism is 
used for cellular and BBB influx. If this is the case, mechanistic information on the cellular influx can 
be used to predict the BBB uptake of CPPs and can help to unravel the BBB transport mechanism of 
peptides. Therefore, it is important to further characterize the peptides that can cross the BBB. 
Detailed information about the in vivo serum and brain metabolization is also required to obtain the 
full picture. For example, during in vitro incubation of pVEC in serum, the formation of a metabolite 
representing the pVEC peptide cleaved from the N-terminal hydrophobic amino acid residues was 
demonstrated. Based on a structure-activity relationship study of pVEC, this metabolite is assumed to 
be not cell-penetrating. If both peptides show brain influx, the BBB transport properties cannot be 
attributed solely to their cell-penetrating properties. This is valuable information for the study of the 
structural features determining the BBB transport of (cell-penetrating) peptides. For identification 
and quantification of the formed metabolites in vivo, new advanced sample preparation and MS 
detection systems, designed to quantify very small amounts of peptides, are required. Moreover, 
with the introduction of these very sensitive MS systems and suitable sample preparation methods, 
the use of radiotracers becomes superfluous. 
 
SUMMARY & GENERAL CONCLUSIONS 
  
 
220 
During this research, an in vivo mouse model was used to study the BBB transport of CPPs as this still 
is the “golden standard”. However, suitable in vitro BBB models have eminent advantages. The 
search for in vitro models showing good correlation with in vivo models is challenging because of the 
complex nature of the BBB and the interplay between the cells and other components of the 
neurovascular unit. A promising in vitro model is the triple co-culture of endothelial cells, pericytes 
and astrocytes. These in vitro models can be used to obtain a large data set of BBB transport data of 
(cell-penetrating) peptides, required for reliable QSPR study, but can also be applied to study the 
possible mechanism of BBB transport.  
Chemo-molecular descriptors numerically expressing the peptide structure are also needed for 
performing QSPR studies. During this research, it was noted that peptide-specific descriptors are 
limited available, and if disposable, they show limited applicability mostly due to their restricted use 
for peptide structures only consisting of natural L-amino acids. New descriptors for the 
hydrophobicity, secondary structure and charge characteristics are urgently needed. Moreover, 
current commercially available descriptor calculation packages are developed for small molecules 
leading to difficulties in the interpretation of the descriptor meaning for larger peptide structures. 
Thus, use of peptide-specific descriptors, which can be calculated for all peptide and peptoid 
structures, will bring QSPR studies of peptides to a higher level and will allow to distract more 
relevant information.   
Peptides are omnipresent in the human body being endogenously formed, i.a. through 
metabolization of proteins, or of exogenous origin. Peptide structures show a high specificity and 
potency, implying that small amounts of peptides can exert a prolonged effect. Therefore, it is of 
general importance to know which peptides can gain access to the brain, which brain regions they 
reach, how long they reside in the CNS and what their possible pharmacodynamic effects are. 
Models based on QSPR studies can be used to identify peptide structures that might be able to cross 
the BBB. This evaluation is of importance during the development of peptide medicines that gained 
increased interest from the pharmaceutical industry. BBB transport of peptides is expected to be a 
prerequisite in case of CNS therapeutics or the QSPR models can be used as a tool to evaluate the 
CNS toxicity profile of the new peptide medicine. These models can also be applied to scan protein 
and peptide libraries for sequences that possibly can cross the BBB. This information is highly 
relevant for peptide structures that can exert a biological effect and thus also can affect the CNS 
function. The proposed approach allows to identify peptide sequences hidden in the protein 
structure that can cross the BBB once formed after metabolization of the parent protein. For these 
hidden peptide structures, so-called cryptic peptides, it can be further investigated whether they can 
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affect and modulate the CNS function. Imaging MS is a relatively new technique allowing to evaluate 
the temporal-spatial distribution of the peptide in the brain. This information can be used to 
evaluate region-specific uptake in the brain, which can be of therapeutic interest or can help to 
unravel the potential role or function of the peptide in the CNS. The temporal distribution provides 
information of the time frame in which the peptide resides in that brain region.  
Aging is known to be associated with increased BBB permeability. This is relevant for drug therapy in 
the elderly causing changes in the brain distribution and CNS (side) effects, which is currently 
neglected during the development of geriatric medicines. Availability of biomarkers for BBB 
dysfunction or models for BBB permeability can assist in dose adjustment of medicines in the elderly 
or can be used to evaluate potential risks of drug therapy in this patient population. Possible markers 
could be the pro-inflammatory cytokines of which the blood levels are increased with aging or the 
gut microbiota composition, which is known to influence the BBB function and shows alterations in 
composition with aging. Gender differences should also be taken into account as sex steroidal 
hormones are known to influence the BBB permeability. The role of BBB dysfunction is acknowledged 
for neurodegenerative diseases. Another important question is whether BBB dysfunction is 
associated with the etiology of other CNS diseases like epilepsy, autism, schizophrenia, depression 
or brain cancer, which might offer new therapeutic options. 
By demonstrating the selective ability of CPPs to cross the BBB, we have laid the fundaments of 
further research. We demonstrated that current available studies evaluating both cellular influx and 
BBB transport of peptides are characterized by inconsistencies in experimental set-up and 
methodologies. Therefore, we introduced unified responses for the cellular uptake and BBB influx of 
peptides. Harmonization and standardization of these protocols, including consistent evaluation of 
positive and negative controls, would allow to more reliably compare peptides with regards their 
cell- and BBB-penetrating properties, helping to answer open questions like the used mechanism and 
required structural features both for cellular influx and BBB transport. Finally, the fact that CPPs can 
be formed endogenously, stresses the importance for the characterization of possible biological 
(CNS) effects of these peptides. 
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SAMENVATTING & ALGEMENE CONCLUSIES 
De doelstelling van dit onderzoeksproject is het kwantitief onderzoeken van het bloed-
hersenbarrière (BBB-)transport van cel-penetrerende peptiden (CPPs). Zoals beschreven in 
Hoofdstuk I, zijn CPPs een groep van structureel verschillende peptiden, die celmembranen kunnen 
passeren. Deze peptiden zijn gekenmerkt door een laag toxiciteitsprofiel, maar kunnen ook een 
biologische activiteit vertonen. Cel-penetrerende peptiden worden voornamelijk onderzocht als 
mogelijke vectoren voor cel-ondoorlaatbare moleculen en er zijn reeds talrijk succesverhalen 
gerapporteerd, ook voor gerichte toediening in de hersenen. De BBB is samengesteld uit de 
endotheelcellen van de capillairen onderling verbonden via hechte netwerken van eiwitten (“tight 
junctions”) en reguleert nauwgezet het transport van ionen, water, (macro)moleculen en bloedcellen 
van en naar de hersenen, opdat de hersenhomeostase kan gehandhaafd blijven, wat essentieel is 
voor een normale functie van het centraal zenuwstelsel. Deze barrière is niet statisch en kan 
gereguleerd en gewijzigd worden, zoals geïllustreerd door verschillende studies waarin de 
mogelijkheid van peptiden om de BBB te passeren wordt aangetoond. Tijdens het 
verouderingsproces vertoont de BBB een verhoogde doorlaatbaarheid als gevolg van structurele en 
functionele veranderingen, wat verder kan verergerd worden door ouderdomsziekten. 
In Hoofdstuk II werden de modelpeptiden voor dit onderzoek geselecteerd op basis van de 
exploratie van de chemische diversiteit van een set van 186 (niet-)CPPs met behulp van multivariate 
data-analysetechnieken. Op basis van verschillen in de chemische structuur konden de geselecteerde 
peptiden onderverdeeld worden in zes groepen, waarbinnen nog acht kleinere subgroepen konden 
onderscheiden worden. De kwantitatieve data voor celopname die beschikbaar zijn voor deze 186 
geselecteerde peptiden werden gebruikt om de CP-respons, een universele response die de mate van 
celopname uitdrukt, te berekenen. Deze CP-respons werd geïntroduceerd om een directe 
vergelijking van de cel-penetrerende eigenschappen van peptiden toe te laten, ondanks de 
inconsistentie in de gebruikte experimentele protocollen. De CP-respons werd ook gebruikt om een 
kwantitatieve structuur-eigenschapsrelatie-onderzoek (QSPR) uit te voeren. Deze studie bood 
nieuwe inzichten in de structurele eigenschappen van peptiden die bepalend zijn voor celopname, 
zoals het belang van de vorm, structuurcomplexiteit en -compactheid, en daarnaast werd het belang 
van de positieve lading en amfipaticiteit bevestigd. 
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In Hoofdstuk III werd een classificatiesysteem voor peptiden op basis van hun BBB-influx 
geïntroduceerd. Zoals vastgesteld voor de celopnamestudies, worden er ook een diversiteit aan 
methoden en experimentele protocollen gebruikt om het BBB-transport van peptiden te 
karakteriseren. Tijdens de exploratie van de Brainpeps database werden vier verschillende types van 
BBB-influxresponsen geselecteerd, waarvoor kwantitatieve data beschikbaar waren. Op basis van de 
verdeling van deze data werden vijf klassen van een bepaalde BBB-influx grootte-orde gedefinieerd, 
gaande van zeer lage tot zeer hoge influx. Deze klassen werden omgezet naar een BBBin-respons, een 
getal van 0 (zeer lage influx) tot 10 (zeer hoge influx), dat onafhankelijk is van de BBB-influxrespons 
waarvan het afkomstig is. Dit classificatiesysteem en de BBBin-respons laten een objectieve evaluatie 
toe van de BBB-influxresultaten, zoals de evaluatie van afwijkende resultaten, maar kunnen ook 
gebruikt worden tijdens het uitvoeren van QSPR-studies.  
De kwaliteitscontrole van de onderzochte peptiden is beschreven in Hoofdstuk IV. Vijf kationische 
CPPs werden geanalyseerd met behulp van vijf verschillende C18-chromatografische systemen die 
onderling verschilden in kolompartikelgrootte (HPLC versus UHPLC), zuurcomponent van de mobiele 
fase (mierenzuur (FA) versus trifluoro-azijnzuur (TFA)) en kolomtemperatuur (30°C versus 60°C). De 
prestatie van de verschillende chromatografische systemen, gebruikt voor de analyse van deze 
peptiden, werden vergeleken. Er werd aangetoond dat het gebruikte chromatografische systeem 
bepalend is voor de finale kwaliteitscontroleresultaten. Het C18-UHPLC-systeem, met 
kolomtemperatuur 30°C en met TFA in de mobiele fase, was geïdentificeerd als het meest geschikte 
systeem. Mobiele fasen die TFA bevatten zijn compatibel met “single quad” massaspectrometrie 
(MS) detectorsystemen, waarvan het routinematig gebruik tijdens de kwaliteitscontrole van peptiden 
werd aangetoond, aangezien het informatie kan verschaffen over de identiteit en de zuiverheid van 
de pieken in de bekomen chromatogrammen. Voor alle peptiden waarvan het BBB-transport 
onderzocht werd, lag de zuiverheid boven de vereiste 95% en werd hun identiteit bevestigd met 
behulp van HPLC-UV/MS. 
De hoofdonderzoeksvraag van deze thesis werd beantwoord in Hoofdstuk V, waarin de in vivo BBB-
transporteigenschappen van de CPPs wordt beschreven. The herseninflux, verdeling naar het 
hersenparenchym en -capillairen en efflux uit de hersenen van vijf “traditionele” CPPs, nl. pVEC, 
TP10, TP10-2, SynB3 en Tat 47-57, en “nieuwe” CPPs, meer bepaald vier korte, proline-rijke 
antimicrobiële peptiden (PrAMPs), apidaecin Api137, oncocin, drosocin en drosocin Pro5Hyp, en drie 
disulfide-rijke (cyclische) peptiden, MCoTI-II, cVc1.1 en chlorotoxin, werden kwantitatief onderzocht. 
De “nieuwe” CPPs zijn peptiden die ook cel-penetrerende eigenschappen bezitten en gelijkaardige 
chemische eigenschappen vertonen als de CPPs. De resultaten tonen aan dat de onderzochte 
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peptiden uiteenlopende BBB-transporteigenschappen vertonen, gaande van een zeer hoge tot zeer 
lage herseninflux, van hoofdzakelijk distributie naar het hersenparenchym tot captatie in de 
endotheelcellen van de capillairen en in sommige gevallen efflux uit de hersenen. De 
weefseldistributie, die sterk verschilde tussen de onderzochte peptiden, alsook de in vitro metabole 
stabiliteit van de peptiden, werd onderzocht. Uitgaande van deze resultaten kan geconcludeerd 
worden dat peptiden met cel-penetrerende eigenschappen de BBB passeren op een selectieve 
manier. 
Tot slot, werd volgens de traditie op het DruQuaR labo, een regulatoir aspect van dit onderzoek 
behandeld. De BBB is verondersteld in tact te zijn tijdens de studie van BBB-transport van peptiden, 
gezien een gezond en jong muismodel werd gebruikt. Tijdens het verouderingsproces vertoont de 
BBB een verhoogde permeabiliteit, wat dus een wijziging in BBB-transport kan veroorzaken. Ander 
orgaansystemen vertonen ook functionele veranderingen met ouder worden, wat gevolgen heeft 
voor het medicatiegebruik bij ouderen, een populatiegroep waarvan, wereldwijd, het aantal 
exponentieel toeneemt. Daarom werd in Hoofdstuk VI onderzocht hoe deze leeftijdsgebonden 
functionele veranderingen in rekening worden gebracht tijdens de ontwikkeling van geneesmiddelen 
voor geriatrische patiënten en welk regulatoir kader momenteel wordt geboden. De kijk van de 
verschillende betrokken partijen hierop werd geanalyseerd en de uitdagingen geïdentificeerd. Er kan 
geconcludeerd worden dat vandaag, een enorme lacune bestaat in de informatie over de risico-
batenverhouding van het gebruik van geneesmiddelen door ouderen, doordat ze vaak minimaal 
geïncludeerd worden in klinische studies. Niet-bindende richtlijnen zijn beschikbaar, maar de 
regulatoire autoriteiten zijn zich bewust van deze informatielacune. Alle betrokken partijen, die elk 
een verschillend aspect van de ontwikkeling van geriatrische geneesmiddelen vertegenwoordigen, 
zouden betrokken moeten worden bij het regulatoire proces met als ultieme doel het voorzien van 
veilige en effectieve geneesmiddelen voor deze patiëntenpopulatie. 
Op basis van de onderzoeksresultaten kan de hoofdonderzoeksvraag van deze thesis, nl. “In welke 
mate passeren CPPs selectief the BBB?”, beantwoord worden: JA, CPPs passeren de BBB in 
verschillende mate. De onderzochte modelpeptiden verschilden chemisch en vertoonden een 
verschillende mate van celopname, numeriek uitgedrukt door de CP-respons. Voor de onderzochte 
peptiden kon niet worden aangetoond dat de CP-respons gecorreleerd was met de mate van BBB-
influx, uitdrukt door de BBBin-respons. Daarom kan geconcludeerd worden dat cel-penetrerende 
eigenschappen van peptiden niet automatische efficiënte herseninflux impliceren. 
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Tijdens het beantwoorden van de hoofdonderzoeksvraag van dit Ph.D.-project doken nieuwe 
onderzoeksmogelijkheden op. Een eerste vraag die zich stelt is of een gelijkaardig mechanisme 
wordt gebruikt voor celopname als voor BBB-influx. Indien dit het geval is kan mechanistische 
informatie over de celopname gebruikt worden om de BBB-influx van CPPs te voorspellen en om het 
BBB-transportmechanisme van peptiden helpen te ontrafelen. Daarom is het belangrijk om peptiden 
die in staat zijn om BBB te passeren verder te karakteriseren. Gedetailleerde informatie over de in 
vivo serum- en hersenmetabolisatie is ook vereist om een volledig beeld te krijgen van het BBB-
transport van peptiden. Zo werd bijvoorbeeld tijdens de in vitro incubatie van pVEC in serum de 
vorming van een metaboliet, zijnde pVEC waarvan de N-terminale hydrofobe aminozuren zijn 
gekliefd, aangetoond. Op basis van de structuur-activiteitsrelatiestudie van pVEC, is verondersteld 
dat deze metaboliet geen CPP zal zijn. Als beide peptiden BBB-influx vertonen, kunnen de BBB-
transporteigenschappen van CPPs niet enkel toegekend worden aan hun cel-penetrerende 
eigenschappen. Dit is waardevolle informatie voor de studie van de structurele kenmerken die 
bepalend zijn voor BBB-transport van (cel-penetrerende) peptiden. Nieuwe, geavanceerde 
staalvoorbereidingstechnieken en MS-detectiesystemen, ontwikkeld om kleine hoeveelheden van 
peptiden te kwantificeren, zijn vereist voor de identificatie en kwantificatie van de in vivo gevormde 
metabolieten. De introductie van deze zeer gevoelige MS-systemen en geschikte 
staalvoorbereidingsmethoden maken bovendien het gebruik van radioactieve labels overbodig.  
Tijdens dit onderzoek werd een in vivo muismodel gebruikt om het BBB-transport van CPPs te 
onderzoeken, gezien dit nog steeds geldt als de “gouden standaard”. Daarentegen hebben geschikte 
in vitro BBB-modellen aanzienlijke voordelen. De zoektocht naar in vitro modellen met goede 
correlatie met de in vivo modellen is niet eenvoudig, wegens de complexe samenstelling van de BBB 
en het samenspel van BBB met de cellen en andere componenten van de neurovasculaire unit. Een 
veelbelovend in vitro model is de tripel co-cultuur van endotheelcellen, pericyten en astrocyten. 
Deze in vitro modellen kunnen gebruikt worden om grote datasets van BBB-transportresultaten van 
(cel-penetrerende) peptiden te verkrijgen, wat vereist is om een betrouwbare QSPR-studie te kunnen 
uitvoeren, maar ze kunnen ook gebruikt worden om de BBB-transportmechanismen op te helderen.  
Chemo-moleculaire descriptoren die numeriek de peptidestructuur uitdrukken zijn ook nodig om 
QSPR-studies uit te voeren. Tijdens dit onderzoek werd vastgesteld dat peptide-specifieke 
descriptoren slechts beperkt beschikbaar zijn, en indien beschikbaar, vertonen ze vaak beperkte 
toepasbaarheid, voornamelijk doordat ze enkel kunnen berekend worden voor peptiden opgebouwd 
uit de natuurlijk voorkomende L-aminozuren. Nieuwe descriptoren die de hydrofobiciteit, secundaire 
structuur en ladingseigenschappen van peptiden uitdrukken, zijn dringend nodig. De huidige 
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commercieel beschikbare descriptorpakketten zijn ontwikkeld voor kleine organische moleculen, 
waardoor de interpretatie van de descriptorbetekenis voor de grotere peptidestructuren bemoeilijkt 
wordt. Het gebruik van peptide-specifieke descriptoren, die zowel voor peptide- als 
peptoidestructuren kunnen berekend worden, zal QSPR-studies van peptiden naar een hoger niveau 
tillen en zal toelaten om meer relevante informatie uit deze studies te distilleren.  
Peptiden zijn alomtegenwoordig in het menselijk lichaam en kunnen zowel endogeen gevormd 
worden tijdens metabolisatie van proteinen of kunnen van exogene oorsprong zijn. 
Peptidestructuren zijn gekarakteriseerd door een hoge specificiteit en potentie, wat impliceert dat 
een kleine hoeveelheid peptide een langdurig effect kan uitoefenen. Het is daarom van algemeen 
belang dat we weten welke peptiden zich toegang kunnen verschaffen tot de hersenen, welke 
hersendelen ze bereiken, hoe lang ze in het centraal zenuwstelsel verblijven en wat hun mogelijke 
farmacodynamische effecten zijn. Modellen die gebaseerd zijn op QSPR-studies kunnen gebruikt 
worden om peptidestructuren te identificeren die mogelijks de BBB kunnen passeren. Deze evaluatie 
is van belang tijdens de ontwikkeling van peptidegeneesmiddelen, die steeds meer interesse 
verwerven van de farmaceutische industrie. Bloed-hersenbarrièretransport van peptiden is een 
vereiste in het geval van geneesmiddelen voor aandoeningen van het centraal zenuwstelsel, of deze 
QSPR-modellen kunnen gebruikt worden als instrument om de toxiciteitsprofiel voor het centraal 
zenuwstelsel van het nieuw geneesmiddel te evalueren. Een andere toepassing van deze modellen is 
het screenen van proteine- en peptidebibliotheken naar sequenties die mogelijks de BBB kunnen 
passeren. Deze informatie is relevant voor peptiden die een biologisch effect kunnen uitoefenen en 
dus ook mogelijks het centraal zenuwstelsel kunnen beïnvloeden. De voorgestelde aanpak laat toe 
om peptidesequenties verscholen in proteinestructuren, die mogelijks de BBB kunnen passeren, te 
identificeren. Voor deze verscholen peptidestructuren, de zogeheten cryptische peptiden, kan dan 
verder onderzocht worden of ze de werking van het centraal zenuwstelsel kunnen beïnvloeden. 
Beeldvormingsmassaspectrometrie is een vrij recente techniek die toelaat om de temporale en 
spatiale distributie van de peptiden in de hersenen te bestuderen. Deze informatie kan gebruikt 
worden om de na te gaan of de hersenopname regio-specifiek gebeurt, wat interessant kan zijn voor 
therapeutische toepassingen of kan helpen bij het ontrafelen van de mogelijke functie van deze 
peptiden in het centraal zenuwstelsel. De temporale distributie levert informatie op over het 
tijdsduur dat het peptide in een bepaald hersendeel aanwezig is.  
Verouderen is geassocieerd met een verhoogde permeabiliteit van de BBB. Hoewel momenteel vaak 
niet onderzocht tijdens de ontwikkeling van geriatrische geneesmiddelen, is dit zeer relevant voor de 
medicinale therapie bij ouderen, gezien het veranderingen in de hersendistributie en bijwerkingen in 
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het centraal zenuwstelsel kan veroorzaken. De beschikbaarheid van biomerkers voor de BBB- 
dysfunctie of modellen voor BBB permeabiliteit kunnen helpen bij de dosisaanpassing van 
geneesmiddelen toegediend aan ouderen of ze kunnen gebruikt worden om de potentiële risico’s in 
te schatten van een bepaalde geneesmiddelentherapie bij ouderen. Mogelijke merkers zouden de 
pro-inflammatoire cytokines kunnen zijn, waarvan de bloedwaarden verhoogd zijn bij ouderen, of de 
samenstelling van de microflora van de darm, dat de BBB-functie beïnvloedt en wijzigingen vertoont 
tijdens verouderen. Verschillen tussen man en vrouw zouden ook in acht moeten genomen worden, 
gezien geslachtshormonen ook de BBB-functie beïnvloeden. De rol van de BBB-dysfunctie in 
neurodegeneratieve aandoeningen is reeds erkend. Een ander belangrijke vraag is of BBB-dysfunctie 
geassocieerd is met de etiologie van andere aandoeningen van het centraal zenuwstelsel zoals 
epilepsie, autisme, schizofrenie, depressie of hersenkanker, wat weer nieuwe therapeutische opties 
zou kunnen bieden.  
Met het aantonen van de mogelijkheid van de CPPs om selectief de BBB te passeren, hebben we de 
fundamenten gelegd voor verder onderzoek. We hebben aangetoond dat de huidige beschikbare 
studies die zowel de celopname als het BBB-transport van peptiden bestuderen, inconsistentie 
vertonen in de experimentele opstelling en methodiek. Daarom hebben we universele responsen 
geïntroduceerd, zowel voor celopname als voor BBB-influx van peptiden. Een harmonisatie en 
standaardisatie van deze protocollen, met onder andere de consequente evaluatie van een positieve 
en negatieve controle, zouden toelaten om de celopname en de BBB-transporteigenschappen van 
peptiden op een meer betrouwbare manier met elkaar te vergelijken. Dit zal ook helpen om 
openstaande vragen te beantwoorden, zoals de gebruikte mechanismen en de vereiste structurele 
eigenschappen voor celopname en BBB-transport. Tot slot, het feit dat CPPs endogeen kunnen 
gevormd worden, onderstreept het belang van het onderzoek van de mogelijke biologische effecten 
(op het centraal zenuwstelsel) van deze peptiden. 
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“Success is not final, failure not fatal:  
It is the courage to continue that counts.” 
 
Winston Churchill 
(°1874 - †1965, Former Prime Minister of the United Kingdom) 
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